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ABSTRACT 
 
Pseudomonas aeruginosa is found in numerous environments and is an 
opportunistic pathogen affecting those who are immunocompromised. Its large genome 
encodes tremendous metabolic and regulatory diversity that enables P. aeruginosa to 
adapt to various environments. We are interested in how P. aeruginosa senses and 
responds to the host-derived compounds, carnitine and acylcarnitines. Acylcarnitines can 
be hydrolyzed to carnitine, where the liberated carnitine and its catabolic product glycine 
betaine can be used as osmoprotectants, for induction of the virulence factor 
phospholipase C, and as sole carbon, nitrogen, and energy sources. P. aeruginosa is 
incapable of de novo synthesis of carnitine and acylcarnitines and therefore imports these 
compounds from exogenous source. Short-chain acylcarnitines are imported by the ABC 
transporter CaiX-CbcWV. Medium- and long-chain acylcarnitines are hydrolyzed 
extracytoplasmically and the liberated carnitine is transported through CaiX-CbcWV. 
Once in the cytoplasm, short-chain acylcarnitines are hydrolyzed by the L-enantiomer 
specific hydrolase, HocS. The transcriptional regulator CdhR is divergently transcribed 
from the carnitine catabolism operon and we have identified the upstream activating 
region, the binding site sequence, and essential residues required for CdhR binding and 
induction of the carnitine operon. Carnitine catabolism is repressed by glucose and 
glycine betaine at the transcriptional level. Furthermore, using two different cdhR 
translational fusions we show that CdhR enhances its own expression and that GbdR, a 
related transcription factor, contributes to cdhR expression by enhancing the level of 
basal expression. These studies are the first to determine the mechanism of O-
acylcarnitine transport, metabolism, and the regulation of these processes, which 
contribute to utilization of these compounds for P. aeruginosa survival in diverse 
environments.  
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1.1 Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a Gram-negative bacterium that is ubiquitous in 
nature. P. aeruginosa is capable of living in many different environments due to its large 
genome that encodes diverse metabolic pathways. The genome is over 6.2 megabases and 
has over 5,570 predicted open reading frames that enable tremendous functional diversity 
[1]. With over 10 % of the genome predicted to be involved in metabolism and 8.4 % to 
regulation of gene expression, it’s no wonder P. aeruginosa readily adapts to changing 
environmental conditions and nutrient sources [1]. Even though its respiration is 
primarily aerobic, P. aeruginosa can respire anaerobically using nitrate as an electron 
acceptor in the absence of oxygen. P. aeruginosa has a polar monoflagellum and Type IV 
motile pili making it highly motile, allowing the bacterium to actively find nutrients, 
attach to surfaces, and seek desirable environments [2]. Furthermore, it is this versatility 
that makes P. aeruginosa such a widespread pathogen [3], causing disease in plants [4, 
5], nematodes [6], insects [7], and most notably, as an opportunistic pathogen in 
immunocompromised people. 
To successfully cause infection, P. aeruginosa must incorporate and metabolize 
molecules derived from the host. General maintenance and expression of virulence 
factors are minimal requirements, while efficient catabolism and resultant growth can 
lead to successful colonization and improved evasion of immune-mediated clearance. 
The host-derived compound carnitine is abundant in host tissues and is readily used by P. 
aeruginosa [8]. Carnitine can be transported into the cell or acquired from metabolic 
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precursors, where it can serve directly as a compatible solute for stress protection, or be 
metabolized through one of a few distinct pathways as a nutrient source [9]. 
 
1.1.1. Infections caused by P. aeruginosa: acute and chronic 
 P. aeruginosa is one of the leading causes of nosocomial infections in the world 
[10] and often spreads from contaminated hospital materials (bedding, floors, sinks, etc.) 
and hospital personnel [11], although the actual routes of transmission from the 
contaminated sources to the patients have not been definitively shown. When P. 
aeruginosa establishes an infection it can develop into either an acute or chronic 
infection. This process is regulated via internal and external signals, often related to 
metabolism and nutrient acquisition, that alter motility and virulence expression to 
promote either an acute or chronic infection [12, 13].  
Acute infections are severe, progressive infections that can result in septicemia 
and death if not treated properly. Virulence factors and toxins are often associated with 
acute infections. The exoenzyme type 3 secretion system (T3SS) of P. aeruginosa 
significantly enhances the pathogens ability to cause acute lung disease [14]. The 
Exotoxin (Exo) T and ExoS are GTPase-activating proteins that alter host actin 
cytoskeleton [15-17], while ExoU has patatin-like phospholipase activity affecting lipid 
metabolism and membrane integrity [18]. Together these exotoxins decrease host wound 
healing, cell motility and phagocytic capabilities, leading to septicemia and death [19]. 
People with severe burns are highly susceptible to infection due to breach in the natural 
skin barrier [11]. P. aeruginosa is the leading cause of infection in burns because  
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elements such as elastase, exotoxin A, phospholipases, quorum sensing, and the ability to 
be motile, enable P. aeruginosa to persist in the wound and disseminate [20, 21]. Other 
common acute infections are folliculitis [22], ulcerative keratitis [11], urinary tract 
infections [23], green nail syndrome [24], and episodes of pulmonary exacerbation in the 
lung diseases cystic fibrosis and chronic obstructive pulmonary disorder [25].  
Chronic infections are those that can last months to a lifetime and are slow 
progressing. Cystic fibrosis (CF) is an autosomal recessive disorder caused from a 
mutation in the CF transmembrane conductance regulator (CFTR) gene, an ABC 
transporter that moves chloride ions across epithelial cell membranes. CF affects many 
organ systems but the altered lung physiology is currently the leading cause of death. The 
dysfunction of water balance across the respiratory epithelium and resultant impact on 
mucociliary clearance leads to a thick viscous mucus layer, a perfect environment for 
bacterial colonization [26]. After childhood, P. aeruginosa is the most common pathogen 
in the lungs and generally persists as a chronic infection despite extensive eradication 
regimes [27]. Infection of the lungs and the resultant lung function decline is the leading 
cause of mortality and morbidity in CF patients and more than 95% of CF patients die 
from respiratory failure, although only 70% of these are now from P. aeruginosa [28, 
29]. In chronic infections, P. aeruginosa cells form biofilms, repress flagella expression, 
change their metabolic profile, and can become phenotypically mucoid by producing 






 The ability of P. aeruginosa to infect a wide range of hosts and cause significant 
disease and mortality is mediated by numerous factors that can be categorized as either 
virulence factors or virulence determinants [31]. Virulence factors, in the strictest 
definition, are secreted from the cell and damage the host. The most important group of 
secreted virulence factors are those secreted from the type three secretion systems 
(T3SS). The T3SS apparatus is a syringe-like complex that injects effector proteins 
directly into host cells to manipulate them [14]. In addition to T3SS, proteins can be 
secreted into the environment. Exotoxin A inhibits protein biosynthesis by inactivating 
elongation factor 2, resulting in cell death [32]. Phospholipase C, encoded by plcH, is 
secreted and cleaves phosphatidylcholine and sphingomyelin, components of eukaryotic 
cell membranes and lung surfactant. PlcH activity has been found to negatively impact 
lung function during infection, and can function to induce a proinflammatory response, 
suppress oxidative burst in neutrophils, degrade pulmonary surfactant, and increase 
endothelial cell death [33-38]. Elastases and proteases are other secreted virulence factors 
used by P. aeruginosa [11]. One of the most visually recognized virulence factors is 
pyocyanin because of its blue color. Pyocyanin is a redox-active secondary metabolite 
that not only kills eukaryotic host cells but also has the capacity to kill other bacteria 
through a myriad of mechanisms [31, 39].  
Virulence determinants are factors that contribute to infection and disease, but not 
those that are for housekeeping maintenance [40]. Motility by flagella and pili are 
virulence determinants that contribute to pathogenicity through adherence, persistence in 
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wound sites, and dissemination throughout the host [41]. Quorum sensing is a virulence 
determinant used by bacteria to communicate and determine cell population density, and 
adjusts gene expression accordingly, impacting virulence [42, 43]. It was recently 
demonstrated that quorum sensing activates dispersal of biofilms [44], a community-
based lifestyle.  Biofilms are a developmental process leading to long duration 
attachment to a surface, where the cells are highly resistant to antimicrobials making it 
difficult to eradicate the bacteria [42]. A virulence determinant often overlooked is 
catabolism of host compounds. For a pathogen to colonize the host, the bacterium must 
acquire and catabolize host compounds to serve as nutrients, which are discussed in 
greater detail later in the chapter. 
 P. aeruginosa is a successful opportunistic pathogen because of metabolic 
diversity, secreted virulence factors, and resistance to antimicrobials and drug therapies. 
Virulence and antibiotic resistance are not mutually exclusive; alginate production, 
quorum sensing, and biofilm formation directly contribute to drug resistance. Resistance 
is largely attributed to intrinsic features in the microbe. For starters, the P. aeruginosa  
outer membrane is more restrictive than many other Gram-negative bacteria, with a 
permeability 12-100 times lower than in E. coli [45], excluding passage of many 
antibiotic compounds. Efflux pumps contribute to antibiotic resistance by pumping those 
antibiotics that passed the limited permeability barrier of the outer membrane back out of 
the cell. Overexpression of the MexAB-OprM, MexXY-OprM, and MexEF-OprN efflux 
systems removes β-lactams, quinolones, aminoglycosides, carbapenems, and 
disinfectants, respectively [46]. Another intrinsic resistance method that P. aeruginosa 
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possess is a chromosomal ampC gene, encoding a periplasmic β-lactamase that can 
inactivate β-lactam antibiotics [47]. Horizontal gene transfer and mutations can be 
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1.2 Carnitine in bacterial physiology and metabolism 
1.2.1. Summary 
Carnitine is a quaternary amine compound found at high concentration in animal 
tissues, particularly muscle, and is most well-studied for its contribution to fatty acid 
transport into mitochondria. In bacteria, carnitine is an important osmoprotectant and can 
also enhance thermotolerance, cryotolerance, and barotolerance. Carnitine can be 
transported into the cell or acquired from metabolic precursors, where it can serve 
directly as a compatible solute for stress protection, or be metabolized through one of a 
few distinct pathways as a nutrient source. In this review, we summarize what is known 
about carnitine physiology and metabolism in bacteria. In particular, recent advances in 
the aerobic and anaerobic metabolic pathways as well as the use of carnitine as an 
electron acceptor have addressed some long-standing questions in the field. 
 
1.2.2. Introduction 
Carnitine (gamma-trimethylamino-beta-hydroxybutyric acid) (Fig. 1) is a 
quaternary amine compound that can be produced by all domains of life and was 
discovered in muscle extract in 1905 by Gulewitsch and Krimberg (Gulewitsch & 
Krimberg, 1905), and Kutscher (Kutscher, 1905). It was shown to be essential for larval 
development of the mealworm, Tenebrio molitor, and was originally designated vitamin 
BT based on this requirement. Later it was discovered that carnitine can be synthesized in 
mammals and is now considered to be a quasi-nutrient or conditionally essential nutrient 
(Flanagan et al., 2010), as neonates have reduced biosynthesis and rely on placental 
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transfer of carnitine in utero and exogenous sources after birth (Combs Jr., 2012). Fifty 
years after the discovery of carnitine, it was demonstrated that assorted Gram positive 
and Gram negative bacteria could use carnitine in either aerobic or anaerobic 
environments for a variety of cellular functions, including as an electron acceptor, as a 
compatible solute to survive environmental insults, or as a sole carbon, nitrogen, and 
energy source. Bacterial carnitine metabolism was most recently reviewed fifteen years 
ago (Bieber, 1988; Bremer, 1983; Kleber, 1997; Rebouche & Seim, 1998), and the field 
has seen important advances. This review summarizes what we knew at the time of the 
previous reviews and emphasizes what we have learned since, including: (i) how 
anaerobic bacteria synthesize and utilize crotonobetaine and carnitine as final electron 
acceptors, (ii) the impact of carnitine degradation by the intestinal microbiota and the 
genes responsible for this anaerobic conversion, (iii) the genes involved in aerobic 
degradation of carnitine, and (iv) how carnitine as a compatible solute impacts survival 
within and outside of the host.  
 
1.2.3. Carnitine in the environment 
 Recent work makes it clear that while animals represent the most readily 
accessible source of carnitine, carnitine is often present and sometimes abundant in soil 
and natural waters. Quaternary ammonium compounds are abundant in a number of soil 
ecosystems, including comprising a quarter of the most abundant organic nitrogen 
compounds in the soil water of a sub-alpine grassland (Warren, 2013a). In this 
environment, carnitine was the most abundant quaternary ammonium compound (0.49 
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µM) and third most abundant soluble nitrogen compound overall, while acetylcarnitine 
was present at a slightly lower concentration (0.33 µM) (Warren, 2013a). It is apparent 
that carnitine concentration varies depending on sample location (Warren, 2013b), but 
there is need for a more thorough quantification of carnitine in other environments. The 
carnitine levels in soil and water may vary dependent on the bacterial flora at the site and 
whether the bacteria inhabiting those environments are capable of carnitine metabolism. 
The presence and utility of carnitine in the environment is supported, in part, by the 
number of bacteria capable of carnitine metabolism, including a few newly identified 
species such as Burkholderia caribensis (Achouak et al., 1999), Bacillus decisifrondis 
(Zhang et al., 2007), Pseudomonas kilonensis (Sikorski et al., 2001) from soil, and 
Shewanella pacifica from sea water (Ivanova et al., 2004).  
 
1.2.4. The importance of carnitine to animals (like us) 
Carnitine is most abundantly associated with animals, and its physiology in 
animals provides an important backdrop to our review of microbial processes. Carnitine 
is a zwitterion and can exist as either D- or L-enantiomers, but the D stereoisomer is not 
utilized for normal physiology in animals and can inhibit acylcarnitine transferases, 
thereby resulting in tissue depletion of L-carnitine (Bieber, 1988). Therefore, unless 
specifically noted, we are discussing L-carnitine. Animals use the L-carnitine shuttle to 
transport long to short chain fatty acids in and out of the mitochondria by reversibly 
esterifying the beta carbon hydroxyl group with a fatty acid to form O-acylcarnitine (Fig. 
1). Beta oxidation of very long- chain fatty acids starts in the peroxisome, and once they 
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have been converted to medium- or short fatty acid chain lengths, carnitine is employed 
to traffic them out of the peroxisome and into the mitochondria where beta oxidation is 
completed (Reddy & Hashimoto, 2001; Steiber et al., 2004; Wanders & Waterham, 
2006). Acetyl-CoA derived from beta oxidation can be used to generate ATP via the 
TCA cycle, while beta oxidation allows the cell to maintain the acetyl-CoA:CoA ratio, 
and enables removal of specific harmful acylcarnitines derived from endogenous 
substances or from xenobiotics (Bieber, 1988). In humans, about 95% of total carnitine is 
found in skeletal and cardiac muscle, with the remaining 5% circulates in the plasma 
(Cave et al., 2008). Approximately 75% of carnitine is obtained through diet; with foods 
from animal origin like meat and dairy having the highest carnitine content (Steiber et al., 
2004). The remaining 25% of carnitine is synthesized endogenously from the essential 
amino acids L-methionine and L-lysine in the liver, kidney, testes, and brain (Bremer, 
1983; Flanagan et al., 2010; Rebouche, 2014). The body maintains homeostatic levels of 
carnitine by balancing carnitine absorption from the small intestine lumen, reabsorption 
by the kidneys, and modest endogenous synthesis (Rebouche & Seim, 1998). Carnitine 
and acylcarnitines are primarily absorbed from the lumen of the small intestine where 
they are actively transported into enterocytes and diffuse past the serosal membrane into 
the circulatory system where they can then be transported into all other cells (Marciani et 
al., 1991; Rebouche, 2004). Dietary carnitine that is not absorbed in the small intestines 
is metabolized by bacteria in the large intestine - there are no animal enzymes to break 
down carnitine (Rebouche & Chenard, 1991). Over the past decade, gut microbiome 
metabolism has become a topic receiving close review and recently Koeth and colleagues 
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associated the degradation of carnitine by intestinal microbiota with cardiovascular 
disease (CVD) and the promotion of atherosclerosis (Koeth et al., 2013). Some intestinal 
bacteria can convert carnitine to trimethylamine, which is subsequently oxidized in the 
liver to the proatherogenic species trimehtylamine-N-oxide (TMAO) (Koeth et al., 2013), 
a metabolic pathway we discuss in more detail below. The role of bacterial metabolism of 
carnitine directly promoting CVD has been shown in multiple studies (Hartiala et al., 
2014; Koeth et al., 2013; Kuka et al., 2014), but is still up for discussion in the scientific 
and medical communities (Johri et al., 2014). However, there is no debate that bacteria, 
intestinal and otherwise, utilize carnitine in many different ways for their benefit (Ussher 
et al., 2013). 
 
1.2.5. The physiologic benefits of carnitine for bacteria 
Animals have been the focus of research on carnitine since its discovery in 1905 
(Gulewitsch & Krimberg, 1905), and microbial carnitine metabolism wasn’t described 
until almost fifty years later (Fraenkel & Friedman, 1957). In the intervening years, 
microbiologists have described the roles for carnitine in bacteria, where it can be used as 
a final electron acceptor, a compatible solute, or as a sole carbon, nitrogen, and energy 
source. Regardless of its eventual role, carnitine is transported into the bacterial cytosol 
by one of two different mechanisms. The first method is an ATP-dependent ABC 
transport system utilizing the canonical three subunits – a transmembrane domain, an 
ATPase, and a periplasmic binding protein (also known as a substrate binding protein). 
The second method of import is by BCCT (betaine-choline-carnitine) transporters that 
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can be driven by the sodium or proton motive force, but in many cases where carnitine is 
the substrate, often functions as a carnitine:gamma butyrobetaine antiporter (Ziegler et 
al., 2010). Carnitine import or import of immediate precursors is critical for bacterial 
acquisition of carnitine, as Verheul et al. demonstrated that de novo synthesis of carnitine 
does not occur in Escherichia coli (Verheul et al., 1998), and to the best of our 
knowledge, de novo synthesis of carnitine has not been demonstrated in any bacterial 
species. 
 
Carnitine: an organic compatible solute 
Outside of the cozy confines of the laboratory, bacteria are subject to constantly 
changing environments to which they must respond rapidly to survive and thrive. One 
way to accommodate stresses caused by changing water content, salt, temperature, or 
pressure is by synthesis or import of compatible solutes. Compatible solutes can be 
accumulated at high concentrations in the cytoplasm while not interfering with cellular 
processes, thus contribute to proper protein function and cellular homeostasis (Brown & 
Simpson, 1972). Compatible solutes are typically organized into categories: 
carbohydrates, amino acids, methylamines, methylsulfonium solutes, and specific 
inorganic ions. Organic solutes that are either non-charged or zwitterions with no net 
charge at physiological pH are preferred compatible solutes, the intracellular 
concentration of which are carefully regulated to maintain protein stability and cell 
physiology (Fitzsimmons et al., 2012; Hoffmann et al., 2013). Carnitine is an ideal 
compatible solute that can be imported and/or generated from direct precursors by many 
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bacteria and its abundance for infectious microbes in the host and presence in many 
natural environments suggests it is readily accessible (Warren, 2013a; Warren, 2013b). 
 
Osmoprotection 
Drastic changes in water content in the environment can result in osmotic stress to 
the cell. Low external solute concentration is hypoosmotic, with resulting pressure to 
drive water into the cell causing an increase in cell turgor pressure. Conversely, increased 
external solute concentration due to added solutes or loss of water is hyperosmotic, with 
resulting pressure leading to water efflux from the cell, reducing turgor pressure. In 
addition to the altered physiology imparted by these turgor changes, both conditions can 
lead to cell death due to irreversible plasmolysis (loss of water) or cytolysis (too much 
water). To overcome osmotic stress, bacteria can either acquire or synthesize 
osmoprotectants, a process that is universal for bacteria. One way bacteria can overcome 
osmotic stress is by utilizing carnitine as an osmoprotectant and/or osmolyte. 
 
Gram negative osmoprotection by carnitine 
The Gram negative opportunistic pathogen Pseudomonas aeruginosa uses 
carnitine as both an osmoprotectant and an osmolyte. Intracellular carnitine can be 
accumulated directly via transport from extracellular sources through a BCCT (Malek et 
al., 2011) or ABC transporter (Chen et al., 2010), or indirectly by degradation of O-
acylcarnitines (Lucchesi et al., 1995; Meadows & Wargo, 2013). P. aeruginosa, like 
many environmental proteobacteria, can also metabolize carnitine to the osmolyte glycine 
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betaine (Fig. 2) (Aurich et al., 1967; Bastard et al., 2014; Wargo & Hogan, 2009). 
Escherichia coli also use carnitine as an osmolyte, where it functions in aerobic, 
anaerobic, and high salt conditions (Verheul et al., 1998). Import is primarily mediated 
through the ProU transport system, a substrate binding protein-dependent ABC 
transporter, along with modest uptake from the MFS-family transporter ProP in anaerobic 
and osmostressed aerobic cells.  Although CaiT functions as a carnitine antiporter, its 
activity is not sufficient to confer osmoprotection (Verheul et al., 1998). Yersinia 
enterocolitica also employs carnitine as an osmolyte, where unlike most Gram negative 
bacteria, nuclear magnetic resonance observations demonstrated that added carnitine was 
not metabolized to the more potent osmolyte glycine betaine (Park et al., 1995).  
 
Gram positive osmoprotection by carnitine 
The lactic acid bacteria, Tetragenococcus halophile and Lactobacillus plantarum, 
can import and use D- and L-carnitine as osmolytes (Kets et al., 1994; Robert et al., 
2000). Brevibacterium linens can also use D- and L-carnitine as osmolytes, and while L-
carnitine can be metabolized to glycine betaine, it is further metabolized as a sole carbon 
or nitrogen source (Jebbar et al., 1998). Bacillus subtilis imports D- and L-carnitine, 
acetylcarnitine, crotonobetaine, gamma-butyrobetaine, and octanoylcarnitine via the ABC 
transporter, OpuC. Both stereoisomers and the carnitine resulting from acetyl- and 
octanoylcarnitine degradation function as osmolytes to protect the cell from hyperosmotic 
stress (Kappes & Bremer, 1998). The carnitine generated or imported by B. subtilis 
cannot be metabolized further and therefore is thought to function primarily as an 
20 
 
osmoprotectant. Staphylococcus aureus, a common member of the skin and nasal flora 
that is an important opportunistic pathogen, uses carnitine as a compatible solute in high 
salt (Vilhelmsson & Miller, 2002).  
Carnitine appears to be particularly important for the common foodborne 
pathogen Listeria monocytogenes. L. monocytogenes primarily imports carnitine through 
the OpuC ABC transporter (Fraser & O'Byrne, 2002; Fraser et al., 2000; Verheul et al., 
1995; Verheul et al., 1997), where it functions as an osmolyte in high salt conditions 
(Beumer et al., 1994). Mice infected with L. monocytogenes perorally show that OpuC is 
important for survival and infection in the small intestine, and for the proliferation and 
dissemination of the bacteria into other organs, including the liver and spleen (Sleator et 
al., 2001; Sleator et al., 2003; Wemekamp-Kamphuis et al., 2002). One of these studies 
postulated that bacterial destruction of the intestinal epithelial layer allows carnitine 
release, which then alleviates the effects of the hyperosmotic environment of the small 
intestine, where salt concentrations are two times higher than the blood (Sleator et al., 
2001). Additional mouse infections comparing mutants in the glycine betaine transport 
systems BetL and Gbu to mutants of OpuC led to the conclusion that carnitine transport 
is more important than glycine betaine for Listeria during infection (Sleator et al., 2003; 
Wemekamp-Kamphuis et al., 2002).  
 
Beyond salt: the role of carnitine in cryoprotection, bile tolerance, and barotolerance 
In addition to osmoprotection, compatible solutes can protect bacteria from 
additional sources of stress. Listeria and Bacillus have both been well-studied in relation 
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to carnitine uptake, and are good examples of bacteria that employ carnitine to protect 
against multiple stress conditions.  
Listeria is a foodborne pathogen that has multiple lifestyles, thriving on decaying 
plant material and transiently living in the gastrointestinal tract of some animals, 
including humans. Any bacterium that lives or passes through the small intestine has to 
cope with bile salts, which aid in digestion of lipids, have antimicrobial activity, disrupt 
membranes and proteins, and induce oxidative stress and DNA damage (Begley et al., 
2005). The OpuC carnitine transport system in L. monocytogenes is important for 
protecting the bacteria against bile stress and its expression is coregulated with the bile 
efflux system BilE (Watson et al., 2009). Mice infected perorally with an opuC mutant 
strain had significantly reduced numbers of bacteria in the feces and a decrease in 
systemic infection, measured as bacteria in the liver and spleen (Watson et al., 2009). 
Carnitine enhances bile tolerance and is important for dissemination and survival in the 
small intestine (Gahan & Hill, 2014; Sleator & Hill, 2010; Watson et al., 2009). 
Unlike many bacteria, L. monocytogenes is capable of growing at refrigeration 
temperatures (4°C), making it a common contaminant of dairy, meats, fruits, and 
vegetables (Ryser & Marth, 2007). Cold or chill stress affects protein structure (Jaenicke, 
1990), protein stability (Privalov & Gill, 1988), and membrane fluidity (Rudolph et al., 
1986), and compatible solutes, like carnitine, can alleviate these negative effects due to 
cold (Bayles & Wilkinson, 2000). The expression of the carnitine uptake system opuC is 
increased at low temperatures, allowing the cell to acquire carnitine and maintain growth 
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(Angelidis & Smith, 2003; Angelidis et al., 2002; Sleator et al., 2009; Wemekamp-
Kamphuis et al., 2004).  
The ability to survive low temperature stress is not the sole domain of bacteria in 
our refrigerators, but rather a required feature of bacteria that inhabit the environment, 
where average soil surface temperatures range from 0 – 18 °C, average freshwater ranges 
from 3 – 25 °C, and while the average ocean surface temperature is ~17 °C the bulk of 
ocean water maintains a temperature of about 3 °C. Therefore, it is not surprising that 
successful environmental bacteria have also evolved pathways for cold tolerance that 
involve carnitine. In Bacillus subtilis, carnitine and its related metabolites crotonobetaine 
and gamma butyrobetaine have been shown to protect against both cold stress (15 °C) 
and heat stress (52 °C), via uptake through the OpuC transporter (Hoffmann and Bremer, 
2011). It is likely that utilization of carnitine as a cryo- and thermo-protectant is not 
restricted to Listeria and Bacillus and the taxonomic breadth and ecological impact of 
this process requires further examination. 
Pressure is another assault that Listeria has adapted to, as food processing uses 
high pressure for food preservation. Listeria exposed to elevated osmolarity and high 
pressure survives better and demonstrates substantial barotolerance when the compatible 
solute carnitine is present and imported into the cell (Smiddy et al., 2004).  
 
1.2.6. Carnitine metabolism 
Carnitine can be utilized in different metabolic pathways to play a variety of 
physiologic roles. Figure 2 illustrates multiple described pathways for carnitine 
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metabolism and highlights bacteria in which particular reactions have been demonstrated. 
For each of the pathways described below, it is important to note that strain-specific 
utilization of carnitine via particular pathways can be governed by alternative regulation 
or the presence/absence of metabolic genes. For example, Pseudomonas syringae B728a 
carries the genes for carnitine conversion to glycine betaine, while P. syringae DC3000 
has lost the entire carnitine catabolic operon (Chen & Beattie, 2007; Chen et al., 2010).  
 
Carnitine as a nutrient 
Carnitine can be catabolized for use as a carbon source via two routes. The first 
pathway cleaves the backbone carbon-nitrogen bond to yield trimethylamine and malic 
semialdehyde, in which the latter enters the TCA cycle. The second route begins with the 
metabolism of carnitine to glycine betaine, which is then subjected to three successive 
demethylations to yield glycine, which can enter central metabolism.  Carnitine can also 
be used as a sole nitrogen source, most commonly via the glycine betaine route, where 
glycine conversion to serine is followed by deamination to form pyruvate and ammonia. 
Formation of trimethylamine from carnitine leaves the nitrogen unusable for most of the 
organisms covered in this review, but many bacteria can use trimethylamine as a nitrogen 
source, carbon source, osmoprotectant, and, when oxidized to TMAO, functions as an 






Carnitine to glycine betaine: a gateway reaction  
Carnitine can be metabolized to glycine betaine via a multistep process, the first 
steps of which are encoded on genes located in the carnitine catabolism operon 
(Uanschou et al., 2005; Wargo & Hogan, 2009). First, carnitine is converted to 3-
dehydrocarnitine by the enzyme carnitine dehydrogenase (CDH, EC 1.1.1.108), an 
NAD
+
-dependent oxidoreductase. P. aeruginosa (Aurich et al., 1967; Kleber & Aurich, 
1967; Kleber et al., 1967), Xanthomonas translucens (Arima et al., 2010; Mori et al., 
1988), Enterobacter sp. (Hwang & Bang, 1997), P. putida (Kleber et al., 1978), P. 
fluorescens (Hung & Kleber, 1985), Burkholderia cepacia (Dalmastri et al., 2003), 
Rhizobium sp. (Arima et al., 2010), and Agrobacterium sp. (Hanschmann et al., 1996) all 
encode CDH enzymes that are specific for L-carnitine. 3-dehydrocarnitine is relatively 
unstable, therefore if there is no ATP or Coenzyme A (CoA) present, it will 
spontaneously decarboxylate to yield trimethylaminoacetone (N,N,N-
trimethylaminopropanone) and carbon dioxide (Lindstedt et al., 1967). If sufficient ATP 
and CoA are present, then 3-dehydrocaritine is converted to acetylacetone and glycine 
betaine-CoA by the beta-keto acid cleavage enzyme (BKACE).  The gene encoding the 
carnitine specific BKACE is located directly upstream of the CDH gene(s) in the 
carnitine catabolism operon (Uanschou et al., 2005), and is designated cdhC in P. 
aeruginosa (Bastard et al., 2014; Wargo & Hogan, 2009). The identification of this gene 
was part of a massive biochemical screen of various bacterial BKACE members, and 
proved very valuable for the identification of these CoA-dependent cleavage enzyme 
substrates (Bastard et al., 2014). The glycine betaine-CoA derived from BKACE activity 
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is then converted to glycine betaine and CoA by a CoA transferase, likely the DhcAB 
enzyme in P. aeruginosa (Wargo & Hogan, 2009), which appears to function as a general 
amino acid CoA transferase (Palmer et al., 2013). After carnitine is metabolized to 
glycine betaine, it can function as an osmolyte (as described above), or be utilized as a 
sole carbon, nitrogen, and energy source if the organism encodes the necessary enzymes, 
as in the case for P. aeruginosa (Wargo et al., 2008), Xanthamonas translucens (Arima et 
al., 2010; Mori et al., 1988), Enterobacter sp. (Hwang & Bang, 1997), Rhizobium sp. 
(Arima et al., 2010; Goldmann et al., 1991), Sinorhizobium meliloti (Goldmann et al., 
1991), Burkholderia cepacia (Dalmastri et al., 2003), and Agrobacterium sp. 
(Hanschmann et al., 1996; Nobile & Deshusses, 1986), and metabolism and homeostasis 
of glycine betaine has recently been reviewed (Wargo, 2013).   
 
Cleaving the backbone carbon-nitrogen bond 
An alternative pathway to use carnitine as a sole carbon source is to cleave the 
carbon-nitrogen bond of carnitine to form trimethylamine and malic acid. It has been 
known since the mid 1960’s that Serratia marcescens aerobically splits the carbon 
nitrogen bond of both D- and L-carnitine to form trimethylamine and malic acid, and that 
this reaction does not occur in anaerobic conditions since it requires uptake of oxygen 
(Unemoto et al., 1966).  Through the same reaction, Acinetobacter calcoaceticus can also 
use both D- and L-carnitine as sole carbon sources (Kleber, 1977; Miura-Fraboin et al., 
1982), yet the responsible enzymes remained elusive until recently. The genes encoding 
the enzymes that are essential for the conversion of carnitine to trimethylamine and malic 
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semialdehyde were recently identified as a two-subunit oxidoreductase in Acinetobacter 
baumannii (Zhu et al., 2014), with CntA being a Rieske-family iron-sulfur cluster 
oxygenase, and CntB being the reductase. The CntAB proteins likely function 
analogously to GbcAB, which comprise the oxidoreductase that demethylates glycine 
betaine to dimethylglycine (Wargo et al., 2008). Both sets of proteins cleave one of the 
C-N bonds in a quaternary amine compound, and these enzymes may represent a general 
evolutionary strategy for quaternary amine metabolism. Orthologs and homologs of the 
cntAB genes are found in a variety of gut microbiota: Gammaproteobacteria (Klebsiella 
pneumoniae, E. coli, Citrobacter, Providencia, and Shigella), Betaproteobacteria 
(Achromobacter), and Firmicutes (Sporosarcina) (Zhu et al., 2014). The malic 
semialdehyde produced during this reaction is converted to malic acid, which enters the 
TCA cycle. Trimethylamine formed from carnitine by gut bacteria is correlated to human 
cardiovascular health (Koeth et al., 2013), where it is oxidized to trimethylamine-N-oxide 
(TMAO) by hepatic flavin monooxygenases in the liver (Bennett et al., 2013). Therefore, 
the identification of CntAB provides a target for monitoring gut microbiota capacity for 
trimethylamine production and is a critical step forward in our understanding of carnitine 
metabolism by bacteria. 
 
Carnitine as a final electron acceptor 
Bacteria that live strictly or transiently in anaerobic environments, where oxygen 
cannot serve as the final electron acceptor, can use alternate electron acceptors, including 
sulfates, nitrates, ferric iron, carbon dioxide, and fumarate, among others. In cases where 
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the common electron acceptors are not present, some Enterobacteriaceae (E. coli, S. 
typhimurium, and Proteus spp.) can use carnitine and its catabolic product crotonobetaine 
as final electron acceptors in the absence of oxygen and in the presence of additional 
carbon and nitrogen sources (Seim et al., 1982a; Seim et al., 1982b; Seim et al., 1982c). 
Use of these compounds as electron acceptors is regulated by the transcriptional 
activator, CaiF, and the regulatory proteins CRP and FNR, which regulate expression of 
the divergently transcribed operons caiTABCDE and fixABCX; both required for carnitine 
metabolism in E. coli (Buchet et al., 1998; Buchet et al., 1999; Eichler et al., 1995; 
Eichler et al., 1996). For its role as an electron acceptor, carnitine is imported by the 
substrate:product antiporter, CaiT, which exchanges carnitine for its metabolic product 
gamma-butyrobetaine (Jung et al., 1990; Jung et al., 2002; Kalayil et al., 2013). Co-
expression of these two operons is induced by carnitine and crotonobetaine, but repressed 
by oxygen, glucose, gamma-butyrobetaine, and more desirable final electron acceptors 
such as nitrate and fumarate (Jung et al., 1987; Seim et al., 1982a; Seim et al., 1982b). 
Expression of the carnitine metabolism genes in E. coli and Proteus spp. is also 
detectable in aerobic environments in the presence of inducing compounds, but to a much 
lesser extent than under anaerobic conditions (Elssner et al., 1999; Engemann & Kleber, 
2001; Obon et al., 1999).  
The fix operon is predicted to be involved in transferring electrons to carnitine 
(Eichler et al., 1995; Eichler et al., 1996; Walt & Kahn, 2002). The transformation of 
carnitine to crotonobetaine is reversible (Jung et al., 1989) and was originally thought to 
occur via the single carnitine dehydratase, CaiB, with the cosubstrates gamma-
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butyrobetainyl-CoA or crotonobetainyl-CoA (Eichler et al., 1994a; Elssner et al., 2000; 
Jung et al., 1989). However Elssner et al. demonstrated that “L-carnitine dehydratase 
does not exist” and two enzymes are responsible for the reversible conversion of carnitine 
to crotonobetaine (Elssner et al., 2001). CaiB is a CoA transferase that transfers CoA 
from gamma-butyrobetainyl-CoA, crotonobetainyl-CoA, or carnitinyl-CoA to form 
gamma-butryobetaine, crotonobetaine or carnitine. CaiD has enoyl-CoA hydratase 
activity and can dehydrate carnitinyl-CoA to crotonobetainyl-CoA, or can hydrate 
crotonobetainyl-CoA to carntinyl-CoA, thus CaiD has two potential names: 
crotonobetainyl-CoA hydratase or carnitinyl-CoA dehydratase. These enzymatic 
processes also allow carnitine to be synthesized from crotonobetaine and vice versa, 
(Figure 3) (Elssner et al., 2001; Engemann et al., 2001; Engemann et al., 2005). 
Crotonobetaine can be reduced to gamma-butyrobetaine by two proteins, CaiB, with one 
of the cosubstrates gamma-butyrobetainyl-CoA or crotonobetainyl-CoA, and the 
unidirectional enzyme crotonobetaine reductase, CaiA, which reduces crotonobetainyl-
CoA to gamma-butryobetainyl-CoA (Engemann et al., 2005; Preusser et al., 1999; Roth 
et al., 1994). Two other proteins necessary for anaerobic carnitine catabolism are CaiC 
and CaiE. CaiC is a betaine:CoA ligase with CoA transferase activity in vitro, but is not 
sufficient in vivo to compensate for a caiB deletion. Therefore, CaiC is likely required for 
activation of trimethylammonium compounds (Bernal et al., 2008; Eichler et al., 1994b). 
The function of CaiE is still somewhat mysterious, but it is postulated to be required for 
activation or synthesis for an unknown cofactor necessary for carnitine metabolism 
(Eichler et al., 1994b).  
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The enzymes for converting gamma-butyrobetaine into carnitine, best described 
in the Enterobacteriaceae, are predicted to be present in other bacterial groups. The 
Betaproteobacterium Achromobacter cycloclast and the Gammaproteobacterium 
Acinetobacter calcoaceticus are predicted to have similar enzymes as no gamma-
butyrobetaine hydroxylase was detected during degradation of gamma butyrobetaine to 
carnitine. For A. calcoaceticus, after gamma butyrobetaine is degraded to carnitine, the 
carnitine can then be broken down to trimethylamine and malic acid where it uses it as a 
carbon source (Miura-Fraboin et al., 1982), whereas the fate of the newly synthesized 
carnitine was not investigated in A. cycloclast (Naidu et al., 2001). 
 
1.2.7. Sensing and binding carnitine 
 For osmotic adaptation to, or metabolism of carnitine, it is important for bacteria 
to regulate the expression of genes involved in these processes. To our knowledge, 
carnitine is sensed to regulate activity at the transcriptional level using so-called ‘one-
component’ regulators, i.e. single polypeptides that sense ligand and regulate 
transcription. However, compared to our understanding of carnitine transport and 
metabolism, the detection of carnitine for transcriptional regulation is much more poorly 
understood. We know of only two transcription factors that sense carnitine to regulate 
transcription: CaiF in E. coli and CdhR in Pseudomonas aeruginosa. Both are 
transcriptional activators and induce transcription in response to carnitine (Buchet et al., 
1999; Wargo & Hogan, 2009), although importantly, direct interaction of either protein 
with carnitine has not been demonstrated. 
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In E. coli, the cai and fix operons (described above) are regulated by the global 
regulator CRP and the carnitine-responsive activator CaiF. The CaiF protein is small and 
is predicted to contain two AraC-like helix-turn-helix (HTH) domains and likely 
functions similar to the MarR ‘HTH-only’ activators (Buchet et al., 1999). Interestingly, 
the lack of a canonical ligand-binding domain suggests that detection of the ligand occurs 
within what is typically thought of as the DNA binding domain of the protein or is 
mediated by an independently encoded sensor protein. Using the Phyre2 protein 
prediction server (Kelley & Sternberg, 2009), CaiF has high structural homology to GrlA 
from Enterohemorrhagic E. coli (EHEC), where the two-component response regulator 
GrlR has been shown to interact with GrlA, modulating transcriptional regulation 
(Creasey et al., 2003; Russell et al., 2007). While we have found no obvious GlrR 
homologs in the fix and cai operons, it remains a possibility that carnitine detection 
occurs via a GlrR ortholog or a cognate sensor kinase, like GlrK (Yamamoto et al., 
2005).  
In P. aeruginosa, the transcription factor CdhR functions as the carnitine-
responsive activator of the genes encoding the carnitine dehydrogenase enzymatic 
pathway (Wargo & Hogan, 2009). CdhR is a member of the glutamine amidotransferase-
1 (GATase-1) sub-family of the AraC transcription factor family and has the canonical 
AraC-family structure consisting of an N-terminal ligand sensing and dimerization 
domain and a C-terminal DNA binding domain comprised of two HTH motifs. Orthologs 
of CdhR are found divergently transcribed from the aerobic carnitine dehydrogenase 
genes in a variety of organisms including many species in the families 
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Pseudomonadaceae, Burkholderiaceae, and Rhizobiaceae, as well as in Mesorhizobium 
loti, and Silicibacter sp. (Uanschou et al., 2005). Given the conservation of the gene 
arrangement and predicted functions, we propose that further understanding of CdhR will 
yield insights into this regulation beyond Pseudomonas.  
 In Gram positive bacteria, the carnitine dehydrogenase operons contain a TetR-
family transcription regulator that likely functions as the carnitine sensor for regulated 
expression of these operons. Compared to the Gram negative bacteria, presence of the 
carnitine dehydrogenase and its cognate TetR-like regulator is much more restricted, 
occurring in Brevibacterium linens, Staphylococcus epidermidis, Streptomyces 
coelicolor, and Oceanobacillus sp. (Uanschou et al., 2005). For the first two organisms 
on this list, acquisition of this predicted horizontally-acquired operon makes teleological 
sense given the prevalence of carnitine in milk and in the skin, respectively.  
 An integral part of transport, metabolism, and transcriptional activation is 
binding of the target molecule. In the case of carnitine, crystal structures have been 
solved in complex that include carnitine in complex with the periplasmic binding protein 
OpuCC (Du et al., 2011), the carnitine:gamma butryobetaine antiporter CaiT (Schulze et 
al., 2010; Tang et al., 2010), and similar aromatic cage architecture of the quaternary 
amine binding site with gamma butyrobetaine has been determined for gamma 
butyrobetaine hydroxylase (Tars et al., 2014). Therefore, like the situation for glycine 
betaine (Schiefner et al., 2004) high affinity binding of carnitine and its metabolites 
seems to occur via an aromatic cage enabling the cation-pi interaction with the 
trimethylamine moiety coupled with properly spaced hydrogen bonding residues to 
32 
 
coordinate the carboxylic acid. While this binding arrangement has been demonstrated 
for transport and metabolic proteins, neither carnitine nor the related compounds choline 
or glycine betaine have been crystalized with their cognate transcriptional regulators. 
Given the specificity and affinity provided by the cation-pi interaction, it has been 
hypothesized that glycine betaine and carnitine-sensitive transcription factors utilize a 
functionally similar binding site (Bremer, 2011). 
 
1.2.8. Multiple paths for carnitine acquisition 
De-novo carnitine synthesis 
 While bacteria can synthesize the quaternary amine compounds choline and 
glycine betaine from single unrelated carbon sources during growth on minimal media, 
such de novo synthesis of carnitine has not been demonstrated. Rather, as discussed 
below, carnitine is typically generated by metabolizing appropriate trimethylated 
precursors. While evidence for true de novo synthesis is lacking, N
Ɛ
-trimethyllysine is the 
starting point for mammalian carnitine synthesis (Vaz & Wanders, 2002), and bacteria 
are known to synthesize N
Ɛ
-trimethyllysine (Barbier et al., 2013; Klagsbrun & Furano, 
1975). Therefore, it remains a formal possibility that bacteria can use this N
Ɛ
-
trimethyllysine to synthesize carnitine in a manner similar to mammals. 
 
D-carnitine… not a dead end after all 
Animals only synthesize and respond physiologically to L-carnitine, thus the 
presence of the D stereoisomer arises from bacterial processes on carnitine and its 
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derivatives, or from ingested food based on abiotic racemization. Despite the relative 
abundance of L-carnitine, some bacteria are capable of utilizing D-carnitine as a sole 
carbon and nitrogen source, including Agrobacterium sp., Agrobacterium radiobacter, 
and Enterobacter (Hanschmann & Kleber, 1997; Hwang & Bang, 1997; Kluttermann et 
al., 2002). Agrobacterium expresses both an L-CDH and a D-CDH and its utilization of 
D-carnitine is dependent on the loss of chirality upon conversion of D-carnitine to the 
achiral 3-dehydrocarnitine (Hanschmann & Kleber, 1997). Enterobacter sp. KC-006 is 
also able to use D-carnitine as a sole carbon and nitrogen source. Mutations that 
significantly impair L-CDH activity permitted growth on D-carnitine as well as wild 
type, suggesting that a carnitine racemase was likely not responsible (Hwang, 1997). 
However, the D-carnitine metabolic pathway in Enterobacter has not been fully 
described. While Enterobacter likely does not have a carnitine racemase, there are 
bacteria that employ such an enzyme for D-carnitine metabolism. In Pseudomonas sp. 
AK1, a cytoplasmic carnitine racemase converts D-carnitine to L-carnitine, which is 
subsequently metabolized to glycine via glycine betaine to supply the cell with carbon 
and nitrogen (Monnich Iet al.., 1995). E. coli 044 K74 also expresses carnitine racemase 
activity, which is induced in the presence of L-carnitine or crotonobetaine and repressed 
by glucose, oxygen, and fumarate (Canovas et al., 2003; Castellar et al., 1998; Jung & 
Kleber, 1991). CaiD was initially suggested to function as the racemase, as the caiD gene 
is required for racemase activity (Eichler et al., 1994b; Jung & Kleber, 1991; Jung et al., 
1987), however this has not been directly tested. CaiD is still postulated to be involved in 
racemization of D-carnitine, since CaiC was shown to activate D-carnitine by adding a 
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CoA group to produce D-carnitinyl-CoA, which is then theorized to be converted to L-
carnitinyl-CoA by CaiD (Bernal et al., 2008). 
 
Carnitine synthesis by gamma-butyrobetaine hydroxylase  
The direct route to the formation of carnitine from gamma-butryobetaine occurs 
through the enzyme gamma-butryobetaine hydroxylase (EC 1.14.11.1). It has been 
identified in Pseudomonas sp. AK1 (Lindstedt et al., 1970a; Lindstedt et al., 1970b; 
Ruetschi et al., 1993), and Pseudomonas sp. L1 (Lu et al., 2012), and both enzymes are 
homologous to the animal gamma-butyrobetaine hydroxylase in their requirement for 
oxygen and the cofactors iron, ascorbate, and α-ketogluterate (Lindstedt & Lindstedt, 
1970; Lindstedt et al., 1968). 
  
Acylcarnitine 
A fatty acid moiety can be conjugated to the third carbon of carnitine resulting in 
O-acylcarnitines (Fig. 1), which can serve as sources of carnitine but also can alter 
bacterial physiology directly (Nguyen et al., 2012). P. aeruginosa can utilize 
acylcarnitines with 2-16 fatty acid chain lengths as sole carbon, nitrogen and energy 
sources, with the exception of octanoylcarnitine, although the reason for this utilization 
gap is unknown (Meadows & Wargo, 2013). Short-chain acylcarnitines (acetyl- and 
butyrylcarnitine) are hydrolyzed to L-carnitine and a short-chain fatty acid by the esterase 
HocS (Meadows & Wargo, 2013), while the medium- and long-chain acylcarnitine 
hydrolase(s) has not yet been identified. P. putida can utilize L-acylcarnitines with 10-16 
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fatty acid chain lengths as sole carbon and nitrogen sources (Kleber et al., 1978). The L-
enantiomers of short-chain acylcarnitines acetyl-, propionyl-, butyryl-, and iso-
butyrylcarnitine, the medium chain lauroylcarnitine, and the long-chain 
palmitoylcarnitine can be hydrolyzed to carnitine in Acinetobacter calcoaceticus (Kleber 
et al., 1977). Hydrolysis of D- and L-octanoylcarnitine has been assessed for a 
consortium of yeast, bacteria, and fungi resulting in the findings that B. subtilis ATCC 
6633, B. subtilis sp. IMAM, and Penicillium notatum IMAM were capable of 
hydrolyzing D- and L-octanoylcarnitine, while P. fluorescens IMAM, Rhodotorula 
gracilis IMAM, and Fusarium oxysporum sp. lini IMAM had specificity for the L-
enantiomer only. However, in this study, the biological function of the resulting carnitine 
or fatty acid in these strains was not assessed (Aragozzini et al., 1986). An acylcarnitine 
hydrolase has also been purified from an Alcaligenes species and was capable of 
hydrolyzing acetyl-, propinoyl-, hexanoyl-, octanoyl-, decanoyl-, lauroyl-, myristoyl-, 
palmitoyl-, and stearoylcarnitine (Takahashi & Ueda, 1995), however, the gene encoding 
this enzyme was not determined.  
 
Other carnitine derivatives 
Carnitine is used in nutritional supplements, energy drinks, to replace carnitine 
lost during dialysis, and in treatments for carnitine uptake disorders. Because D-carnitine 
is inhibitory to uptake and metabolism in mammals, these industries have searched for 
cost-effective methods to synthesize the L-carnitine enantiomer. One strategy for L-
carnitine synthesis is to start with a more easily synthesized enantiomeric precursor, like 
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L-carnitine nitrile or L-carnitine amide, in order to decrease the cost and streamline the 
production of L-carnitine. A bacterium isolated from the soil, DSM 6230 (no taxonomic 
classification has been published) metabolizes L-carnitine amide into L-carnitine and 
ammonia by a novel enzyme L-carnitine amidase (Kula & Joeres, 1993; Ulrich & Kula, 
1994). The identified carnitine amidase is highly specific for L-carnitine amide and the 
D-enantiomer inhibits the enzyme and cannot be used as a substrate (Kula et al., 1996). 
Another compound that can be metabolized to form carnitine is carnitinenitrile. A 
nitrilase from Corynebacterium, carnitinenitrile hydrolase, converts D- or L-
carnitinenitrile into its corresponding D- or L-carnitine and ammonia (Kakayama, August 
1991). Norcarnitine is a deriviative of carnitine that has a diethylamino group instead of 
trimethylamino group, can be used as a sole carbon and nitrogen source in P. putida 
(Kleber et al., 1978). The biological importance of these carnitine related enzymes has 
not yet been examined, but the findings suggest that there is either enzymatic flexibility 
in some of the carnitine metabolic enzymes, or that there are additional, naturally-
occurring carnitine-like compounds in the environment. 
 
1.2.9. Conclusions and Future Directions 
 Bacteria import, synthesize, and metabolize carnitine through various pathways 
that have different physiological effects. Our understanding of carnitine transport and 
metabolism is derived from studying extracellular or facultative intracellular bacteria and 
examining how carnitine is obtained from either the environment or within an animal 
host. However, there are a number of important questions that remain to be addressed 
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related to carnitine-dependent transcriptional regulation, the ecological roles of carnitine, 
the role of carnitine in obligate intracellular bacteria, and its importance during non-
pathogenic interactions like symbioses.  
In relation to obligate intracellular pathogens, we know surprisingly little. For 
instance, to date, no spirochetes have been identified to use carnitine, but the causative 
agent of syphilis, Treponema pallidum, is predicted to harbor a carnitine transporter 
(Saier & Paulsen, 2000; Smajs et al., 2005). With T. pallidum only having a thousand 
genes (Fraser et al., 1998), carnitine transport may be important survival in certain 
environments and for establishing infection. Furthermore, it is tempting to speculate that 
intracellular pathogens and symbionts can likely use carnitine based on the role of 
carnitine-fatty acid transport systems in the mitochondria, particularly in light of the 
endosymbiotic source of these organelles. As such, one might expect a role for carnitine 
import in the Rickettsiales.  
Beyond pathogens and symbionts, the impact of environmental metabolism of the 
osmoprotectants glycine betaine and dimethylsulfionylproprionate (DMSP) has been 
reasonably well studied (reviewed in (Curson et al., 2011; Welsh, 2000)), but carnitine 
has not received much attention in relation to its contributions outside of animal infection 
and likely deserves additional scrutiny. For instance, the source of carnitine detected in 
the environment (Warren, 2013a; Warren, 2013b) is unknown and we know very little 
about its half-life as a soluble compound in the environment or the flux rate of carnitine 
in any environment. A priori, one would assume an important role for carnitine 
metabolism, both aerobic and anaerobic, during animal decomposition on land or in 
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marine environments. In the deep oceans in particular carnitine utilization from fish and 
marine mammal carcasses might represent an important pathway to scavenge all 
available nutrients in this harsh environment. 
Finally, we know almost nothing about the mechanisms by which carnitine is 
bound and detected to mediate transcriptional regulation. Further investigations into 
CdhR-like, CaiF-like, and the predicted carnitine-sensing TetR-family regulators in Gram 
positives will be needed to understand how ligand detection is accomplished and 
converted into regulation of gene expression. Of particular import will be understanding 
the binding pocket of these regulators to determine if they maintain the cation-pi binding 
aromatic cage that typifies the known quaternary amine binding proteins crystalized to 
date. From an evolutionary perspective, CdhR likely arose after gene duplication from a 
GbdR-like ancestor, while the Gram positive TetR-family proteins are reasonably similar 
to the choline binding transcription factor BetI. Thus, characterization of any of these 
quaternary amine binding transcription factors will provide crucial understanding of 
ligand binding and, by homology, present likely binding residues in their respective 
paralogs. Beyond direct ligand-sensing transcription regulators, we do not know of any 
two-component systems or chemotaxis regulators that sense and response to carnitine. 
The GlrA/GlrK system may represent the actual carnitine-sensing input that impinges on 
CaiF to establish carnitine-sensitive gene induction. Additionally, many bacteria have 
been shown to chemotax towards the quaternary amines DMSP and glycine betaine 
(Miller et al., 2004; Seymour et al., 2010; Stocker & Seymour, 2012), and therefore any 
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1.2.11. Figures  
Figure 1. Structures of carnitine and related compounds discussed in this review. 
 
Figure 2. Diagram of the multiple pathways for carnitine metabolism in bacteria. 
Based on Uanschou et al. (2005). Metabolic steps described in this review are noted with 
numbered circles: (1) acylcarnitine hydrolase, HocS, ACH, EC 3.1.1.28; (2) gamma 
butyrobetaine hydroxylase, GBBH, EC 1.14.11.1; (3) oxidoreductase CntAB, EC 
1.14.13.-; (4) carnitine racemase, EC 5.1.-.-; (5) L-carnitine dehydrogenase, L-CDH, EC 
1.1.1.108; (6) D-carnitine dehydrogenase, D-CDH, EC 1.1.1.108; (7) beta-keto acid 
cleavage enzyme, BKACE, EC 3.-.-.-; (8) No ATP, spontaneous decarboxylation; (9) 
Nitrilase, EC 3.5.5.1; (10) Carnitine amidase, EC 3.5.1.73; (11) Carnitine methylase. 
Note that not all enzymatic steps have full EC descriptors at this time. 
 
Figure 3. Diagram of the Gamma butyrobetaine-Crotonobetaine-Carnitine cycle. 
Primarily based on Elssner et al. (2001), with additions based on Bernal et al. (2008) and 
Cánovas et al. (2003). GBB – gamma-butyrobetaine, CaiA - crotonobetaine reductase, 
CaiB - CoA transferase, CaiC - betaine:CoA ligase, CaiD - enoyl-CoA hydratase, 
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1.3 Catabolism of host-compounds during extracellular bacterial infections 
1.3.1 Abstract  
Efficient catabolism of host-derived compounds is essential for bacterial 
survival and virulence. While these links in intracellular bacteria are well-studied, such 
studies in extracellular bacteria lag behind, mostly for technical reasons. The field has 
identified important metabolic pathways, but the mechanisms by which they impact 
infection and in particular, establishing the importance of a compound’s catabolism 
versus alternate metabolic roles has been difficult. In this review we will examine 
evidence for catabolism during extracellular bacterial infections in animals and known or 
potential roles in virulence. In the process, we point out key gaps in the field that will 
require new or newly adapted techniques. 
 
1.3.2 Introduction 
To successfully cause infection, a bacterium must incorporate and metabolize 
molecules derived from the host. General maintenance and expression of virulence 
factors are minimal requirements, while efficient catabolism and resultant growth can 
lead to successful colonization and improved evasion of immune-mediated clearance. 
Here we will use the strict definition of catabolism: degradation of a compound yielding 
energy [Russell and Cook, 1995]. When we view bacterial catabolism in this way, the 
most straightforward analogy is to view the host as the growth medium [Brown et al., 
2008]. This paradigm, while it’s been around for 135 years and has seen intermittent 
resurgence [Garber, 1960; Pasteur, 1878], has seen many contributions within the last 
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two decades. Armed with the powerful techniques of modern bacteriology, solving the 
problems of in vivo bacterial catabolism, growth, and resultant virulence should be easy, 
right? 
In one sense the answer is, undoubtedly, yes. In the case of intracellular 
pathogens, the eukaryotic host cells generate the correct 'growth medium' in the infected 
compartment. Experiments in tissue culture, presuming the correct cell type and growth 
condition, can very closely mimic the experience of the bacteria in a similar cell within 
the whole organism. These in vitro systems benefit tremendously from a few handy 
simplifications: (i) one or a few host cell types, (ii) high bacteria to host cell ratio, and 
(iii) facile monitoring and manipulation of both sides of the interaction. For many 
intracellular pathogens, their tractability has led to a reasonably good understanding of in 
vivo catabolism and its connection to virulence, particularly for Legionella, Listeria, 
Salmonella, and Mycobacterium, which have been well reviewed previously [Eisenreich 
et al., 2010] and will not be repeated here. Instead, this review focuses on extracellular 
bacterial pathogens; the little that is known, the vast areas that are not, and some thoughts 
about how to address the current unknowns. Our principle goal is to discuss what is 
known about the catabolic pathways governing in vivo growth and survival. 
For extracellular bacteria, the primary technical issue can be boiled down to one 
thing: not knowing the growth medium. What looks to be straightforward turns out to be 
fraught with problems. We have certainly made important headway by using overly-
simplified models, but we are left with a wide gap between these models and reality. We 
lose the dynamic, homeostatic nature of the extracellular niche when we remove this 
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niche from the organism or reconstitute it from parts [Smith, 2000]. Such in vitro 
characterizations of the extracellular milieu lack dynamics, while in vivo experiments are 
plagued with the problems readily overcome when studying intracellular pathogens: (i) 
numerous host cell types, tissues, and organs compared to a specific microenvironment 
within a specific cell type; (ii) overwhelming number of host cells to bacterial invaders; 
and (iii) poor spatial and temporal resolution of goings-on within the infection ([Smith, 
2000] provides a thought provoking analysis of conceptual and technical problems 
associated with the study of catabolism in vivo). These issues do not make identifying 
important metabolic pathways overly difficult, rather they make dissecting the specific 
mechanism by which an implicated pathway alters in vivo growth, catabolism, and 
virulence incredibly hard. To bridge this gap in knowledge we need new techniques, 
greater incorporation of techniques from other fields, and a push towards mechanistic 
understanding of the importance of in vivo catabolism and specific catabolic pathways.  
 
1.3.3. Assessing catabolism vs. alternate metabolic usage 
 Catabolism has been extensively studied in vitro, where chemostats, 
microcalorimeters, and oxygen utilization measures have helped biochemists and 
microbiologists decipher the multiple roles of metabolized compounds during growth. 
Even within these in vitro systems, determining a compound’s actual utilization requires 
both growth measures and flux analyses to extract information about the role of a 
compound in energy production versus growth yield [Russell and Cook, 1995]. Overlaid 
onto the challenges of studying catabolism in vivo is the issue that many important 
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compounds have multiple roles within the cell. Amino acids can be catabolized as an 
energy source, but they also participate in protein synthesis, are interconverted to other 
amino acids, and can have other functions: proline is a useful osmoprotectant [Csonka 
and Hanson, 1991]; serine is used to synthesize phosphatidylserine and as part of the C1 
acquisition cycle [Anthony, 2011; Geiger et al., 2010]; tryptophan feeds into formation of 
many secondary metabolites including virulence-related molecules like PQS produced by 
P. aeruginosa [Farrow and Pesci, 2007], etc. Amino acids are not alone in having 
multiple functions: host-derived carbohydrates can often be used to decorate pathogen 
surfaces and incorporated into exopolysaccharides, while lipids can impact efflux 
mechanisms and envelope stress. In this review, we have tried to catalogue the strength of 
evidence for catabolism itself versus alternate usage of host-derived compounds. We will 
examine major classes of compounds in the following subsections, which are summarized 
in Table 1. 
 
1.3.4. Carbohydrates 
 Colonization of mucosal surfaces is a key step in pathogenesis for many 
opportunistic pathogens. The mucosal surface is dominated by mucins, large 
glycoproteins that coat mucosal surfaces to trap particles and infectious agents [Thornton 
et al., 2008]. Mucins are enriched in sialic acid, an anionic nine-carbon carbohydrate 
[Vimr et al., 2004], thus it is not surprising that many mucosal pathogens have acquired 
pathways for sialic acid utilization. Some of the best evidence for catabolism of 
carbohydrates as a major source of energy is utilization of sialic acid by intestinal 
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pathogens. Pathogenic species of Vibrio can be transmitted by the ingestion of 
contaminated food or water and subsequently colonize the host intestine. V. cholerae 
causes acute diarrheal disease and V. vulnificus results in gastroenteritis that can lead to 
septicemia in immunocompromised individuals. V. vulnificus carries the nan genes for 
sialic acid degradation on its core chromosome, whereas V. cholerae strains have the nan 
genes on the Vibrio Pathogenicity Island 2 (VPI-2) [Almagro-Moreno and Boyd, 2009; 
Jeong et al., 2009]. In vitro, deletion of the nan genes in both species results in the 
inability to utilize sialic acid as a sole carbon and energy source and in vivo studies 
demonstrate colonization and survival defects in the intestine of infected mice [Almagro-
Moreno and Boyd, 2009; Jeong et al., 2009]. In vitro growth assays for both species 
reveal no toxic effects from sialic acid accumulation intracellularly or in the growth 
medium due to this defective catabolism, suggesting that the observed growth defects in 
vitro correlate with the colonization defect in the intestine. Jeong et al. postulate that 
sialic acid catabolism contributes to pathogenesis by contributing directly to 
multiplication (energy production and growth yield) and Almagro-Moreno et al. point out 
that it may serve as a carbon source in times of high competition when colonizing the 
intestine. Both groups concur that sialic acid catabolism as an energy source ensures 
survival during infection [Almagro-Moreno and Boyd, 2009; Jeong et al., 2009]. 
 As with many potential catabolic substrates, sialic acid has other uses for some 
pathogens that can cloud the interpretation of in vivo studies. Sialic acid can be used to 
sialate lipids or exopolysaccharides as a means of immune evasion by bacterial pathogens 
[Vimr et al., 2004]. Deletions in genes encoding sialidases or sialic acid transporters have 
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been shown to cause colonization and survival defects in non-typeable Haemophilus 
influenzae, the major causative agents of middle ear infections [Jurcisek et al., 2005], as 
well as respiratory tract infections by Streptococcus pneumoniae [Marion et al., 2011]. In 
these studies, while sialic acid utilization as a catabolic substrate is possible, alterations in 
sialylation are also a potential mechanism. In addition, it is critical to separate catabolism 
from incorporation. It is possible that while sialic acid is broken down as an energy 
source by some of these pathogens, its importance may be for supplying carbohydrate 
substrates for sugar-intensive biosynthetic processes like capsule synthesis or biofilm 
formation. Degradation of sialic acid requires an initial investment of ATP and produces 
acetate and ammonia during partial metabolism even prior to the catabolic steps that 
would lead to energy production [Vimr et al., 2004]. The resultant ammonia could 
function as a nitrogen source, while the acetate may be important in a more global sense 
because acetate, and its co-regulated acetyl-CoA and acetate phosphate pools, impact 
lysine acetylation [Verdin and Ott, 2013]. Lysine acetylation has been implicated in 
global regulation of central metabolism and multiple catabolic pathways [Wang et al., 
2010]. Consequently, such metabolic byproducts can impact catabolism of other 
substrates indirectly. 
 The carbohydrates deoxyribose and fucose have been implicated as catabolic 
substrates for pathogenic strains of Escherichia coli. E. coli is a Gram negative bacterium 
that is a normal inhabitant of the human intestinal flora. Pathogenic strains can be 
transmitted through fecal-oral or fecal-ureter route where they can colonize the intestine 
or the urinary tract resulting in extreme diarrhea or urinary tract infections, respectively. 
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For deoxyribose, many pathogenic E. coli contain the deoK operon encoding proteins for 
deoxyribose catabolism, allowing these organisms to use deoxyribose as a carbon source 
[Bernier-Febreau et al., 2004; Jonsen et al., 1959]. Strains incapable of deoxyribose 
catabolism have defects in intestinal colonization and are outcompeted by those strains 
capable of deoxyribose catabolism [Martinez-Jehanne et al., 2009]. It is known that 
deoxyribose is present in the intestinal mucus, the colonization defect of the deoK mutant 
is clear, and the presence of the deoK gene on one of the pathogenicity islands underlines 
its contribution to virulence, however, the evidence for direct catabolism is not strong.  
It is well documented that the gut is populated with a variety of bacteria and that 
metabolite sharing is a common phenomenon. Freter’s nutrient theory states that in order 
for invading bacteria to compete and thrive in the intestine it must be able to more 
efficiently utilize a limiting nutrient better than resident bacteria [Freter et al., 1983]. 
Although E. coli can utilize fucose as a carbon source [Hacking and Lin, 1976], they do 
not contain genes encoding fucosidases [Hoskins et al., 1985], which cleave fucose from 
glycans. But by being in close proximity with the gut commensal Bacteroidetes 
thetaiotamicron and other strains, E. coli can capitalize on B. thetaiotamicron’s fucose 
cleavage by importing and catabolizing released fucose [Salyers et al., 1977; Xu et al., 
2003]. In a bovine rectal colonization model, wild type E. coli O157:H7 out-competed a 
fucose catabolic mutant, fucAO (fucose aldolse and oxido-reductase respectively) 
exhibiting the importance of fucose utilization for E. coli colonization and maintenance 
of the population [Snider et al., 2009].  
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E. coli in vitro gene expression studies showed that genes involved in 
catabolism of gluconate and other sugars were highly induced when cells were grown in 
intestine-like conditions, 50% mouse cecal mucus. Gluconate was shown to be the 
preferred nutrient in vitro through mutation in edd, which encodes a 6-phosphogluconate 
dehydratase, which catalyzes a key step in gluconate entry into the Entner-Doudoroff 
pathway. In a mouse cocolonization model, the edd mutant had a defect in initiation and 
maintenance of intestinal colonization [Chang et al., 2004]. The gluconate catabolism 
was also shown to be important for intestinal colonization of V. cholerae, as the edd 
mutant failed to colonize the intestine in an infant mouse model [Patra et al., 2012]. 
 
1.3.5. Amino Acids 
 We previously remarked on the pleiotropic roles of amino acids within the cell. 
This integration with the whole metabolome often makes concrete conclusions about 
amino acid catabolism difficult. The best evidence for catabolic utilization comes from 
Campylobacter jejuni, for which serine is a preferred carbon and energy source [Leach et 
al., 1997]. C. jejuni is commensal to avian species but is spread to humans through the 
consumption of contaminated food and causes acute gastroenteritis. Mutations in L-serine 
deaminase (sdaA), which converts serine to pyruvate, lead to major C. jejuni colonization 
and survival defects in both the avian and mouse intestines, and the mouse liver 
[Hofreuter et al., 2012; Velayudhan et al., 2004]. Likewise, in uropathogenic E. coli 
(UPEC), L-serine can also be catabolized as a sole carbon and energy source [Su and 
Newman, 1991]. For UPEC, L-serine utilization is important for colonization of the 
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bladder, as an sdaAsdaB double mutant was defective in colonization of the mouse 
bladder [Anfora et al., 2007]. The reaction catalyzed by serine deaminase directly 
produces pyruvate, strongly suggesting serine as a catabolic substrate. However, pyruvate 
is also a central player in anabolic reactions and while separable in vitro, in vivo 
attribution of mechanism is difficult. Also, given the additional product of the reaction, 
ammonia, the role of L-serine as a nitrogen source in these infection models cannot be 
wholly discounted.  
 As mentioned above, C. jejuni has a propensity to utilize amino acids within the 
intestines of mice and birds, rather than the dietary and mucin-derived carbohydrates that 
are often preferred by other intestinal pathogens [Velayudhan and Kelly, 2002]. 
Therefore, it is not surprising that C. jejuni genes responsible for amino acid catabolism, 
including aspartate and proline, have also been shown to be important in intestinal 
colonization [Guccione et al., 2008; Hofreuter et al., 2012]. Proline is also important 
during Staphylococcus aureus burn infections and abscess formation [Schwan et al., 
1998]. In these studies, it is not easy to ascertain the role being played by proline, as the 
gene disruptions were made in the proline transporter. Proline can be transported into the 
cell and accumulated in the cytosol, where it can function as an osmoprotectant. 
Accumulation of various host-derived osmoprotectants is important for a variety of 
infectious agents and infection sites [Sleator et al., 2001], therefore it is likely proline 
plays this role for S. aureus, though catabolism has not been ruled out. 
 Mekalanos’ group took a top down approach when it came to identifying factors 
that contribute to the virulence of V. cholerae. Using a suckling mouse intestine model, 
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they paired individual LysR-type transcriptional regulator mutants with the parental strain 
and tested for in vivo fitness of the mutant compared to the wild type [Bogard et al., 
2012]. Of the 38 LysR-family mutants tested, two mutants were impaired in colonizing 
the intestine, one of which was metR, the methionine biosynthesis regulator that also has 
a role in catabolism [Bogard et al., 2012]. Two MetR controlled genes that are 
particularly important for mouse intestine colonization are metJ which encodes a 
methionine repressor and glyA1 which encodes serine hydroxymethyltransferase [Bogard 
et al., 2012]. GlyA1 is potentially interesting, as it controls the flux of glycine to pyruvate 
via serine, but also glycine biosynthesis via serine. Based on the evidence from C. jejuni 
infections mentioned previously, serine may be abundant in the intestine and could play a 
role in either the catabolic or anabolic reactions; particularly the later if glycine or other 
glycine precursors are limiting. 
 The concentrations of host-derived metabolites are substantially altered during 
bacterial infection, particularly near the site of infection [Beisel, 1975; Smith, 2000]. A 
dramatic case of such metabolic change occurs during chronic lung infections of people 
with the genetic disorder cystic fibrosis by the opportunistic pathogen Pseudomonas 
aeruginosa [Burns et al., 1998]. During these chronic infections, tissue damage, immune 
response, and bacterial activities sculpt the mileu, resulting in thick mucus plugs in 
airways that can be expectorated as sputum [Boucher, 2004]. P. aeruginosa catabolizes 
many amino acids within sputum from cystic fibrosis patients in vitro, but displays a 
preference for alanine [Palmer et al., 2007]. The importance of alanine catabolism was 
demonstrated in a chronic rat lung infection model, showing that P. aeruginosa mutants 
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incapable of converting alanine to pyruvate could not compete well against wild-type P. 
aeruginosa [Boulette et al., 2009]. Similar to the cases of serine catabolism in C. jejuni 
and UPEC, this is a deamination in P. aeruginosa, resulting in the formation of ammonia 
along with pyruvate. Therefore, while loss of alanine catabolism is among the likely 
mechanisms driving the mutant phenotype, the impact of pyruvate-dependent anabolic 
pathways and the role of the released ammonia need to be considered.  
 
1.3.6. Other compounds 
 Glycerol can be phosphorylated and incorporated into glycolysis and is also a 
critical contributor to phospholipid synthesis. In Borrelia burgdorferi, the causative agent 
of Lyme Disease, deletion of the glycerol catabolism gene glpD, which converts glycerol 
to dihdroxyacetone phosphate (DHAP), results in clear replication defects within the 
adult tick vector and nymph stage, while the deletion did not have any effect on growth 
or survival within the mouse model of infection [He et al., 2011; Pappas et al., 2011]. 
Deletion of glpD with the rest of the glpDFK operon resulted in a robust growth defect 
within the tick [He et al., 2011], likely because deletion of the entire operon limits 
glycerol incorporation into phospholipids in addition to elimination of a shunt of glycerol 
into glycolysis [Pappas et al., 2011].  
 L-lactate can be the sole energy source and is the preferred carbon source for the 
opportunistic dental and endocardial pathogen Aggregatibacter actinomycetemcomitans 
(Aa), even in the presence of high-yield compounds such as glucose or fructose [Brown 
and Whiteley, 2009]. Like many bacteria, Aa exists in multispecies communities and is 
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often found in conjunction with oral streptococci, which produce L-lactate as a catabolic 
product.  Streptococcus gordonii and an Aa lctD (NAD independent L-lactate 
dehydrogenase) mutant co-inoculated into a mouse thigh abscess model was used to show 
that lactate catabolism in Aa is important in vivo for establishing polymicrobial infections 
[Ramsey et al., 2011].  
 The conversion of pyruvate to lactate by lactate dehydrogenase (ldh) is also an 
important part of NAD+ regeneration in fermentative systems, which allows the 
continued operation of glycolysis. An example can be found in Enterococcus faecalis, a 
pathogen that can cause endocarditis, bacteremia, urinary tract infections and meningitis. 
E. faecalis has two ldh genes and when both are deleted there is a defect in colonization 
and persistence of the bacterium in an intravenous mouse model infection in the liver and 
kidney [Rana et al., 2013]. While NAD+ also functions in other metabolic processes, the 
flux required by glycolysis suggests that the ldh activity in E. faecalis plays its main role 
in enabling robust glycolysis. 
 
1.3.7. The importance of catabolism and its link to virulence 
Catabolism of host-derived compounds is necessary for successful infection. 
These compounds may be derived directly from the host or by scavenging compounds 
released by other pathogenic or commensal bacteria [Freter et al., 1983]. The studies 
described above have determined metabolic pathways important for bacterial survival and 
growth within the host, but in most cases, direct evidence for catabolism contributing to 
the in vivo phenotype is limited (well described in [Vimr, 2013]). From the most human-
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centric standpoint, the exact mechanism is not critical to drive therapeutic development – 
efficacy and safety trump mechanism. However, we think that understanding the direct 
mechanism may lead to better future therapies by suggesting synergistic targets to inhibit 
with the appropriate drug cocktail. For example, if serine was truly a major energy source 
for a pathogen, combining the serine pathway inhibitor with an inhibitor of the next most 
important energy source would likely boost efficacy. However, if the importance of 
serine is to provide a ready supply of glycine or contribution to C1 or C2 biosynthetic 
units, a better strategy would be to target alternate pathways that produce the limiting 
intermediate. Therefore, a more complete understanding of the nature of the metabolic 
deficiency during infection will benefit future antimicrobial therapeutic development. 
 Determining the link between catabolism and virulence can be difficult. It is 
obvious that eliminating catabolism of host-derived compounds decreases the 
pathogenicity of the bacterial population. On the other hand, microbiologists often look at 
virulence in terms of production of anti-host products termed virulence factors, while 
catabolic pathways important for survival would fall under the term virulence 
determinant.  
Under the heading of virulence determinant, we can certainly include all of the 
metabolic pathways discussed in this review. Each genetic mutation reduced the survival 
or growth of the bacteria and thus contributed to virulence in the model discussed. While 
virulence determinants can work indirectly, all of the bacterial species mentioned here 
also produce secreted virulence factors. Most of these are transported through the general 
or type III secretion systems and target host cells or specific pathways to boost 
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pathogenesis by increasing host damage and decreasing immune clearance. In the 
simplest sense, producing virulence factors requires energy and therefore are dependent 
on catabolic pathways. However, it is interesting to note two things. First, secreted 
proteins are generally less energy intensive than membrane or cytosolic proteins [Smith 
and Chapman, 2010] and consequently metabolically cheaper. Second, secreted virulence 
factors are a good investment during nutrient stress, as many described virulence factors, 
particularly extracellular enzymes transported by the general secretion system, can also 
be thought of as nutrient requisition systems [Rohmer et al., 2011], providing amino acids 
(proteases), sugars (glycosidases), nucleic acids (nucleases), and lipids, glycerol, and 
polar headgroups (lipases). The direct regulatory links between specific catabolism and 
virulence factor production are less readily apparent. However, it is very clear that, 
globally, the cell’s nutrient and energy status strongly impacts virulence factor 
production, reviewed in [Poncet et al., 2009]. 
 
1.3.8. Methods: current and a call for renewed and newly-adapted techniques 
Most studies of bacterial catabolism have not started as such. With some 
exceptions described here, catabolic pathways have often been identified during medium 
or high-throughput screens to identify mutants with altered in vivo survival. Moderate 
throughput has generally relied on direct counts of surviving colonies, often in 
competition with wild type cells. High-throughput techniques that have been particularly 
successful are in vivo expression technology (IVET) [Slauch et al., 1994], signature-
tagged mutagenesis (STM) [Lehoux and Levesque, 2000], and transposon insertion 
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sequencing (TnSeq) [van Opijnen et al., 2009], all of which offer ways to assess large 
numbers of mutants simultaneously during infection. While generally useful, there are 
caveats associated with these methods of identification of catabolic pathways. One 
complication is that there are a variety of available carbon sources in a host – many at 
very high concentrations – so the contribution of any one carbon source may be relatively 
small, particularly for catabolically versatile bacteria. 
Direct labeling: In the very simplest sense, we want to identify what compounds 
bacteria are eating in the host to provide them with energy, carbon, and nitrogen. There 
are direct and indirect ways to do this. A classic and still very useful method is to track 
the fate of radiolabeled substrates. While simple in vitro, many technical issues crop up in 
vivo. In general, a substrate is fed or injected into the animal and conversion of the 
substrate into radiolabeled CO2, acetate, or some other catabolic product is monitored. 
By comparing to an uninfected animal one can determine the proportion of compound 
utilized during infection. However, practically this is made very difficult for two reasons. 
First, host metabolism changes during infection, alterations due to bacterial processes are 
difficult to separate from changes due to the way the host changes its metabolism to fight 
the pathogen [Beisel, 1975]. Second, there is the gut microbiota, which by sheer numbers, 
provide a huge catabolic reservoir to convert substrates of interest. This leaves direct 
labeling useful mainly in two cases: gnotobiotic mice and compartmentalized substrates. 
While the former eliminates or reduces issues with gut metabolism, the later takes 
advantage of the fact that many compartments and organs maintain stable pools of 
compounds that are not rapidly converted or moved from the compartment. Examples 
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include particular proteoglycans in the joints, certain glycosphingolipids in the brain, and 
choline in the lung and brain. Other compounds that can be studied with this technique 
are those that are not catabolized by the host, such as L-carnitine, which while utilized in 
the carnitine/acylcarnitine shuttle system, is not catabolized by host cells [Peluso et al., 
2000], although its anaerobic breakdown by the gut flora shows important links to 
cardiovascular health [Koeth et al., 2013]. 
Stable isotope probing: Stable isotope probing has been exceptionally useful for 
the study of catabolic processes in microbial ecology [Neufeld et al., 2007]. Briefly, an 
organism catabolizing a heavy-isotope substrate will incorporate the isotope into their 
DNA and the DNA of an otherwise ‘light’ organism will shift towards ‘heavy’. This shift 
is assessed with cesium gradient ultracentrifugation followed by fractionation. This 
technique falls victim to the same issues as direct radiolabeling, but the cesium gradient 
method allows discrimination of the source of the DNA by specific nucleic acid 
hybridization techniques. This technique, however, directly assesses the incorporation of 
label into DNA, an anabolic process. While these building blocks can be derived from 
catabolic end products and siphoned from catabolic intermediates, it is not a direct 
marker of catabolism. 
Using transcriptional evidence to understand catabolism: One of the best ways 
to understand the range of possible food choices for the bacteria (but not their relative 
importance) is to look at the genes whose expression is induced in response to the host. 
As with the rest of bacterial catabolism in the host, the intracellular pathogens have 
yielded much more compelling transcriptional stories than their extracellular counterparts 
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at the site of infection. For extracellular pathogens, the staggeringly abundant host RNA 
has generally made sensitive measurement of the bacterial transcriptome difficult. There 
are some exceptions, where bacterial abundance or localized infections have allowed ex 
vivo transcriptomics [Bielecki et al., 2008; Chaffin et al., 2012; Larocque et al., 2005], 
although this field is changing rapidly with many host RNA subtraction techniques and 
massively parallel sequencing. Therefore, many host-pathogen systems are now 
sufficiently sensitive to determine the transcriptome of the bacterial population during 
infection.  
A particularly useful application of these techniques would be to couple 
transcriptomics and metabolomics during infection in order to determine what 
compounds the bacteria senses and simultaneously measure the fate of the related 
metabolites. In most infection sites, the bacteria may not be able to exceed host 
homeostasis for many metabolites, therefore simultaneous analysis of the local 
transcriptome of the host may help determine compounds that the host senses it must 
make more of, essentially responding to a small decrease by making or transporting more 
of a given compound. 
While global transcriptomics has its place, often we are asking questions about 
specific pathways or genes. In these cases, sensitive and quantifiable reporters are critical 
tools for analysis. The current generation of reporter genes works well for microscopic 
evaluation (fluorescent proteins) and high levels of expression (lux and lacZ). While 
these are both quantifiable under optimal conditions, a better proposition might be to use 
the power of reporter genes in combination with the sensitivity of radiodetection. One 
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potential method we have been discussing is to use the SNAP and CLIP proteins (NEB) 
as reporters, with increasing the sensitivity and specificity by labeling with radioactive 
substrates instead of fluorescent or biotin-linked substrates. A strain carrying one of the 
reporters as a translational fusion to the gene of interest and the other to a control gene 
would allow relative expression values to be sensitively determined by SDS-PAGE of the 
labeled tissue homogenate followed by autoradiography.  
  
1.3.9. Conclusions 
Bacterial nutrition is a critical component of understanding infection and developing 
effective treatments. Part of this nutrition is utilization of compounds as energy sources, 
i.e. catabolism. Here we have provided some glimpses of specific compounds used by 
pathogens, but we’re confident that the current work only scratches the surface of 
important host-derived compounds. The challenge for the field is to generate methods or 
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1.4. Carnitine transport 
1.4.1. Background 
 In order for nutrients to get into the cell and for waste products to exit they must 
cross cytosolic membrane. Gram-negative bacteria have an additional membrane, the 
outer membrane that is semi-permeable and slows the diffusion of small hydrophilic 
molecules while inhibiting the passage of large and charged molecules [1, 2]. The outer 
membrane has transmembrane protein channels called porins that can allow passage of 
specific or nonspecific cargo and have many functions, one of which is to allow entry of 
nutrients and solutes [3, 4]. The cytoplasmic membrane acts as a semi-permeable barrier 
that prevents passive leakage of the cytosolic components but does not completely inhibit 
small or nonpolar molecules from diffusion, like oxygen or carbon dioxide. Large, 
hydrophilic, or charged molecules must be transported in and out of the cell. 
 Transport of nutrients into the cytoplasm occurs via simple diffusion, facilitated 
diffusion, or active transport. Simple diffusion is the movement of small, hydrophobic as 
nonpolar molecules directly across the membrane. Facilitated diffusion moves larger, 
polar, charged, and hydrophilic molecules into the cell using membrane proteins that span 
the cytosolic membrane. Both simple and facilitated diffusion are typically put in the 
same category of passive transport because neither requires energy and the molecules 
move from a higher concentration to a lower concentration or are driven by the 
electrochemical gradient of the cell [5]. However, active transport requires energy in 
order to translocate molecules and is often coupled with ATP hydrolysis or actively 
maintained ion gradients [5]. 
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Carnitine is a polar zwitteronic compound that cannot pass through cell membrane and is 
actively transported using either ATP hydrolysis, ion motive force, or driven by a 
substrate:product antiporter. Many bacteria utilize and benefit from carnitine transport by 
using it as osmoprotectants, inducers of virulence factors, or as sole carbon, nitrogen, and 
energy sources [6], as discussed earlier in this section. 
 
1.4.2. ATP-Binding Cassette transporter 
 ATP-binding cassette transporters, ABC transporters for short, are conserved 
through all domains of life [7] and have been present in every species studied as of 2006 
[8]. The majority of characterized eukaryotic ABC transporters export substrates out of 
organelles or the cell, whereas most bacterial ABC transporters import substrates [9]. 
ABC transporters are composed of four core domains that span the lipid membrane and 
drive translocation of solutes by ATP hydrolysis. The core transporter forms a pore which 
ligand is transported into the cell, and is composed of two transmembrane domains 
(TMD) that bind ligand and two nucleotide binding domains (NBD) that bind and 
hydrolyze ATP. The core forms inward and outward facing configurations: the inward 
conformation has the TMD open to the cytoplasm, and the outward conformation has the 
TMD open to the periplasm [10]. ABC transporters also have substrate binding proteins; 
periplasmic in Gram-negative bacteria, or tethered to the cell membrane in Gram-
positive, which binds ligand and delivers it to the TMD [7, 9].  
ABC importers are divided into three classes or types. Type I and Type II transporters 
differ in that  Type I have an inward facing TMD and fewer transmembrane domains, 
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whereas Type II have more transmembrane domains, an outward facing TMD. 
Additionally, the interaction between the substrate binding protein (SBP) and the core 
transporter is weakened upon binding of substrate in Type II transporters [11, 12]. A 
recently categorized ABC transporter is Type III or ECF for energy-coupling factor. Type 
III transporters consist of the TMD-NBD and an S component instead of the SBP [11]. 
The S component binds substrates that are typically metal ions and vitamins [13]. 
 
1.4.3. Components of ABC transporters 
 Bacterial import of molecules via an ABC transporter requires a substrate 
binding protein that binds the substrate for delivery to the core transporter TMD-NBD. 
The SBP is either tethered to the cell membrane by an N-terminal lipid anchor or is 
covalently attached the TMD, as in Gram-positive bacteria. In Gram-negative bacteria, 
the untethered SBP is periplasmic [14, 15] and is in stoichiometric excess compared to 
the core components to increase the probability of substrate import. A good example of 
this is the E. coli maltose import system, which has 30 fold more SBP than TMD-NBD 
[16]. To date, all SBPs have the same tertiary structure with two lobes joined by a hinge. 
The SBP is in an open conformation until substrate binding when the lobes close around 
the substrate, described by the “venus fly trap” model [17]. Each SBP binds one substrate 
molecule at a time and delivers it to the TMD [18].  Ligand specificity of a SBP is not 
necessarily limited to one substrate, and some SBPs have multiple ligands; notable 
examples are OpuC in B. subtilis (carnitine, crotonobetaine, and γ-butyrobetaine) [19, 
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20], LivJ in E. coli (leucine, isoleucine, and valine) [21], and CbcX in P. aeruginosa 
(choline and glycine betaine) [22]. 
The transmembrane domain of the ABC transporter spans the cytoplasmic 
membrane and is composed of two homodimers or heterodimers. Although each dimer 
typically has 6 alpha helices, 10-20 alpha helices have been reported [11]. TMD’s have 
one or two substrate binding sites, although the two binding site configuration is more 
common [23]. A crystal structure of the E. coli BtuCD TMD revealed a 16 amino acid 
helix-turn-helix EAA motif, also known as the L loop, is conserved and located in the 
cytoplasm [24, 25].  This EAA motif that interfaces with the NBD and this interaction is 
likely how NBD conformational changes driven by ATP hydrolysis are transduced to the 
TMD [14]. Similar to the SBP, TMDs can bind and interact with multiple SBPs, which is 
observed in P. aeruginosa CbcWV [22] and Salmonella typhimurium HisQMP [26]. 
 Energy required to drive import and export is generated from ATP hydrolysis. 
NBDs are highly conserved and are homologous throughout the family with seven 
domains: aromatic, Walker A, Walker B, ABC signature domain (LSGGQ), and Q, D, 
and H loops [7]. Two NBDs are required for each transporter complex and both must be 
functional for ATP hydrolysis and transport of substrates [9]. 
 
1.4.4. Mechanism of action 
 Import by ABC transporters begins with the SBP binding to its ligand and 
interacting with the TMD causing a conformation change, which is thought to initiate 
binding of ATP to the NBD [7]. The two NBDs each bind a magnesium-ATP, which 
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catalyzes dimerization, wherein the TMDs switch between the inward and outward 
conformation (or outward to inward depending on type of transporter). This interaction, 
ATP binding, and switching of the TMDs, is thought to transmit a signal to the SBP to 
release the substrate into the middle of the TMDs [9]. ATP hydrolysis takes places, 
releasing ADP, inorganic phosphate, and substrate resulting in what is called the “power 
stroke”, all of which resets the NBD and TMD for the next cycle of import [9, 12]. 
 
1.4.5. Carnitine and ABC transporters 
Gram-positive and Gram-negative bacteria use ABC transporters to import 
carnitine for multiple uses: osmoprotection, cryoprotection, barotolerance, bile tolerance, 
and as a carbon, nitrogen, and energy source [6]. The components of the P. aeruginosa 
carnitine ABC transporter are located in two separate operons: the TMD and NBD are in 
the cbcXWV operon, and the SBP, caiX, is encoded in the carnitine catabolism operon. 
cbcV encodes the NBD and the TMD encoded by cbcW is predicted to have six 
transmembrane alpha helices, resulting in a total of 12 helices in the membrane spanning 
component upon homodimerization [27]. The SBP caiX is in the first gene in the 
carnitine catabolism operon and imports carnitine, acetylcarnitine, and butyrylcarnitine. 
The molecular details of how CaiX binds its ligands are not known but may be similar to 
the B. subtilis OpuCC protein, which binds carnitine, glycine betaine, and choline [20]. 
The cleft of OpuCC has an aromatic girdle composed of four tyrosine residues that 
interact with the trimethylammonium through cation-ᴨ and hydrophobic interactions and 
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the carboxyl group is bound by hydrogen bonding to the amino acids glutamine, serine 
and asparagine within the binding pocket [20]. 
 
1.4.6. Betaine/choline/carnitine transporters (BCCT) 
BCCT transporters, as the name would suggest, transport the compatible solutes 
choline, carnitine, and glycine betaine, all of which are quaternary amine compounds. 
More recently the substrate specificity has been broadened to include other compatible 
solutes: proline betaine, acetylcholine, and dimethylsulphoniopropionate [28]. 
Structurally, BCCTs typically have 12 transmembrane domains with the N- and C-
termini extending into the cytosol. The driving force behind transport of substrate is 
either proton motive force, sodium motive force, or less commonly by substrate: product 
antiport, including a quaternary amine carnitine:γ-butyrobetaine antiporter. The most 
widely studied carnitine BCCTs are the CaiT orthologs from E. coli and Proteus 
mirabilis. CaiT is a substrate:product antiporter that imports carnitine during anaerobic 
conditions when glucose and a final electron acceptor are absent [29]. Under those 
conditions, carnitine and its metabolite crotonobetaine work as final electron acceptors 
and are both converted to gamma butyrobetaine, which is exported as the product in the 
antiporter system [29]. Recent studies demonstrate that CaiT binds carnitine or γ-
butyrobetaine, which is similar to the substrate binding protein OpuCC (mentioned 
above). CaiT binds the positively charge amine head group using cation-ᴨ and van der 
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1.5.  Regulation of bacterial gene expression 
In order for bacteria to be able to prosper and survive in their environment, they 
need to be able to precisely control the expression level and timing of critical genes. P. 
aeruginosa PAO1 has a large genome that consists of 5,570 predicted open reading 
frames that encode systems for exceptional metabolic diversity [1]. It would not be 
advantageous for bacteria to transcribe and translate unnecessary genes, as it uses the 
energy and resources of the cell. Therefore, the cell tightly regulates gene expression and 
protein function in many ways. So, as part of this dissertation centers on two different 
transcription factors and how they contribute to carnitine regulation, the focus of this 
section will be on initiation of transcription, one of the steps for gene regulation. 
 
1.5.1. Initiation of transcription 
 Transcription is a concerted effort between multiple proteins to make a RNA 
transcript. Chromosome size, compactness, DNA binding proteins, and epigenetics all 
play a role in initiation of transcription, but the required protein for transcription is the 
multisubunit RNA polymerase (RNAP). In order for RNAP to initiate transcription at a 
promoter, it must first interact with a sigma factor subunit to form the RNAP 
holoenzyme. P. aeruginosa PAO1 has 24 sigma factors that recognize and bind to the -10 
and -35 elements (or functionally equivalent elements) of the promoter DNA, which are 
located 10 and 35 bases upstream from the transcriptional start site [2, 3]. The -10 site 
interacts with domain 2 and the -35 site interacts with domain 4 of the RNAP sigma 70 
subunit, the housekeeping or primary sigma factor. Once the RNAP is bound, the DNA is 
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denatured and forms an open promoter complex. The sigma factor dissociates and allows 
for elongation of the transcript to occur [4].  
  
1.5.2. Transcription factors: inhibiting or promoting initiation 
 Transcription factors (TF) are proteins that couple environmental or internal 
signals and to gene expression. By binding specific DNA sequences TF activate or inhibit 
transcription by recruiting or blocking RNAP from binding promoter regions [5]. TF are 
divided into families based on protein structure but typically have a sensing domain and 
an effector domain. Transcription factors generally are two-domain proteins (ligand and 
DNA binding domains), meanwhile two component regulatory systems consist of a 
membrane bound kinase and a cytoplasmic response regulation that interacts with the 
DNA to regulate gene expression [6]. In order to be able to respond to a wide array of 
environmental signals, bacteria need many different regulatory proteins and in P. 
aeruginosa PAO1 there are over 400 transcriptional regulators [7]. TFs can act as 
activators or repressors, with some having dual activity.   
Activators bind DNA sequences called enhancers and are classified by the 
mechanism they use to recruit RNAP. Class I activators bind upstream of the promoter 
region and bind to the alpha subunit C-terminal domain (αCTD) of RNAP. Class II 
activators have an enhancer site that overlaps the promoter -35 element. Lastly, class III 
activators bind enhancers near or overlapping the promoter, resulting in a conformational 
change of the promoter DNA to an orientation that is favorable to RNAP binding [5].  
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Repressors inhibit transcription by impeding RNAP from binding the promoter. 
There are three basic mechanisms of repression: (i) repression by steric hindrance, 
typically by binding the promoter region and blocking RNAP from binding the promoter, 
(ii) looping the DNA making the promoter site inaccessible, and (iii) by modulating an 
activator [5]. 
Many promoters are controlled by two or more TFs that work in concert to tune gene 
expression to match environmental signals. Multiple activators can work together to 
recruit RNAP, or an activator can inhibit a repressor allowing for a second activator to 
initiate transcription. The regulatory circuit combinations are vast [5].  
 
1.5.3. The AraC transcription factor family 
 Proteins of the AraC transcription factor family, named after the arabinose 
responsive regulator in E. coli, are present in Gram-positive and Gram-negative bacteria 
and function as activators or repressors [8]. The family is defined by a conserved 99 
amino acid C-terminal domain [8], which consists of two helix-turn-helix motifs that bind 
to the major grooves of the DNA. Each monomer contacts one of the two half sites in the 
DNA binding sequence, typically oriented in direct repeats or inverted repeats [9]. While 
the N-terminal domain functions in ligand binding and dimerization, the sequence and 
structure of the N-terminus is not conserved, such that there are a number of subfamilies 
based on the identities of the N-termini. [10, 11]. The first 18 amino acids of the N-
terminal domain is the arm, which interacts with the DNA binding domain in the absence 
of ligand and holds the protein in a conformation not amenable to dimerization. On the 
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hand, in the presence of ligand the arm undergoes a conformational change to fold over 
the ligand [12, 13]. Both domains are linked together by a flexible linker that tethers the 
two domains together. The length, flexibility, and structure of the linker play a role in the 
regulation between the two domains [14, 15].  
The mechanism for AraC regulation of the arabinose operon araBAD in E. coli 
has been established and is termed the “light switch” mechanism (figure 1). In the 
absence of arabinose, the N-terminal arm binds the C-terminal DNA-binding domain 
allowing for a conformation that promotes the DNA-binding domains to bind the half 
sites I1 and O2, looping the DNA and inhibiting transcription [16]. When arabinose binds, 
it is more favorable for the arm to dissociate from the DNA-binding domain and interacts 
with the dimerization domain and ligand [17, 18]. It is then energetically favorable for the 
DNA-binding domains to bind I1 and I2 instead of looping the DNA and this leads to 
transcriptional induction [16, 17]. This mechanism has been studied extensively with 
AraC but is not ubiquitous for all AraC TFs. 
Schleif and colleagues constructed a chimeric protein consisting of the AraC ligand 
binding domain and LexA DNA binding domain that showed the LexA DNA binding 
domain bound its operator in an arabinose dependent manner, suggesting that the two 
domains can function independently from one another, at least in the case of AraC [19]. 
The N-terminal domain provides the ligand and sensory specificity for the regulator. The 
variability in the N-termini among the AraC-family TFs allows for control and regulation 
of carbon metabolism, stress responses, and virulence [8]. Rob, MarA, and SoxS are a 
few AraC TFs that respond to stresses such as antibiotic, oxidative stress, or organic 
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solvents, respectively [20]. Carbon metabolism of arabinose in E. coli [21] is the most 
studied AraC-family TF and is described in detail above [22]. Lastly, AraC-family TFs 
can regulate virulence. ToxT regulates the toxin-coregulated pilus and cholera toxin, two 
virulence factors controlled by environmental stimuli. Bicarbonate increases the affinity 
of ToxT to the promoters while unsaturated fatty acids decrease DNA binding affinity 
[23, 24]. 
 
1.5.4. The GATase-1 AraC transcription factor subfamily 
The varied AraC N-terminal domains are divided into subfamilies, one of which 
is a focus in our laboratory: the Type 1 glutamine amidotranferase- like domain 
(GATase-1, pfam00117). Glutamine amidotransferases are enzymes that have a catalytic 
triad of cysteine, glutamine, and histidine that remove an ammonia group from glutamate 
and transfer it to a substrate. The GATase-1 domain is conserved in some AraC TFs in P. 
aeruginosa and the members do not have a catalytic triad, and instead have a conserved 
cysteine residue at the nucleophilic elbow. The TFs CdhR and GbdR presented in this 
thesis belong to the GATase-1 AraC TF subfamily and together allow detection of the 
charged amine compounds carnitine, glycine betaine (GB), and dimethylglycine (DMG).  
P. aeruginosa GbdR, the glycine betaine-dimethylglcyine regulator, has been 
studied to a much greater extent and regulates carbon metabolism and virulence [25]. 
Eukaryotic plasma membranes and lung surfactants contain significant amounts of 
phosphatidylcholine (PC) and sphingomyelin (SM). Phospholipase C (PlcH) 
enzymatically cleaves PC or SM to yield phosphorylcholine, which is dephosphorylated 
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by PchP [26, 27]. In vitro experiments show plcH and pchP transcripts were induced in 
the presence of surfactant  and are dependent on GbdR [25], and in vivo mouse lung 
pneumonia models show that PlcH reduces lung function [28]. Choline liberated from 
PC/SM is catabolized to GB and subsequently to pyruvate. This pathway is primarily 
controlled by GbdR [29, 30] and serves multiple purposes for P. aeruginosa by 
generating an osmoprotectant [31], inducing plcH [25], and producing carbon, nitrogen, 
and energy sources [32]. Import of choline and GB is also partially regulated by GbdR 
[29, 30, 33].  
The lesser known of the two GATase-1 TFs is CdhR, the carnitine dehydrogenase 
regulator. CdhR is divergently transcribed from the carnitine catabolism operon. Prior to 
the work presented here, our lab demonstrated that CdhR is required for growth on 
carnitine and is necessary for induction of the carnitine catabolism operon [22]. 
 
1.5.5. Post-transcriptional regulation 
Regulation is complex and there can be many layers of control. As soon as a 
ribosome binding site (RBS), also known as the Shine-Delgarno sequence, of an mRNA 
exits the RNAP, translation can start, and in bacteria this can be concomitant with 
transcription. However, it is now appreciated that most translation occurs on free mRNAs 
[34]. With that being said, there is post-transcriptional regulation that often modulates 
stress responses and metabolic pathways [35].  
 RNA secondary structure can influence translation. Riboswitches are hairpin 
loop structures in the RNA 5' UTR that respond to environmental signals (temperature, 
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uncharged tRNAs, or metabolites) in a protein independent manner to modulate gene 
expression [36]. Typically genes that control metabolite synthesis or import are next to 
the riboswitch [36]. Riboswitches can activate but more often repress gene expression by 
forming a termination stem loop blocking or allowing RNAP access to the ribosome 
binding site [37]. Small RNAs (sRNA), usually small noncoding snRNA, are cis- or 
trans-encoded regulatory elements that bind RNA resulting in negative gene expression 
by inhibiting translation, or by promoting RNA degradation or cleavage. However, 
stimulation of gene expression can occur by sRNAs but is not as common. The sRNAs 
act by relieving secondary RNA structures that would normally inhibit ribosome binding 
but upon binding causes a conformational change stimulating translation [35]. Post-
transcriptional regulation can also be controlled by proteins interacting with 5' UTR, 
affecting RNA stability and translation. In times of decreased nutrient availability or 
entry into stationary phase, the E. coli CsrA protein will bind RNA to modify gene 
expression of proteins involved in carbon metabolism and motility [38, 39]. 
 
1.5.6. Other forms of regulation beyond RNA 
 These other forms of regulation are vast and expansive subjects as well, but will 
not be discussed in detail. The experiments in this dissertation examine transcriptional 
regulation, with limited analysis of post-transcriptional regulation, and how they impact 
growth. Post-translational modification (PTM) occurs after protein translation, often in 
response to environmental changes or factors with more than 300 types known as of 2010 
[40]. Enzymes chemically modify proteins allowing for quick and specific changes that 
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alter the proteins function, localization, and activity. One of the most common forms of 
PTM is the reversible process of phosphorylation. Specific proteins will have a phosphate 
group(s) added or removed to change their activity. Protein degradation is a very useful 
way to regulate processes. Bacterial pathogens S. typhimurium and Listeria have even 
found a way to hijack the host ubiquitin protein degradation system to degrade their 
effector proteins [40]. Some other common PTMs are glycosylation, acetylation, 




Figure 1. The regulatory region of the araCBAD genes. O1, I1, and I2 are half-sites 
that a single subunit of AraC binds. When there is no arabinose, the AraC monomers bind 
to half sites O1 and I1 and cause the DNA to loop and inhibit transcription. In the 
presence of arabinose an AraC monomer switches from the O1 to the I2 half site resulting 
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To survive in varied environments, from host tissue to soil, opportunistic bacterial 
pathogens must be metabolically flexible and able to use a variety of nutrient sources. We 
are interested in Pseudomonas aeruginosa’s catabolism of quaternary amine compounds 
that are prevalent in association with eukaryotes. Carnitine and acylcarnitines are 
abundant in animal tissues, particularly skeletal muscle, and are used to shuttle fatty acids 
in and out of the mitochondria where they undergo β-oxidation. We previously identified 
the genes required for carnitine catabolism as the first four genes in the carnitine operon 
(caiXcdhCAB, PA5388-PA5384). However, the last gene in the operon, PA5384, was not 
required for carnitine catabolism. We were interested in determining the function of 
PA5384. Bioinformatic analyses along with the genomic location of PA5384 led us to 
hypothesize a role for PA5384 in acylcarnitine catabolism. Here we have characterized 
PA5384 as an L-enantiomer specific short-chain acylcarnitine hydrolase that is required 
for growth and hydrolysis of acetyl- and butyrylcarnitine to carnitine and the respective 
short-chain fatty acid.  The liberated carnitine and its downstream catabolic product 
glycine betaine are subsequently available to function as osmoprotectants in 
hyperosmotic environments and induce transcription of the virulence factor 
phospholipase C, plcH.  Furthermore, we confirmed that acylcarnitines from 2 to 16 
carbon chain lengths, except for octanoylcarnitine (8-carbon), can be utilized by P. 
aeruginosa as sole carbon and nitrogen sources. These findings expand our knowledge of 
short-chain acylcarnitine catabolism and also point to remaining questions related to 




Carnitine and acylcarnitines are quaternary amine compounds that are abundant in 
mammalian tissues and play important roles in eukaryotic metabolism (1). Carnitine 
facilitates the translocation of fatty acids into the mitochondrial matrix where they 
undergo β-oxidation to produce energy for the cell (2, 3). This translocation is dependent 
on the formation of an ester linkage between the fatty acid and the hydroxyl oxygen on 
carbon three; this esterified carnitine is referred to as O-acylcarnitine or, as we will use 
throughout this study, acylcarnitine. While there are no eukaryotic enzymes that 
catabolize carnitine (2), free carnitine can be utilized by some bacteria, including 
Pseudomonas aeruginosa, as a sole carbon, nitrogen and energy source (4, 5). The 
concentration of carnitine and acylcarnitines in humans range from 50 µM in plasma to 
the low mM range in tissues, thus these compounds are potential sources of energy in 
colonization and infection (2, 6, 7). In P. aeruginosa, carnitine and its downstream 
catabolic product, glycine betaine, can function as osmoprotectants (8-10) and may be 
important for enhanced growth in hyperosmotic conditions, such as the environment of 
the lungs of people with cystic fibrosis and the urinary tract (11, 12). The generation of 
glycine betaine via carnitine catabolism also allows carnitine to induce expression of the 
virulence factor hemolytic phospholipase C, PlcH (8). During infection, PlcH can 
function to induce a proinflammatory response, suppress oxidative burst in neutrophils, 
degrade pulmonary surfactant, and increase endothelial cell death (13-18).  
We previously identified the metabolic pathway responsible for carnitine 
catabolism in P. aeruginosa and determined that all but the last gene in the carnitine 
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catabolism operon are required for carnitine degradation (19). The last gene in the 
operon, PA5384, is immediately downstream of the carnitine dehydrogenase genes 
(CDH), but is not required for growth on carnitine (19). However, the genomic location 
of PA5384 provided insight into its potential function. Uanschou et al. compared the 
genomic sequences of predicted CDH genes in Gram positive and Gram negative bacteria 
and determined that many of the CDH-containing operons had an unidentified 
esterase/lipase downstream of the CDH gene(s) (7). PA5384 fits this pattern, as it is 
immediately downstream of cdhB, and is bioinformatically predicted to be a lipolytic 
enzyme (19, 20). The prediction made by Uanschou et al. that PA5384 and homologs 
encode an acylcarnitine hydrolase, has not been directly tested. Previous work has briefly 
biochemically characterized an acylcarnitine hydrolase from an Alcaligenes sp. (21) that 
is used as a diagnostic tool for measuring acetylcarnitine in serum. However, this study 
provided no genetic identification associated with the purified hydrolase (22). 
Acylcarnitine catabolism has been studied in Pseudomonas putida (23) but it was not 
known if P. aeruginosa can hydrolyze acylcarnitines or employ them as a sole carbon 
and nitrogen source.  
 In this study we demonstrate that P. aeruginosa can utilize acylcarnitines as sole 
carbon, nitrogen, and energy sources. We also demonstrate that hydrolysis of 
acylcarnitines enables osmoprotection via production of carnitine and the downstream 
catabolite glycine betaine; improving cell survival in hyperosmotic environments and 
inducing the expression of the virulence factor PlcH. In addition, we characterize the 
function of the PA5384 enzyme and determine its role in acylcarnitine metabolism. 
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2.3. Materials and Methods 
2.3.1. Strains and growth conditions 
P. aeruginosa PA14 (24), PAO1 (25), and derivative strains were maintained on 
Pseudomonas Isolation Agar (PIA, Difco) plates or in LB broth with gentamicin added 
when necessary at 50 µg ml
-1
 or 40 µg ml
-1
, respectively.  E. coli NEB5α was maintained 
on LB plates or in LB broth supplemented when necessary, with gentamicin at 10 µg ml
-1
 
or 7 µg ml
-1
, respectively, or in LB broth with 100 µg ml
-1
 kanamycin when needed. 
To assess growth on acylcarnitines, P. aeruginosa cultures were pre-grown 
overnight at 37°C on a rotary wheel in 3 ml of MOPS minimal medium with 20 mM 
pyruvate and 5 mM glucose added as carbon sources (26). When necessary, gentamicin 
was added to these minimal media cultures at 20 µg ml
-1
. Cells from these overnight 
cultures were added to MOPS media without a nitrogen source or MOPS media with 20 
mM of the specified carbon source in 48 well plastic culture dishes at a final OD600 of 
0.05. These plates were shaken at 170 rpm for 24 hours at 37°C for carnitine and 
acylcarnitines with 2-14 carbon chain lengths (designated 2C, 4C, …16C) or at room 
temperature for palmitoylcarnitine due to micelle formation of palmitoylcarnitine at 
37°C. Growth was assessed by OD600 on a Synergy 2 BioTek plate reader. Measurement 
of growth at OD600 was not possible for palmitoylcarnitine due to the optical interference 
from the micelles that formed; therefore, triplicate serial dilutions were plated onto PIA 
and incubated for 24 hours to determine CFU ml
-1
. The suppliers for the compounds are 
as follows: L-carnitine, L-acetylcarnitine, and D,L-palmitoylcarnitine are from Sigma, L-
butyrylcarnitine and D-acetylcarnitine are from Crystal Chem., D,L-hexanoylcarnitine, 
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D,L-decanoylcarnitine, D,L-lauryolcarnitine and D,L-myristoylcarnitine are from 
Biotrend Chemicals and D,L-acetylcarnitine is from Tocris Bioscience. The D,L-
octanoylcarnitine was purchased from two different suppliers, Tocris Bioscience and 
Biotrend Chemicals. Biotrend Chemicals synthesize their compounds onsite in Germany, 
whereas Tocris Bioscience purchased the D,L-octanoylcarnitine from a producer in the 
United Kingdom (ascertained through personal communication). 
 
2.3.2. Octanoylcarnitine competition assay 
To determine if octanoylcarnitine inhibits growth on other acylcarnitines, P. 
aeruginosa PA14 was pre-grown overnight at 37°C on a rotary wheel in 3 ml of MOPS 
media with 20 mM pyruvate and 5 mM glucose added as carbon sources. Cells from the 
overnight culture were added at a final OD600 0.05 to MOPS media with 10 mM of either 
acetylcarnitine or decanoylcarnitine as the carbon source. Octanoylcarnitine (Tocris 
Biosciences or Biotrend Chemicals) was added at 5 mM and the cultures incubated at 
37°C overnight. Growth was assessed by OD600 on a Synergy 2 BioTek plate reader. 
 
2.3.3. Expression and deletion constructs 
The PA5384 deletion construct was generated in the pMQ30 plasmid (27) and the 
deletion in P. aeruginosa PA14 was made by recombination as described previously (28, 
29). Briefly, the upstream and downstream regions of the PA5384 gene were amplified 
by PCR from pMW79 using the primers: PA5384-GOI-A 5’- 
aagcttGCCTGACCTTCCAGGACAT-3’, PA5384-SOE-A 5’- 
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aagtacgaaggcgactcgaccatggGGCGAGGCAGGGTTCTAT-3’, PA5384-SOE-B 5’- 
ccatggtcgagtcgccttcgtacttCCGGAGACAGCGGATACTT-3’, and PA5384-GOI-B 5’- 
gaattcATTGCCCTGGACCTACCTG-3’. Lower case letter sequences in the above 
primers represent complementary regions for splice overlap extension or engineered 
restriction sites. The splice overlap extension PCR product was cloned into the pCR-
Blunt vector (Invitrogen), excised with HindIII and EcoRI, and cloned into similarly cut 
pMQ30 by E. coli-based cloning as described previously to generate pMW86. Donor E. 
coli S17/λpir carrying the PA5384 deletion construct (pMW86) were mated with P. 
aeruginosa PA14 and single crossover mutants selected for growth on PIA plates with 
gentamicin. Recombinants were verified by PCR. Double crossover events were selected 
by growth on 5% sucrose LB plates with no NaCl (28, 30).   
The PA5384 expression vector (pJAM8) was made by amplifying PA5384 from 
the plasmid pMW79 (19) using primers 5384ET30a F 5'-
ggatccGCTGCGAAGTATCCGCTGTCT-3’ and 5384ET30a R 5'-
aagcttCTATTCGCCTGGCTGGTG-3’. This product was cloned into the pCR-Blunt 
vector using the Zero Blunt cloning kit (Invitrogen), with subsequent transformation and 
plasmid preparation as described above. The resulting plasmid was digested with HindIII 
and BamHI-HF (NEB) and the ~1kb fragment was extracted from an agarose gel and 
ligated into the similarly digested pET-30a expression vector (Novagen). The newly 
assembled plasmid, pJAM8, was transformed into chemically competent T7 Express 




2.3.4. Trans complementation of PA5384::tn mutant strains 
To complement the PAO1 PA5384::Tn mutant strains (31) (MJ206 and MJ207), 
we placed the PA5384 gene at the attTn7 site under control of the promoter regulating the 
native operon. The promoter of the carnitine catabolism operon (PA5388) was amplified 
from plasmid pMW79 using primers 5388promfor-5384F 5'- 
TAGCggtaccGGTTGAGGTTGCGCAGCC-3' and 5388promfor5384R 5'-
ATCAggatccCATCGGTCTCCCCTCGTG-3'. The 213 bp product was ligated into the 
pCR-zero blunt vector using the Zero Blunt cloning kit (Invitrogen), with subsequent 
transformation and plasmid preparation as described above. The resulting plasmid was 
digested with KpnI-HF and BamHI-HF (NEB) and the 213 bp fragment was extracted 
from an agarose gel and ligated into the similarly digested pJAM8 to generate pJAM61. 
The pJAM61 plasmid was digested with KpnI-HF and HindIII-HF and the ~1.2 kbp 
fragment was ligated into the similarly cut plasmid pUC18-mini-Tn7T-Gm (32) and 
transformed into chemically competent E. coli NEB5α. Transformants harboring the 
newly generated plasmid, pJAM62, were selected in the presence of 7 µg ml
-1
 
gentamicin. The PA5388 promoter fused to PA5384 was integrated onto the chromosome 
of the PAO1 PA5384::tn mutant strains as previously described (18, 32). Briefly, the 
plasmids pJAM62 and pTNS2 (33) were co-electroporated into each of the PAO1 








2.3.5. Expression and purification of PA5384 
Overnight cultures of JM17, a T7 Express Competent E. coli (NEB) carrying 
pJAM8, in LB with 100 µg ml
-1
 of kanamycin were inoculated into flasks containing 300 
mL LB supplemented with 100 µg ml
-1
 of kanamycin and grown to an OD600 of 0.3-0.4. 
The cultures were then induced with Isopropyl β-D-1-thiogalactopyranoside (IPTG) to a 
final concentration of 1 mM for 3 hours at 37
o
C. Cells were collected by centrifugation 
and the pellet was resuspended in lysis buffer (B-PER, Thermo Scientific) at 4 ml per 1 g 
of cells. Halt
TM
 protease inhibitor cocktail, EDTA-free 100X (Thermo) at 1X 
concentration, 150 mM NaCl, 2 µl ml
-1
 lysozyme (50 units ml
-1
, Thermo Scientific), and 
2 µl ml
-1
 DNase (2500 units ml
-1
, Thermo Scientific), were added to the culture and 
incubated with gentle shaking at 37°C for 20 minutes.  The lysate was clarified by 
centrifugation at 8,000 x g for 20 minutes at 4°C. The clarified lysate was applied to a 
HisPur cobalt-NTA column (Thermo), washed thoroughly with wash buffer #1 (10 mM 
imidazole, 50 mM sodium phosphate, 300 mM sodium chloride, pH 7.4), and wash buffer 
#2 (wash buffer #1 with 33 mM imidazole), and protein eluted off the column with 
elution buffer (70 mM imidazole, 50 mM sodium phosphate, 300 mM sodium chloride, 
pH 7.4). The elution fractions containing N-terminal hexahistidine PA5384, determined 
by SDS-PAGE gel electrophoresis, were pooled and dialyzed in a 20,000 MWCO Slide-
A-Lyzer (Thermo Scientific) in 0.1 M potassium phosphate buffer pH 7.2 and stored at 
4°C. The protein concentration was determined to be 37 µg ml
-1
 by using bovine serum 




2.3.6. Acetylcarnitine hydrolysis assay 
An assay developed to detect acetylcarnitine for a diagnostic application 
previously described by Tomita et al. 2001 (22) was modified for the purpose of 
detecting enzymatic activity of the purified protein encoded by P. aeruginosa PA5384. 
The coupled assay of Tomita et al. was modified as follows. Purified 6xHis-PA5384 in 
0.1 M potassium phosphate buffer pH 7.2 was added to the reaction mixture (0.1 M 
potassium phosphate buffer pH 7.2, 7 mM MgSO4, 50 mM KCl, 2.5 mM ATP, 0.5 M 
phosphoenolpyruvate, 0.3 mM NADH, 20 units ml
-1
 acetate kinase (Sigma), 9 units ml
-1
 
pyruvate kinase (Sigma), and 4 units ml
-1
 L-lactate dehydrogenase (Sigma)) in a 96 well-
plate and incubated with shaking at 30°C (Synergy 2 BioTek) for 15 minutes. After this 
equilibration period, substrate (L-acetylcarnitine, D-acetylcarnitine, D,L-acetylcarnitine, 
or acetylcholine) was added to each well at 250 µM or 125 µM and incubated for an 
additional 3 hours at 30°C. During this incubation the absorbance was read at 340 nm 
every 3 minutes with each read preceded by 15 seconds of shaking. 
 
2.3.7. Hydrolysis reactions for other acylcarnitines and detection of enzymatic 
activity 
The substrate specificity of PA5384 was determined by detecting free L-carnitine 
using a colorimetric L-carnitine assay (BioVision). The assay was performed as described 
by the manufacturer with the modifications described here. First, in a 96 well plate, 15 µl 
of 0.1 M potassium phosphate buffer pH 7.2 was added to each well of L-carnitine 
standard and brought to a final volume of 50 µl with the provided assay buffer. In a 96 
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well plate L-acylcarnitines 2C to 4C were added to a final concentration of 0.5 mM and 
D,L-acylcarnitines 6C to 16C were added to a final concentration of 1 mM in 0.1 M 
potassium phosphate buffer pH 7.2. The assay had technical triplicates and had more than 
three biological replicates for each carbon chain length.  0.5 µg of 6xHis-PA5384 was 
added to each well and incubated at 30°C while shaking for 15 seconds every 3 minutes 
for 3.5 hours. As a control, in triplicate, 0.1 M potassium phosphate buffer pH 7.2 and 0.5 
mM acylcarnitine 2C to 4C or 1 mM 6C to 16C were added to the assay to detect signal 
from free carnitine present in these compounds. Assay controls according to BioVision’s 
protocols were also performed with the modification of adding 0.5 µg 6xHis-PA5384 to 
the background control, which has no converting enzyme. 
 
2.3.8. PA5384-FLAG-tag and localization by western blot 
 For western blot analysis, PA5384 was C-terminally FLAG-tagged via 
chromosomal integration by PCR amplifying the C terminus of PA5384 with primers 
5384Flag F 5'-ggtaccGAGCAGCCCCTGGAGTTC-3' and 5384Flag R 5'- 
aagcttCTACTTATCATCATCATCCTTGTAATCCGGCTTCAGGTTCATCCTG-3' 
which contains the FLAG-tag. The 585 base pair product was cloned into the pCR-Blunt 
vector (Invitrogen) and excised with KpnI and HindIII. The excised product was cloned 
into similarly cut pMQ30 (27).  Donor E. coli S17/λpir carrying the PA5384-FLAG 
construct, pJAM34, underwent conjugation with P. aeruginosa PA14 and single 
crossover mutants selected for growth on PIA plates with gentamicin. Recombinants 
were verified by growth in MOPS with 20 mM acetylcarnitine as a sole carbon source 
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supplemented with 20 µg ml
-1
 gentamicin and by whole lysate western blots using anti-
FLAG monoclonal antibodies (Sigma). The western blots were performed as follows: 
electrophoresis in 8% or 12% SDS-PAGE gel followed by protein transfer to a PVDF 
membrane (Immobilon-P Millipore). The membrane was blocked overnight in 5% nonfat 
dried milk in Tris buffered saline – Tween 20 (TBS-T: 150 mM NaCl, 50 mM Tris HCl, 
0.1% Tween 20, 0.01% sodium azide, pH 7.6). The membrane was washed in TBS-T, 
then incubated for 1 hour with  the anti-FLAG M2 monoclonal antibody (Sigma) or anti-
SadB antibody (34) and washed in TBS-T before detection with anti-mouse IgG HRP 
secondary antibody (GE Healthcare) or anti-rabbit IgG IRDye 800CW (Odyssey). After 
washing with TBS-T, HRP was detected via enhanced chemiluminescence western 
blotting detection reagent (GE Healthcare) prior to exposing membrane to film. 
 PA5384-FLAG strains JM116 and JM117, and control JM141 were grown 
overnight to mid log phase in MOPS with 5 mM glucose, 20 mM carnitine and 15 µg ml
-
1
 gentamicin. JM141 is a control to account for nonspecific binding of the anti-FLAG 
monoclonal antibody to a random pMQ30 integrant (JM141 is with a single crossover 
integrant in PA4921, a gene irrelevant to the CDH pathway). Cells were collected by 
centrifugation at 8,000 x g for 10 minutes, and the supernatant was saved as the 
extracellular fraction. The pellets were resuspended in 20 mM Tris HCl pH 7.3 and lysed 
by repeated passage through a French Press at 9,000 PSI. The lysates were centrifuged at 
8,000 x g for 10 minutes to remove non-lysed cells and large cellular debris. Separation 
of membrane from soluble fraction (cytoplasmic and periplasmic) was performed by 
ultracentrifugation at 100,000 x g for 30 minutes. The whole membrane fraction (outer 
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and inner membrane) was resuspended in 20 mM Tris HCl pH 7.3 and washed three 
times. The soluble fraction centrifuged at 100,000 x g three times to ensure no membrane 
contamination. The protein from the extracellular fraction was concentrated using a 
10,000 MWCO Centriprep Centrifugal Filter (Millipore). The extracellular, soluble, and 
membrane fractions were then analyzed by western blot following the protocol above. 
 
2.3.9. Osmoprotection assay 
 Osmoprotection was determined by first growing P. aeruginosa PA14 WT and 
∆PA5384 overnight at 37°C on a rotary wheel in 3 mL of MOPS medium with 20 mM 
pyruvate and 5 mM glucose. Cells were collected by centrifugation, washed, and 
resuspended to a final OD600 of 0.05 in MOPS (which contains 50 mM NaCl) with an 
additional 800 mM NaCl, 20 mM glucose, and 0.2 mM carnitine or acetylcarnitine in 48 
well plates. Cultures were grown at 37°C for 48 hours, due to the slow growth rate in a 
high salt medium, and growth was determined by OD600.  
 
2.3.10. plcH promoter activity by means of lacZYA fusion 
 Transcriptional induction from the plcH promoter was measured as previously 
described (35). Briefly, the plcH-lacZYA reporter construct, pMW22 (35), was 
transformed by electroporation into P. aeruginosa PA14 WT and ∆PA5384 and 
transformants selected for growth on gentamicin. Cells were grown overnight in MOPS 
with 20 mM pyruvate, 5 mM glucose, and 20 µg ml
-1 
gentamicin. Cells were collected by 




gentamicin with the addition of 1 mM carnitine or acetylcarnitine for induction samples. 
Cells were induced for 5.5 hours at 37°C and β-galactosidase assays were performed 
according to the method of Miller (36). 
 
2.3.11. NPPC assay 
Phospholipase C (PLC) activity was measured by ρ-nitrophenylphosphorylcholine 
(NPPC) hydrolysis according to the method of Kurioka and Matsuda (37), as previously 
modified in our laboratory (18, 35). Briefly, cells were grown overnight in MOPS, 20 
mM pyruvate and 5 mM glucose. Cells were collected by centrifugation, washed, and 
resuspended in MOPS with 20 mM pyruvate and 1 mM carnitine or acetylcarnitine and 
grown overnight at 37°C in a 48 well plate. Supernatants from these cultures were 
obtained and added to 2X reaction buffer (200 mM Tris-HCl pH 7.2, 50% glycerol, 20 
mM NPPC) in a 1:1 ratio. Hydrolysis of NPPC was quantified by measuring absorbance 




.   
 
2.4 Results 
2.4.1. PA5384 is required for growth on acetylcarnitine. 
We previously demonstrated that the first four genes in the caiXcdhCAB-PA5384 
(PA5388-PA5384) operon (Fig. 1A) were critical for aerobic carnitine transport and 
metabolism (19, 38). PA5384, the last gene in the operon, was not required for carnitine 
catabolism (19). We hypothesized that PA5384 may be associated with acylcarnitine 
catabolism based on its presence in the carnitine catabolism operon and bioinformatic 
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prediction of lipase/esterase function. To determine the function of PA5384, we made an 
unmarked deletion of PA5384 (∆PA5384) in P. aeruginosa PA14 and measured growth 
on acetylcarnitine. The PA5384 deletion mutant was unable to grow on acetylcarnitine as 
a sole carbon source (Fig. 1B). To test whether P. aeruginosa could use either 
acetylcarnitine stereoisomer, we used both the L- and D-enantiomers of acetylcarnitine in 
a growth assay, and found that P. aeruginosa can only grow on the L-enantiomer of 
acetylcarnitine (Fig. 1 B). It has been shown that carnitine can be used as a sole nitrogen 
source (23) and we tested if acetylcarnitine can be used as a sole nitrogen source. P. 
aeruginosa PA14 can grow on acetylcarnitine as the sole nitrogen source whereas the 
∆PA5384 deletion strain cannot (Fig. 1C). 
We were unable to complement the acetylcarnitine growth defect of PA5384 
deletion strain using a high-copy constitutive plasmid (PA5384 on the pUCP22 
backbone), or using an arabinose-inducible high-copy system (PA5384 under PBAD 
control on the pMQ80 backbone). Therefore, to test if the growth phenotype in the 
PA5384 mutant strain was due to mutation of PA5384, we constructed a PA5388 (caiX) 
promoter fusion with PA5384 (PcaiX-PA5384) and integrated it onto the chromosome at 
the attTn7 site in two independent PAO1 transposon mutant strains. The two PAO1 
transposon mutants, MJ207 and MJ206, carry a Tn5 transposon that confers resistance to 
tetracycline inserted into the PA5384 coding sequence at base pairs 236 and 570, 
respectively (Fig. 1A) (31). Both strains carrying PcaiX-PA5384 at the attTn7 site (JM118 
and JM119) were able to grow on acetylcarnitine as a sole carbon source (Fig. 1D). These 
data confirm the necessity of PA5384 for growth on acetylcarnitine. 
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2.4.2. PA5384 exhibits acetylcarnitine hydrolase activity.  
P. aeruginosa requires PA5384 for growth on acetylcarnitine (Fig. 1). To 
determine if PA5384 encoded an acetylcarnitine hydrolase, we expressed recombinant 
PA5384 protein with an N-terminal hexahistidine tag (6xHis) and purified it by cobalt 
affinity chromatography and dialysis as described in the methods section. To measure 
acetylcarnitine hydrolase activity of PA5384, we adapted an enzymatic method designed 
to measure acetylcarnitine in serum (22), which uses four coupled enzymatic reactions to 
convert acetate abundance to an increase in NAD+ concentration, resulting in decreased 
UV absorbance at 340 nm dependent upon acetate. We predicted that PA5384 was an 
acetylcarnitine hydrolase that would hydrolyze acetylcarnitine to carnitine and acetate, 
and allow detection of acetate using the coupled reaction system. Using this assay we 
showed that PA5384 has L-enantiomer specific acetylcarnitine hydrolase activity, as it 
hydrolyzes L-acetylcarnitine and not D-acetylcarnitine (Fig. 2). The specificity of 
PA5384 was examined further by determining if the presence of the carnitine backbone 
of acetylcarnitine was necessary for hydrolysis. The inability of PA5384 to hydrolyze 
acetylcholine, which is another quaternary amine containing ester, to choline and acetate 
suggests that the carnitine backbone is necessary for acetylcarnitine hydrolysis and that 
PA5384 is not a general hydrolase (Fig. 2). 
 
2.4.3. PA5384 has specificity for short-chain acylcarnitines. 
As demonstrated above, PA5384 is required for growth on acetylcarnitine and 
purified 6xHis-PA5384 hydrolyzes acetylcarnitine in vitro. In the infection environment, 
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P. aeruginosa encounters a variety of acylcarnitines with different O-acyl chain lengths. 
To determine whether PA5384 was required for growth on O-acyl chain lengths longer 
than acetylcarnitine we compared PA14 wild type to a ∆PA5384 mutant strain for growth 
on acylcarnitines of 2 to 16 carbon (2C to 16C) lengths. Here we show that PA5384 is 
required for growth on short-chain acylcarnitines (2C and 4C), but not for growth on 
medium or long-chain acylcarnitines (Fig. 3A). Interestingly, P. aeruginosa cannot use 
octanoylcarnitine as a sole carbon source (Fig. 3A), nor does octanoylcarnitine inhibit 
growth on acetylcarnitine or decanoylcarnitine as the sole carbon source (data not 
shown). This observation will be addressed in the discussion section.   
We sought to determine if the chain length specificity for the observed growth 
phenotype was due to enzymatic specificity of PA5384. To test in vitro hydrolysis of 
different acylcarnitines by PA5384, we measured L-carnitine release using a colorimetric 
assay for L-carnitine detection (BioVision). Each acylcarnitine from 2C to 16C chain 
length was assayed for free L-carnitine either in the presence or absence of purified 
6xHis-PA5384. The samples with no PA5384 enzyme added allowed for subtraction of 
contaminating free L-carnitine in the starting materials.  The results show that PA5384 
can hydrolyze the short-chain acylcarnitines, acetyl and butyryl, but it has no activity on 
medium-chain and long-chain acylcarnitines (Fig. 3B). Based on the above L-carnitine 
assay and our genetic evidence, PA5384 will now be referred to as HocS (Hydrolase of 





2.4.4. HocS is located in the cytoplasm. 
HocS was bioinformatically predicted to be in the cytoplasm using the PSORTb 
database v3.0 with a cytoplasmic score of 9.97, well above the accepted cut-off of 7.5 
(39, 40). To confirm this prediction, we tracked the localization of a chromosomally 
incorporated C-terminally FLAG-tagged HocS. Cells with the hocS-FLAG allele were 
grown in carnitine to induce expression (19). Western blot analysis was performed on the 
extracellular, soluble, and insoluble fractions and HocS-FLAG was detected by use of an 
anti-FLAG monoclonal antibody (Fig. 4) compared to the untagged HocS control. A 
known cytoplasmic protein, SadB, was used as a control for cytoplasmic localization as 
well as cytoplasmic contamination in the extracellular and insoluble fractions using the 
anti-SadB antibody (34). Based on this data, HocS is most likely cytoplasmic, although 
this data does not conclusively exclude periplasmic localization.  
 
2.4.5. HocS is important for osmoprotection and induction of the virulence factor 
PlcH. 
Carnitine is known to be an osmoprotectant (8) and to induce phospholipase C 
activity (PLC) (8). The ability of HocS to liberate carnitine from short-chain 
acylcarnitines led us to predict its involvement in osmoprotection and PlcH activity under 
conditions where short-chain acylcarnitines were present. To determine if hocS has a role 
in osmoprotection we compared PA14 wild type to the hocS deletion strain for the ability 
to grow in the presence of 850 mM NaCl. Under these conditions carnitine functions as 
an osmoprotectant allowing for growth in wild type and ∆hocS mutant strain (Fig. 5A). 
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Osmoprotection was also observed with acetylcarnitine as the osmoprotectant source in 
PA14 wild type but not in the ∆hocS mutant strain, which had a three-fold decrease in 
growth compared to wild type (Fig. 5A). Choline is oxidized to glycine betaine, a potent 
osmoprotectant (9), and was used as control to show that deleting hocS did not 
compromise the choline catabolic pathway or general osmoprotection. These results 
support two conclusions. First, acetylcarnitine is not an effective osmoprotectant prior to 
hydrolysis, and second, that hydrolysis of acetylcarnitine by HocS can provide 
osmoprotection in hyperosmotic environments.  
Release of carnitine by HocS activity would also be predicted to impact plcH 
transcription and PLC enzyme production by supplying glycine betaine for GbdR 
dependent induction of plcH. To test this prediction, we measured plcH transcription 
using a plasmid based plcH-lacZYA reporter (pMW22) (35), and measured PLC 
enzymatic activity using the NPPC assay (37). Carnitine induced transcription of plcH as 
previously reported (35), in both the PA14 wild type and ∆hocS mutant strains. However 
in the ∆hocS mutant strain acetylcarnitine showed no plcH transcriptional induction 
whereas PA14 wild type showed robust induction (Fig. 5B). Activity of secreted PLC 
was determined for both PA14 wild type and ∆hocS using the NPPC assay. A seven fold 
increase of PLC activity induced by acetylcarnitine was observed in PA14 wild type 
compared to ∆hocS (Fig. 5C). These results demonstrate that hocS hydrolysis of 
acetylcarnitine is required for acetylcarnitine-dependent induction of plcH transcription 





In this study, we identified HocS (PA5384) as a short-chain acylcarnitine 
hydrolase that is required for P. aeruginosa to utilize acetyl- and butyrylcarnitine as sole 
carbon, nitrogen, and energy sources. Using a coupled enzymatic assay we show that 
HocS is specific for acylcarnitines and in conjunction with the L-carnitine assay we 
demonstrate that HocS specifically hydrolyzes short-chain acylcarnitines. The free 
carnitine generated can induce plcH transcription and result in induced PLC activity. P. 
aeruginosa can also utilize the rendered carnitine as an osmoprotectant to promote 
growth in hyperosmotic conditions. Through trans complementation we were able to 
show that hocS is required for P. aeruginosa grow on acetylcarnitine. We speculate that 
plasmid complementation was not successful due to the concentration of HocS compared 
to the other carnitine dehydrogenase proteins. 
Acylcarnitine degradation has only been evaluated in Pseudomonas putida and 
Pseudomonas fluorescens (23, 41), which led us to inquire if P. aeruginosa can utilize 
acylcarnitines as sole carbon and nitrogen sources. In humans, acetylcarnitine is the most 
prevalent acylcarnitine intracellularly and in circulation but medium- and long-chain 
acylcarnitines are also present throughout the body, with long-chain acylcarnitines being 
the dominate acylcarnitine in bile (1).  P. putida cannot utilize acylcarnitines from 2 to 8 
carbon chain lengths but it is capable of using acylcarnitines 10 carbon chain lengths and 
longer as a sole carbon source (23). This led us to hypothesize that P. aeruginosa can 
utilize longer chain fatty acid length acylcarnitines as well. To the best of our knowledge, 
we are the first to show that P. aeruginosa can utilize acylcarnitines from 2 to 16 carbon 
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chain lengths as sole carbon and nitrogen sources (Fig. 1C and Fig. 3A). Interestingly, 
our data illustrate that P. aeruginosa cannot use octanoylcarnitine as a sole carbon source 
and octanoylcarnitine does not inhibit growth on either acetyl- or decanoylcarnitine.  The 
failure to grow on octanoylcarnitine may be due to an inability to transport or hydrolyze 
octanoylcarnitine, either or both of which suggest that P. aeruginosa is specifically 
restricted in its use of octanoylcarnitine (Fig. 3A). We used two different sources of 
octanoylcarnitine that were manufactured in two different sites (United Kingdom and 
Germany) to rule out toxic contaminants and defective synthesis, so we think that this 
restriction is a biological one, although we do not know the mechanism governing this 
restriction. P. fluorescens strain IMAM on the other hand can hydrolyze L-
octanoylcarnitine (41) but no study to date has shown growth on octanoylcarnitine as the 
sole carbon source in the pseudomonads.   
Takahashi demonstrated, through crude purification, that an acylcarnitine 
hydrolase from Alcaligenes could effectively be employed to identify acetylcarnitine in 
biological samples (22, 42, 43). However, the gene responsible for the acetylcarnitine 
hydrolase activity in Alcaligenes was not determined. We successfully identified the gene 
and expressed the protein responsible for hydrolysis of short-chain acylcarnitines in P. 
aeruginosa, PA5384 (HocS), and determined that it is likely localized in the cytoplasm 
(Fig. 4). Data from the L-carnitine assay further illustrate that hocS only hydrolyzes the 
short-chain acylcarnitines acetyl- and butyrylcarnitine (Fig. 3B). Since hocS hydrolyzes 
only substrates with a carnitine backbone, it suggests that an accessible fatty acid alone is 
not sufficient to achieve hydrolase activity and that the hydrolase activity is specific to 
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the bond position on carnitine, which is further supported by the enantiomeric selectivity 
of the enzyme. These data and the ability of ∆hocS mutant strain to grow on medium- or 
long-chain acylcarnitines as the sole carbon source suggest that P. aeruginosa possesses 
an alternate hydrolase(s) that can liberate carnitine from medium- and long-chain 
acylcarnitines. 
An additional goal of this study was to determine if short-chain acylcarnitines 
have a physiological role in P. aeruginosa in addition to use as nutrient sources. The 
virulence factor PlcH is induced by phosphate deprivation and by the products of choline 
and carnitine catabolism; glycine betaine and dimethylglycine (8, 44, 45). As access to 
carnitine enables induction of plcH, we hypothesized that the free carnitine generated by 
HocS hydrolysis of short-chain acylcarnitines would provide a source of carnitine to 
induce plcH. The lack of induction in either plcH transcription or PLC activity in the 
∆hocS mutant in the presence of acetylcarnitine lead us to conclude that the carnitine 
generated from hydrolysis of short-chain acylcarnitines by HocS is sufficient to induce 
plcH expression (Fig. 5B-C).   
The ability of P. aeruginosa to survive in hyperosmotic conditions by employing 
quaternary amine osmoprotectants has long been established (1, 8), such as choline-O-
sulfate, carnitine, and glycine betaine. Even though acylcarnitines had not been evaluated 
in P. aeruginosa as osmoprotectants, our data shows that free carnitine generated by 
HocS hydrolysis acts as an osmoprotectant for P. aeruginosa in hyperosmotic conditions 
but that acetylcarnitine itself is not an osmoprotectant (Fig. 5A). In Bacillus subtilis, 
acetylcarnitine is a precursor to carnitine which is then used as an osmoprotectant (46). In 
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Listeria monocytogenes, acetylcarnitine functions as an osmoprotectant (47, 48), but 
these studies did not address if acetylcarnitine is catabolized to carnitine. P. aeruginosa 
has been shown to catabolize carnitine to glycine betaine in hyperosmotic environments 
(46). Short-chain acylcarnitines are a source of carnitine that can ultimately be converted 
to glycine betaine. 
This study has expanded our knowledge on P. aeruginosa acylcarnitine 
catabolism.  Similar to P. putida, P. aeruginosa can grow on acylcarnitines from 10 to 16 
carbon chain lengths, but P. aeruginosa is additionally capable of utilizing acylcarnitines 
from 2 to 6 carbon chain lengths. P. aeruginosa hydrolyzes short-chain acylcarnitines 
using an L-enantiomer specific hydrolase we have described here, HocS. The liberated 
carnitine from short-chain acylcarnitines hydrolysis has multiple physiological impacts, 
including induction of virulence factors and providing access to osmoprotectants.  
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Figure 1. PA5384 is required for P. aeruginosa growth on L-acetylcarnitine.  
(A) Diagram of the carnitine catabolism operon in P. aeruginosa PAO1. ORFs are 
designated as arrows and are scaled relative to other ORFs. Black triangles represent 
transposon insertion sites in two separate PAO1 PA5384 mutant strains with position of 
insertion noted by base pair number above the triangle. Gene designations are given 
below the arrows (19, 38) along with our proposed gene name for PA5384. (B) PA14 WT 
and ∆PA5384 mutant cells were grown in MOPS minimal media supplemented with 
20mM of carnitine, L-acetylcarnitine (LAC), D-acetylcarnitine (DAC), or racemic mix of 
D- and L-acetylcarnitine (DLAC) as sole sources of carbon. (C) PA14 WT and ∆PA5384 
mutant cells were grown in MOPS minimal media or MOPS minimal media without 
nitrogen supplemented with 20mM of carnitine (Carn) or L-acetylcarnitine (LAC) as the 
sole carbon and nitrogen source. (D) Trans complementation of two independent PAO1 
PA5384 transposon mutants. Cells were incubated in MOPS minimal media with 20 mM 
carnitine or LAC. MJ206 is the strain designation for the PA5384::Tn with transposon 
insertion at bp 570 and the derivative attTn7::PA5384 strain is designated JM118. MJ207 
is the strain designation for PA5384::Tn with transposon insertion at bp 236 and the 
derived attTn7::PA5384 strain is designated JM119. Errors bars represent standard 






Figure 2. PA5384 can hydrolyze L-acetylcarnitine. Coupled enzymatic assay with 
purified 6xHis-PA5384 and substrates (∆) 250 µM L-acetylcarnitine (LAC), (○) 125 µM 
(LAC), (♦) 250 µM D-acetylcarnitine (DAC), (●) 250 µM D,L-acetylcarnitine (DLAC), 
(■) 250 µM acetylcholine (AcCho), (□) no substrate, or (▲) 250 µM LAC with no added 
PA5384. Lines have been added from the key to the absorbance curves to clarify the line 
identities. Errors bars represent standard deviations of triplicate samples and results are 
representative of three separate experiments. 
 
Figure 3. PA5384 encodes a short-chain acylcarnitine hydrolase. (A) PA14 WT to 
16C acylcarnitine chain lengths. Number on x-axis indicates chain length. The y-axis 
shows relative growth of the mutant compared to WT, expressed as a percent of WT and 
the ∆PA5384 mutant were grown in MOPS minimal media with 20 mM of carnitine (0) 
or 2C growth (i.e. WT growth = 100%). Growth for carnitine to acylcarnitines with 12C 
chain lengths was measured by OD600 and growth on acylcarnitines with chain lengths of 
14C and 16C was determined by serial dilution and plating. (*) Neither PA14 WT nor 
∆PA5384 mutant strain grew on octanoylcarnitine as the sole carbon source. (B) Free L-
carnitine generated from hydrolysis of acylcarnitines by 6xHis-PA5384 was detected 
using a colorimetric L-carnitine assay. The dotted line represents the assay sensitivity 
limit, below which measurements of carnitine are not reliable. Errors bars represent 





Figure 4. HocS is likely localized to the cytoplasm. Cells from two independent strains, 
HocS-FLAG-1 (JM116) and HocS-FLAG-2 (JM117) that integrate a C-terminal FLAG-
tag on HocS, and control strain JM141 were grown in carnitine. The extracellular (E), 
soluble (S), and insoluble fractions (I) were prepared as described in the methods section. 
After SDS-PAGE and blotting, the FLAG-tag was detected with a monoclonal anti-
FLAG antibody and the cytoplasmic control, SadB, was detected with an anti-SadB 
antibody. The western blot shown is a representative of four comparable blots. 
 
Figure 5. HocS has a role in osmoprotection and induction of the virulence factor 
plcH. (A) Osmoprotection was determined by growing PA14 WT and ∆hocS mutant cells 
for 48 hours in MOPS minimal media (50 mM NaCl) supplemented with 800 mM NaCl, 
20 mM glucose as the carbon source and with the compatible solutes carnitine or L-
acetylcarnitine (LAC) at a final concentration of 0.2 mM. (B) Induction of plcH-lacZYA 
(pMW22) by carnitine (Carn) or LAC was measured by inducing PA14 WT and ∆hocS 
mutant strain cells for 4 hours prior to the β-galactosidase assay. (C) To measure PLC 
activity, PA14 WT and ∆hocS mutant cells were grown overnight in MOPS 
supplemented with 20 mM pyruvate and either 1 mM carnitine or LAC. The resultant 
culture supernatants were used in an NPPC assay to determine PLC activity. Error bars 
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THE ROLE OF cbcWV AND caiX IN THE TRANSPORT OF  






 The opportunistic pathogen P. aeruginosa can metabolize the compounds 
carnitine and acylcarnitines, which are abundant in host muscle and cardiac tissues. 
Acylcarnitines can be degraded to carnitine, where the liberated carnitine and its 
catabolic product glycine betaine can be used as osmoprotectants, to induce the virulence 
factor phospholipase C, and can function as sole carbon, nitrogen, and energy sources. P. 
aeruginosa is incapable of de novo synthesis of carnitine and acylcarnitines and they 
therefore must be imported from exogenous source. In this study we present the first 
characterization of acylcarnitine transport. Short-chain acylcarnitines are imported by the 
ABC transporter CaiX and CbcWV. Medium- and long-chain acylcarnitines are 




Carnitine and acylcarnitines are quaternary amine compounds (QAC) that are 
present in  all domains of life and are found in soil [1, 2] and plants [3, 4], and are 
abundant in animal tissues [5, 6]. The majority of carnitine is in its free form, but a 
portion is acylated, with acetylcarnitine being the most abundant acylcarnitine [7]. In 
animals, fatty acids are brought into the mitochondria via the carnitine shuttle where they 
undergo beta oxidation to produce energy for the cell. There are no animal enzymes 
capable of degrading carnitine, therefore any breakdown is from bacteria [8].  
Pseudomonas aeruginosa is a Gram-negative bacterium that is nearly ubiquitous 
in nature and is an opportunistic pathogen that is capable of metabolizing carnitine [9] 
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and acylcarnitines [10]. Short-chain acylcarnitines are hydrolyzed in the cytosol by HocS 
[10], but the medium- and long-chain acylcarnitine hydrolase(s) remains unidentified. 
Acylcarnitine hydrolysis yields a free fatty acid and carnitine. The resulting free carnitine 
and its catabolic product glycine betaine function as osmoprotectants in hyperosmotic 
environments [10-12], induce the virulence factor phospholipase C, plcH [11], and can be 
used as sole carbon, nitrogen, and energy sources [10, 13, 14]. The liberated fatty acid 
can also be used as a sole carbon source [15] and the faoAB (fadBA5) genes responsible 
for oxidation of fatty acids twelve carbons and longer were found to be strongly induced 
in cystic fibrosis sputum [16] and important for P. aeruginosa fitness in mouse wound 
models [17]. 
 To date, de novo synthesis of carnitine has not been demonstrated in bacteria 
[18], therefore it must be acquired from the environment. There are two routes to 
carnitine transport: first, a BCCT (betaine/choline/carnitine) transporter, driven by 
sodium motive force, proton motive force, or substrate:product antiport [19]; and second, 
an ATP-binding cassette (ABC) transporter powered by ATP hydrolysis. In bacteria, 
ABC transporters are comprised of multiple proteins: a transmembrane domain, a 
nucleotide binding domain (ATPase), and a substrate binding protein (periplasmic 
binding protein) [20]. In P. aeruginosa, the genes encoding the ABC transporter for 
carnitine import are located in two different operons. The genes encoding the 
transmembrane domain (cbcW) and the nucleotide binding domain (cbcV) are located in 
the cbcXWV operon (PA5378-PA5376) [21], while the caiX gene, encoding the carnitine 
substrate binding protein is located in the carnitine catabolism operon, caiXcdhCABhocS 
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(PA5388-PA5384) [22]. In P. aeruginosa CbcWV interacts with three different substrate 
binding proteins, CaiX, BetX, and CbcX, all of which bind ligand that are QACs: 
carnitine, glycine betaine, and choline (Fig. 1) [21]. caiX and cbcWV were previously 
shown to be required for growth on carnitine [21, 22], but the mechanism for 
acylcarnitine import and utilization in P. aeruginosa had not been studied. 
 Here we report the route of acylcarnitine transport in P. aeruginosa (Fig. 7). 
Through growth and transcriptional reporter assays, we demonstrate that medium- and 
long-chain acylcarnitines are hydrolyzed extracytoplasmically by an unknown 
hydrolase(s) to yield carnitine and a fatty acid. Carnitine and short-chain acylcarnitines 
are imported by the ABC transporter CbcWV and the substrate binding protein CaiX. 
cbcWV is only necessary for utilization of medium- and long-chain acylcarnitines as sole 
nitrogen sources but not osmoprotectants. cbcWV is necessary for short-chain 
acylcarnitines to function as osmoprotectants, but carnitine, medium-, and long-chain 
acylcarnitines are imported by an undefined transporter to provide osmoprotection. 
 
3.3 Materials and Methods 
3.3.1. Strain, growth conditions, and compounds  
P. aeruginosa PA14 wild type [23], ΔcaiX [22], and ΔcbcV [24] strains were 
maintained on PIA plates or in LB liquid and when necessary with 50 µg ml
-1
 or 40 µg 
ml
-1
 of gentamicin, respectively. Carnitine and acylcarnitines were purchased from the 
following vendors: L-carnitine (Acros); L-acetylcarnitine and DL-palmitoylcarnitine 
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(Sigma); L-butyrylcarnitine (Crystal Chem Inc); and DL-hexanoyl-, DL-octanoyl-, DL-
decanoyl-, DL-lauroyl-, and DL-myristoylcarnitine (BioTrends). 
 
3.3.2. Growth assays  
To test the growth of strains carrying deletions in transport components on 
carnitine and acylcarnitines (2-6 and 10-16 fatty acid chain length) as sole carbon 
sources, PA14 wild type, ΔcaiX, or ΔcbcV were grown overnight at 37 °C in minimal 
media MOPS with 20 mM pyruvate and 5 mM glucose. Cells were then collected by 
centrifugation, washed, and inoculated at a final OD600 nm of 0.05 in MOPS with 20 mM 
of the individual acylcarnitine or carnitine. Cultures were grown at 37 °C in a 48-well 
plate on a horizontal shaker for 24 hours. OD600 was measured at the end of the assay on 
a BioTek plate reader. Due to insolubility, growth on palmitoylcarnitine growth was 
determined by CFU counts. 
 To test the use of carnitine and acylcarnitines as a sole nitrogen source, 
overnight cultures and preparation of the cells were the same as above. Cells were 
inoculated into minimal media M63 nitrogen free containing 20 mM pyruvate and 2 mM 
of the acylcarnitine. Palmitoylcarnitine samples had 0.75% deoxycholate added to 
prevent precipitation. Cultures were grown at 37 °C in a 48-well plate on a plate shaker 
for 24 hours. All acylcarnitine growth assays were measured on the BioTek plate reader 





3.3.3. Transcriptional reporter assay  
To assess induction of caiX in response to acylcarnitines in the transport related 
deletion strains ΔcaiX and ΔcbcV, we used the transcriptional reporter PcaiX-lacZYA 
(pJAM22; construction described in Chapter 4).  PA14WT, ΔcaiX, or ΔcbcV carrying 
pJAM22 were grown overnight at 37 °C in MOPS medium, 20 mM pyruvate, 5 mM 
glucose, and 20 µg ml
-1
 gentamicin. Cells were collected by centrifugation, washed, and 
resuspended in MOPS. Cells were inoculated at a final OD600 of 0.05 into a 48-well plate 
containing MOPS medium, 20 mM pyruvate, 20 µg ml
-1
 gentamicin, and 1 mM of the 
induction compound (carnitine or acylcarnitines of 2-16 fatty acid chain length). Cells 
were incubated for 4 hours at 37 °C while shaking and then a β-galactosidase assay was 
performed according to Miller [25]. Due to insolubility of palmitoylcarnitine, OD600 for 
those wells was measured prior to inoculation with cells and subtracted from the final 
OD600 nm reading. 
 
3.3.4. Osmoprotection assay  
Osmoprotection assays were done as previously described with a few 
modifications [10]. Briefly, P. aeruginosa PA14 wild type and ΔcbcV were grown 
overnight in MOPS medium supplemented with 20 mM pyruvate and 5 mM glucose. 
Cells were collected by centrifugation, washed, and resuspended to an OD600 of 0.05 in 
MOPS medium with an additional 800 mM NaCl (850 mM total NaCl), 20 mM glucose, 
and 0.2 mM osmoprotectant (carnitine, acetylcarnitine, decanoylcarnitine, or 
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myristoylcarnitine). 48-well plates were shaken at 37 °C for 48 hours and growth was 
determined by OD600. 
 
3.4. Results 
3.4.1. cbcV is required for growth and induction of caiX in response to short-chain 
acylcarnitines.  
In previous studies we showed that P. aeruginosa can grow on the short-chain 
acylcarnitines (SCAC) acetyl- and butyrylcarnitine [10]. The SCACs are hydrolyzed in 
the cytoplasm by HocS, therefore they must be imported to be used as sole carbon and 
nitrogen sources. It has been shown that the substrate binding protein caiX [22] and the 
core components of the ABC transporter cbcWV are required for growth on carnitine [21] 
(Fig. 2A). We hypothesized that this ABC carnitine transport system has broader 
specificity and can import short-chain acylcarnitines as well. The cbcV deletion strain 
was not able to grow on SCAC as the sole carbon source, (Fig. 2). Based on the growth 
data and HocS’s cytoplasmic location, we predicted that cbcWV was necessary for SCAC 
induction of caiX, the first gene in the carnitine catabolism operon (Fig. 1). PA14WT and 
cbcV deletion mutant carrying the PcaiX-lacZ plasmid (pJAM22) were induced with 
carnitine and SCACs, and caiX transcription was assessed by β-galactosidase assays. 
Carnitine and SCACs induced transcription of caiX in wild type but in the cbcV deletion 
mutant induction was greatly reduced due to the lack of the compounds not entering the 
cytoplasm (Fig. 2B). Taken together, the growth and reporter data indicate cbcWV is 
required for transport of SCACs. 
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3.4.2. CaiX is the substrate binding protein for short-chain acylcarnitines.   
CbcWV is the core ABC transporter for three QAC substrate binding proteins 
(SBP) – CaiX, BetX, and CbcX [21]. Since cbcWV is required for transport of SCACs 
(Fig. 2), this led us to investigate if CaiX was the SBP for SCACs, which the alternate 
possibility that there may be a separate SBP that interacts with CbcWV for SCAC 
transport. To determine if caiX is required for SCAC transport we compared P. 
aeruginosa PA14 wild type to the caiX mutant for their ability to grow on SCACs as sole 
nitrogen sources and β-galactosidase assays were performed as above on PA14 wild type 
and caiX carrying the PcaiX-lacZ plasmid. The caiX mutant was unable to grow on 
SCACs (Fig. 3A) and induce the carnitine operon (Fig. 3B). These results support two 
conclusions, (i), caiX is required for growth on SCACs, and (ii), the ligand specificity of 
CaiX can be expanded to include acetyl- and butyrylcarnitine.  
 
3.4.3. Growth on medium- and long-chain acylcarnitines does not require cbcV. 
Animal and plant cells use medium- and long chain acylcarnitines as sources for 
and intermediate in beta-oxidation [26, 27], and we previously demonstrated that P. 
aeruginosa can use MCAC and LCAC as sole carbon sources [10]. We next tested if 
cbcWV was required for growth on MCAC and LCAC as sole carbon sources. PA14 wild 
type and the cbcV deletion mutant strain were able to grow in MOPS minimal media with 
acylcarnitines 6C and 10C-16C fatty acid chain length as the sole carbon source (Fig. 4). 
These data suggest that MCAC and LCAC require an entirely different transport system 
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or are hydrolyzed in the outside of the cytosol where the free fatty acid can serve as a 
carbon source. 
 
3.4.4. Medium- and long-chain acylcarnitines are hydrolyzed extracytoplasmically. 
To determine the route of medium- and long-chain acylcarnitine being transport, 
we used the carnitine responsive transcriptional reporter PcaiX-lacZYA. [22]. This 
rationale is that carnitine in the cytosol leads to caiX induction. If acylcarnitines can be 
transported into the cytoplasm and subsequently hydrolyzed, the free carnitine will 
induce caiX, whereas hydrolysis outside the cytosol would require the liberated carnitine 
to be transported via CaiX and CbcWV. Therefore, dependence on the free carnitine 
transporter components can allow us to identify the location of medium- and long-chain 
hydrolysis. Here we show that the induction of caiX is decreased by over three fold in a 
caiX and cbcV deletion mutant compared to the wild type for 6C-16C acylcarnitines, 
showing that caiX and cbcV are needed for the induction of caiX (Fig. 5A-B). The 
residual induction in these mutants will be addressed in the discussion section.  
The lack of induction of caiX while retaining the ability to grow in a cbcV mutant 
when MCAC and LCAC were the sole carbon sources, led us to postulate that hydrolysis 
of these compounds occurs outside of the cytosol. A growth assay using 6C-16C 
acylcarnitines as sole nitrogen sources revealed that the caiX and cbcV deletion mutants 
failed to grow when compared to wild type (Fig. 5C). Along with the carbon source 
growth data and induction of caiX (Fig 5A-B, Fig. 4) indicates that hydrolysis of MCAC 
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and LCAC occurs extracytoplasmically by an unidentified hydrolase and CaiX binds the 
liberated carnitine for transport through CbcWV as discussed in detail in the discussion. 
 
3.4.5. Osmoprotection by short-chain acylcarnitines requires cbcWV.  
It has been demonstrated that cbcWV is important for growth on choline but is 
not necessary for osmoprotection in a hyperosmotic environment when choline is the 
osmoprotectant [24]. We predict this is similar for carnitine and that another transporter is 
sufficient for osmoprotection. PA14 wild type and the cbcV mutant were grown in MOPS 
media with a final NaCl concentration of 850 mM, 20 mM of glucose as the carbon 
source, and 0.2 mM of the osmoprotectants carnitine, acetylcarnitine, decanoylcarnitine, 
or myristoylcarnitine. Carnitine, decanoylcarnitine, and myristoylcarnitine can be 
osmoprotectants in a cbcV mutant whereas acetylcarnitine cannot (Fig. 6). Carnitine and 
the free carnitine generated from hydrolysis outside the cytoplasm can circumvent cbcV 
by being imported through an unknown transporter to achieve osmoprotection. 
Acetylcarnitine, on the other hand, must first be imported into the cytoplasm by CbcWV 
for HocS hydrolysis in the cytosol in order to serve as an osmoprotectant [10].  
 
3.5. Discussion 
Acylcarnitines are valuable carbon and nitrogen sources, and its catabolic 
products carnitine and GB can function as osmoprotectants and induces the virulence 
factor phospholipase C, plcH [10]. In P. aeruginosa carnitine is transported by the 
substrate binding protein CaiX and the ABC transporter CbcWV but no work to date has 
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examined acylcarnitine import [21, 22]. Our goal was to understand how acylcarnitines 
are imported and determine if there is any functional overlap between carnitine and 
acylcarnitine transport system. Using growth and reporter assays we show that MCAC 
and LCAC are hydrolyzed extracytoplasmically and the free carnitine is subsequently 
imported by CaiX and CbcWV to be utilized as a sole nitrogen source. Carnitine and the 
free carnitine generated from MCAC and LCAC hydrolysis can function as an 
osmoprotectant, but cbcWV is not required. SCAC require caiX and cbcWV for transport 
into the cytoplasm and are thus necessary for osmoprotection, expression of plcH, and 
use as carbon and nitrogen sources.  
OpuC is an ABC transporter in Bacillus subtilis that imports the structurally 
similar QAC compounds carnitine, crotonobetaine, and gamma butyrobetaine [28]. The 
P. aeruginosa ABC transporter CbcWV is similar, and imports multiple QACs: glycine 
betaine, choline, and carnitine [21]. This led us to inquire if cbcWV imports other QACs 
and is involved in acylcarnitine import. Using growth assays with 2C-16C acylcarnitines 
(excluding octanoylcarnitine) as sole carbon sources, the cbcV mutant only had a defect 
on SCACs  indicating that cbcV is not required for growth of MCAC and LCACs (Figs. 2 
and 4). The substrate binding protein is the other essential component of an ABC 
transporter. Not all substrate binding proteins have a single ligand and some can 
promiscuously bind structurally similar compounds, as seen in B. subtilis [28, 29], P. 
aeruginosa [21], E. coli [30], and others [31]. In this study we have extended the binding 
specificity of CaiX to encompass acetyl- and butyrylcarnitine, as a caiX deletion mutant 
fails to grow on SCACs as sole carbon or nitrogen source. These data suggested two 
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possible methods of transport of MCAC and LCACs:  extracytoplasmic hydrolysis 
yielding carnitine and a fatty acid, or alternatively, import is through an unidentified 
transporter and cytoplasmic hydrolysis, in a manner similar to the SCACs [10]. 
Kappes and Bremer showed that Bacillus subtilis can hydrolyze acetyl- and 
octanoylcarnitine but were not able to determine if hydrolysis was on the cell surface or 
inside the cell [28]. Using the PcaiX-lacZ reporter and nitrogen growth assays, we 
showed that MCAC and LCACs are hydrolyzed outside the cytoplasm and the liberated 
carnitine is transported through CbcWV (Figs. 4 and 5). The ability of the cbcV and caiX 
mutants to use MCAC and LCACs as sole carbon sources but not as sole nitrogen sources 
indicates that the fatty acid is the predominant carbon source in this compound (Fig. 5). 
In the caiX and cbcV mutants there is residual PcaiX-lacZ induction in the carnitine and 
acylcarnitine samples, which we speculate is due to transport of carnitine through an 
unidentified BCCT transporter.  
We previously reported that P. aeruginosa cannot utilize octanoylcarnitine as a 
sole carbon source [10]. Here we show octanoylcarnitine minimally induces caiX 
compared to carnitine in wild type P. aeruginosa (Fig. 5), indicating that hydrolysis is 
inefficient and is likely responsible for the inability of P. aeruginosa to grow on 
octanoylcarnitine [10]. Caprylic acid, the 8C chain fatty acid produced from 
octanoylcarnitine hydrolysis, has antibacterial properties and is commonly used in food 
preservation, medicine, cosmetics, and agriculture [32]. Caprylic acid and other fatty 
acids inhibit growth or kill bacteria, such as Salmonella Enteritidis [33], E. coli O157:H7 
[34], S. aureus [35], and P. aeruginosa [35-37], by disrupting the cell membrane and 
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interfering with processes associate within or at the membrane such as electron transport, 
oxidative phosphorylation [32]. The outer membrane acts as a semi-permeable barrier 
and defense mechanism [32, 38], but octanoylcarnitine may circumvent this natural 
barrier if hydrolysis is periplasmic, producing caprylic acid in the periplasm. P. 
aeruginosa may have evolved a hydrolase that excludes octanoylcarnitine as a substrate, 
in part to evade the antimicrobial effects of caprylic acid. 
Acylcarnitine and carnitine transport into the cell for osmoprotection is well 
established [18]. Glycine betaine is the catabolic product of both carnitine and choline 
catabolism. Initial import of choline is through BetT1 and BetT3, with BetT3 having 
additional roles in growth and osmoprotection [24]. Choline is catabolized to glycine 
betaine which then induces cbcWV in a GbdR dependent manner, making cbcWV 
important for growth but not osmoprotection [24, 39]. Carnitine osmoprotection seems to 
functions similarly, with cbcWV being required for growth but not osmoprotection (Fig. 
6). A carnitine transporter sufficient for osmoprotection has not been identified but may 
be a BCCT transporter, as with choline, and may even be one of the BetT family of 
transporters. 
This study expands our knowledge on P. aeruginosa metabolism and transport of 
acylcarnitines. MCAC and LCACs are hydrolyzed extracytoplasmically by an unknown 
hydrolase to generate carnitine and a free fatty acid. Although cbcWV is not necessary for 
MC- and LCACs to be used as carbon sources, CbcWV provides a route for liberated 
carnitine to be used as a nitrogen source. The liberated carnitine can be used as an 
osmoprotectant via transport through an identified transporter likely a BCCT. We were 
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also able to expand the ligand specificity of CaiX to include acetyl-, and butyrylcarnitine 
which are imported via the ABC transporter CbcWV, which is required for SCAC use an 





Figure 1. Diagram of the operon configuration and ABC transporter in P. 
aeruginosa PA14 [21]. (A) Diagram of the P. aeruginosa PAO1 choline ABC transporter 
operon cbcXWV: choline substrate binding protein, cbcX; transmembrane protein, cbcW; 
and nucleotide binding protein, cbcV. (B) Diagram of the carnitine catabolism operon 
caiXcdhCABhocS: carnitine substrate binding protein, caiX; beta-keto cleavage acid 
enzyme, cdhC; carnitine dehydrogenase protein, cdhAB; and short-chain O-acylcarnitine 
hydrolase, hocS.  
 
Figure 2. cbcV is necessary for growth and induction of caiX on short-chain 
acylcarnitines. (A) PA14WT and ΔcbcV cells were grown in MOPS minimal media 
supplemented with 20 mM carnitine, acetylcarnitine, or butyrylcarnitine. Cultures were 
grown at 37 °C for 24 hours prior to reading them at OD600 nm. (B) PA14 WT and 
ΔcbcV carrying caiXlacZ plasmid (pJAM22) were grown in MOPS, 20 mM pyruvate, 20 
µg ml
-1
 gentamicin, and with or without 1 mM inducing compound carnitine, 
acetylcarnitine or butyrylcarnitine. Cells were induced for 4 hours at 37 °C before 
performing a Miller assay. AC is acetylcarnitine and BC is butyrylcarnitine. Two way 
ANOVA. ns, not significant; ****, P < 0.0001.  
 
Figure 3. CaiX is the substrate binding protein for short-chain acylcarnitines. (A) 
PA14WT and ΔcaiX cells were grown in MOPS minimal media supplemented with 20 
mM carnitine, acetylcarnitine, or butyrylcarnitine. Cultures were grown at 37 °C for 24 
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hours prior to reading them at OD600 nm. (B) PA14 WT and ΔcaiX carrying caiXlacZ 
plasmid (pJAM22) were grown in MOPS, 20 mM pyruvate, 20 µg ml
-1
 gentamicin, and 
with or without 1 mM inducing compound carnitine, acetylcarnitine, or butyrylcarnitine. 
Cells were induced for 4 hours at 37 °C before performing a Miller assay. AC is 
acetylcarnitine and BC is butyrylcarnitine. Two way ANOVA. ns, not significant; ****, 
P < 0.0001 
 
Figure 4. Medium- and long-chain acylcarnitines do not require cbcV for growth. 
PA14WT and cbcV deletion mutant were grown in MOPS with 20 mM of carnitine or 
acylcarnitines 6C, 10C-16C fatty acid chain length for 24 hours at 37 °C. OD600 nm was 
taken on a BioTek plate reader except for palmitoylcarnitine, which was determined by 
CFU due to micelle formation. One way ANOVA. ns, not significant; *, P < 0.05; ***, P 
< 0.001; ****, P < 0.0001 
 
Figure 5. caiX and cbcV are required for growth when acylcarnitines are the sole 
nitrogen source. (A) PA14WT (white bars), ΔcbcV (gray bars), and ΔcaiX (black bars) 
cells were grown at 37 °C in M63 minimal media supplemented with 20 mM pyruvate 
and 2 mM nitrogen source; ammonium, carnitine, or acylcarnitines 6C-16C fatty acid 
chain-length. Growth was assessed after 24 hours by OD600 nm. Two way ANOVA 
comparing carnitine to ΔcbcV and ΔcaiX. ns, not significant; ****, P < 0.0001 (B) 
PA14WT was induced for 4 hours at 37 °C in MOPS with 20 mM pyruvate, 20 µg ml
-1
 
gentamicin, and 1 mM carnitine, or 6C-16C acylcarnitines. Miller assays were 
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performed. ns, not significant; **, P < 0.01 (C) PA14WT, ΔcbcV, and ΔcaiX were 
induced for 4 hours at 37 °C in MOPS with 20 mM pyruvate, 20 µg ml
-1
 gentamicin, and 
1 mM carnitine, or 6C-16C acylcarnitines. Miller assays were performed. ns, not 
significant; ****, P < 0.0001 
 
Figure 6. Short-chain acylcarnitines require cbcWV for osmoprotection in 
hyperosmotic conditions. P. aeruginosa PA14WT and ΔcbcV were grown in MOPS 
supplemented with 800 mM NaCl, 20 mM glucose, and with or without 0.2 mM 
osmoprotectants carnitine, acetylcarnitine, decanoylcarnitine, or myristoylcarnitine for 48 
hours before reading the OD600 nm. ns, not significant; ****, P < 0.0001 
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Figure 6. Short-chain acylcarnitines require cbcWV to function as osmoprotectants 
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CHAPTER 4:  
 





 Pseudomonas aeruginosa is found in numerous environments and is an 
opportunistic pathogen affecting those who are immunocompromised. The large 
metabolically diverse genome and regulatory network that P. aeruginosa possesses make 
it versatile to adapting to various environments. We are interested in how P. aeruginosa 
senses and responds to host-derived compounds. Previously we identified CdhR and 
GbdR, members of the AraC transcription factor family that regulate catabolism of the 
quaternary amine compounds carnitine and glycine betaine (GB), respectively. Our goal 
was to further characterize regulation of carnitine catabolism by the TF CdhR. Here we 
report that CdhR binds in a concentration dependent manner to the enhancer site near the 
carnitine operon promoter (PcaiXcdhCABhocS). We identified the CdhR binding site and 
compared with the known GbdR binding consensus, to show that the two binding sites 
overlap in the caiX-cdhR intergenic region. Carnitine catabolism is repressed by glucose 
and GB at the transcriptional level. Furthermore, using two different cdhR translational 
fusions we show that CdhR enhances its own expression and that GbdR contributes to 
cdhR expression by enhancing the level of basal expression. 
 
4.2. Introduction 
Pseudomonas aeruginosa is a Gram-negative bacterium found in soil, water, on 
skin and on surfaces, such as bed rails, catheters, and other medical devices [1, 2]. From 
the sites it can transition into being an opportunistic human pathogen that is the leading 
cause of infection in people with severe burns [3], and those with lung diseases like 
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chronic obstructive pulmonary disease, ventilator-associated pneumonia, and cystic 
fibrosis, resulting in increased morbidity and mortality [4-7]. With antibiotic resistance 
on the rise [8], P. aeruginosa is difficult to treat and is a burden on our health care system 
[9]. The ability to transition from one environment to the next and cause disease is, in 
part, due to its large genome, with 5% of genes predicted to encode proteins related in 
carbon metabolism [10].  
 Carnitine and O-acylcarnitines are quaternary amine compounds that are 
abundant in host tissues and shuttle fatty acids in and out of the mitochondria for β-
oxidation in animals [11]. There are no animal enzymes that can breakdown carnitine, 
consequently any degradation is due to bacteria [12], like P. aeruginosa [13]. No de novo 
synthesis of carnitine has been demonstrated in bacteria [14], therefore P. aeruginosa 
acquires it from the environment by import through the ABC transporter CbcWV [15]. P. 
aeruginosa contains a carnitine catabolism operon caiXcdhCABhocS, which encode 
enzymes to degrade short-chain acylcarnitines and carnitine for osmoprotection, and its 
catabolic product glycine betaine (GB) induces the virulence factor phospholipase C, 
plcH and be used as sole carbon, nitrogen, and energy source  [16-19]. Medium- and 
long-chain acylcarnitines, with the exception of octanoylcarnitine, can be used as sole 
carbon sources as well, [16]. 
The ability to adapt to numerous environments can be attributed to the large 
regulatory repertoire that P. aeruginosa possesses. More than 9% of the genome is 
dedicated to transcriptional regulation, including regulation of metabolism, giving the 
bacterium metabolic flexibility [10]. One such regulator is CdhR, which is divergently 
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transcribed from the carnitine catabolism operon and is required for growth on carnitine 
and induction of the carnitine operon [17]. Carnitine degradation leads to the formation of 
glycine betaine, whose catabolism is regulated by GbdR [20]. GbdR and CdhR not only 
regulate catabolism of quaternary amine compounds but both are AraC-family 
transcription factors that belong to the same GATase-1 subfamily and are highly similar 
in sequence (62% positive and 44% identities) [21].  
In this study we expand our understanding of the regulation of carnitine 
catabolism, by identifying the enhancer site, essential residues, and showing catabolite 
repression from glucose and glycine betaine function at the level of transcription of the 
carnitine operon. Although an additional CdhR binding site was found upstream of 
cbcWV to which CdhR binds in a concentration dependent manner, we established that 
transcription from this locus is controlled solely by GbdR in response to glycine betaine. 
GbdR is also capable of binding the intergenic region of caiX-cdhR in an orientation 
suggesting regulation of cdhR. Additionally, CdhR positively regulates its own 
expression in the presence of carnitine but represses basal expression in the absence of 
ligand, however GbdR alleviates this repression. We propose that there is a hierarchy to 
CdhR and GbdR binding at their shared binding site with and without ligand. 
 
4.3. Materials and methods 
4.3.1. Strains and growth conditions 
Pseudomonas aeruginosa strains PAO1 and PA14 were maintained on PIA 
plates or Lennox broth (LB) liquid, and when necessary 50 µg ml
-1





gentamicin was added to the media, respectively. Escherichia coli NEB5α or T7 Express 
E. coli (NEB C3016) were maintained on LB plates with 10 µg ml
-1
 gentamicin, LB 
liquid with 7 µg ml
-1
 gentamicin, LB plates/liquid with 125 µg ml
-1
 carbenicillin, or LB 




4.3.2. Deletion and complementation constructs  
A clean deletion of PA5389 (cdhR) in PAO1 was made in the wild type strain 
MJ79. The upstream and downstream regions of PA5389 were PCR amplified from 
PAO1 genomic DNA with the primers 5389GOIF1KpnI, 5389SOEGOIR1, 
5389SOEGOIF1, and 5389GOIR1BamHI. Splice overlap extension PCR product was 
ligated into the Zero Blunt™ plasmid pCR (Invitrogen), excised with EcoRI, and ligated 
into similarly cut pMQ30 to generate pJAM90.  Donor E. coli S17λpir carrying pJAM90 
were mated with PAO1 and screened as previously described [16], generating strain 
JM236. Deletion strain was verified by lack of growth on carnitine and by PCR. 
To make a double mutant of cdhR and gbdR in PA14, the ΔgbdR PA14 strain 
MJ26 was used as the recipient strain for mating with E. coli S17λpir carrying pJAM90 
as described above. Double mutant strain was verified by PCR.  
  
4.3.3. Construction of transcriptional constructs  
To determine the promoter of PA5388 (caiX) four different truncations of the 
upstream region of caiX were cloned as transcriptional reporter constructs. pMW79 was 
used as the PA14 PCR template for amplifying the upstream region of caiX. 
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PA5388promR is the reverse primer used in all four reactions and the forward primers are 
PA5388promF1, PA5388promF2, PA5388promF3, and PA5388promF4. The four PCR 
products were ligated into the Zero Blunt vector pCR, digested with KpnI and HindIII, 
and ligated into a similarly cut pMW5 to yield four different P5388lacZYA transcriptional 
fusions (pJAM22-pJAM25). Each was electroporated into PA14WT and selected on PIA 
gentamicin plates.  
To assess which residues were essential for induction of caiX, seven different 
transcriptional reporters were constructed by amplifying the caiX binding site from 
pMW79 using the 5388promR primer and seven different forward primers: P5388pos, 
P5388mut1, P5388mut2, P5388mut3, P5388mut4, P5388mut5, P5388mut6. PCR 
products were digested with HindIII and KpnI, and ligated into similarly cut pMW5. The 
resulting plasmids pJAM122-pJAM127 and pJAM130 were electroporated into PA14WT 
and selected on PIA gentamicin.  
  
4.3.4. Construction of translational constructs  
To determine translational control of cdhR a divergent fluorescent translational 
reporter with YFP and CFP on either side of the intergenic region of PA5388 and PA5389 
was made. YFP was amplified using primers YFP F Kpn Sal and YFP R HindIII from the 
template pUC18miniTn7T-Gm-eyfp [22]. The YFP fragment was ligated into pCR Zero 
Blunt plasmid, digested with HindIII and KpnI, and subsequently ligated into similarly 
cut pMQ80. The resulting plasmid was digested with EcoRI and SacI and ligated with a 
P. aeruginosa codon-biased CFP made by IDT, which was cut with EcoRI and SacI, to 
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generate pJAM76. The PA5388-PA5389 intergenic region was amplified using primers 
88-89YC-DR#2ycF and 88-89YCDR#2ycR. pJAM76 was then digested with SalI to 
linearize the plasmid for recombination of the PA5388-PA5389 intergenic regions using 
yeast cloning in Saccharomyces cerevisiae via the method of Shanks et al [23]. The 
resultant constructed plasmid was digested with HindIII and ligated into similarly cut 
pUC18-mini-Tn7T-Gm yielding pJAM86, which was coelectroporated with pTNS2 to 
insert CFP-PA5388-PA5389-YFP onto the chromosome at the attTn7 site of strains 
PAO1 wild type, PAO1ΔcdhR and PAO1ΔgbdR. 
 A PA5389 translational lacZ fusion was made by inserting a gBlock™ made by 
IDT that has 320 base pairs of the upstream region of PA5389 to the translational start 
site of PA5389 and then from the translational start site of lacZ to + 850 bases in the lacZ 
gene into pJAM131. pJAM131 was built by PCR amplifying the C-terminal end of lacZ 
with primers 2-lacZCtermFhindcla and 2-lacZCtermRsmakpn, digested with HindIII and 
KpnI, and ligated into a similarly cut pUCP22. The gBlock was digested with HindIII and 
ClaI and ligated into similarly cut pJAM131 to make pJAM135. 
 
4.3.5. Cloning and expression of MBP-CdhR  
The expression plasmid pJAM50, a maltose binding protein (MBP) fusion to the 
amino-terminus of CdhR was made by PCR amplifying cdhR with primers 5389Mal-
C2XF and 5389Mal-C2XR, and the product was ligated into Zero Blunt pCR vector. 
cdhR was extracted with EcoRI and HindIII and ligated into the similarly cut pMal-C2X 
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(NEB), transformed by electroporation into T7 Express E. coli (NEB C2566), and 
selected on LB carbenicillin to make strain JM153.   
 To express MBP-CdhR, 1L of JM153 was grown at 37 °C in LB with 75 µg ml
-1
 
to an OD600 of 0.4. The culture was induced with 1 mM IPTG and grown for an 
additional 3 hours. Cells were collected by centrifugation and resuspended in 20 mM Tris 
HCl, 150 mM NaCl, pH 7.4 with 1X halt protease inhibitor cocktail (Thermo) and lysed 
by French press. DNaseI was added to the lysate and incubate room temperature for 15 
minutes. Samples were centrifuged at 13K rpm for 30 minutes at 4 °C to separate the 
soluble and insoluble fractions.  The soluble fraction was filtered through a 0.22 µm filter 
and applied to an Affi-Gel Heparin Gel (BioRad) column. The column was washed with 
column buffer (10 mM KH2PO4, 150 mM NaCl, pH 7.4 in 1XPBS) and MBP-CdhR was 
eluted from the column with column buffer plus 1.5 M NaCl. Fractions containing MBP-
CdhR were run on a 12% SDS denaturing gel and stained with coomassie brilliant blue 
(Thermo) to verify purity and determine which fractions to use. Elutions containing 
MBP-CdhR were dialyzed in a 20K MWCO slidealyzer (Thermo) overnight at 4 °C in 
buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 7.4).  
  
4.3.6. Primer extension  
Transcriptional start site of caiX and cdhR were determined by growing 
PA14WT carrying pMW79 [17] or PA14WT carrying pJAM135, respectively,  in MOPS, 
20 mM pyruvate, 5 mM glucose, and 20 µg ml
-1
 gentamicin overnight at 37 °C. Cells 
were washed, resuspended to an OD600 nm of 0.3 in MOPS supplemented with 20 mM L-
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carnitine or pyruvate and 20 µg ml
-1
 gentamicin in a 12 well-plate, and grown for 7 hours 
at 37 °C while shaking. Cells were collected by centrifugation and RNA was purified per 
the instructions of the RNeasy Mini Kit (Qiagen).  Primer extension was completed using 
the purified RNA as the template for cDNA generation using the Superscript II RT 
(Invitrogen) and the 5'-fluorescein-labeled primers 5388primerextension or 
5389primerextension. The cDNA products were analyzed by capillary electrophoresed on 
an ABI to determine the size of the DNA fragment of the induced carnitine sample verses 
the uninducing pyruvate and by comparing it to a known DNA size standard. 
 
4.3.7. Beta-galactosidase assays  
Strains were grown overnight at 37 °C in MOPS minimal media supplemented 
with 20 mM pyruvate, 5 mM glucose, and 20 µg ml
-1
 gentamicin. Cells were collected by 
centrifugation, washed, resuspended in MOPS and inoculated into MOPS with 20 mM 
pyruvate, 20 µg ml
-1
 gentamicin, and with or without 1 mM inducing compound 
carnitine. Induction was carried out for 4 hours at 37 °C, and β-galactosidase assays were 
performed according to Miller [24]. 
 
4.3.8. Catabolite repression  
PA14WT carrying pJAM22 was grown overnight at 37 °C in MOPS with 20 
mM pyruvate, 5 mM glucose, and 20 µg ml
-1
 gentamicin. Cells were collected by 
centrifugation, washed, and resuspended in MOPS, and inoculated into MOPS with 20 
mM pyruvate and 20 µg ml
-1
 gentamicin at a final OD600 of 0.05. All samples had 1 mM 
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of the inducting compound carnitine except for the noninducing control (pyruvate alone). 
Catabolite repression samples had either glucose at 2 mM, 4 mM, or 10 mM or glycine 
betaine at 20 mM or 40 mM. Cultures were induced for 4 hours at 37 °C, and β-
galactosidase assays were performed according to Miller [24]. 
 
4.3.9. Electrophoretic Mobility Shift Assays (EMSA)  
To determine binding of MBP-CdhR or MBP-GbdR to promoters, EMSAs were 
performed as previously described [21]. Briefly, caiX, dhc, cbcX, cdhR, or cdhR mutant 
promoter DNA fragments were made by PCR amplification from PA14 genomic DNA 
template with primers listed in the EMSA primer section in Table 2. The DNA probes 
were dialyzed in ¼ TE on a 0.025 µm filter for 20 minutes and verified by PCR. EMSAs 
were conducted by following the LightShift Chemiluminescent EMSA kit instructions 
(Pierce) as modified by Hampel et al [21]. Samples were electrophoresed on 5% TBE 
nondenaturing gels, transferred to BioDyne-B nylon membrane (Thermo), and detected 
using the Chemiluminescent Nucleic Acid Detection Module (Thermo) per 
manufacturer’s instructions. 
 
4.3.10. DNaseI footprinting assay 
DNaseI footprinting was performed as described previously [21]. Briefly, the 
target DNA was made by labeling the 5' end of one the primers PA5388promR or 
PA5388promF2 with 
32
P using T4 polynucleotide kinase and [γ-32P]ATP, and amplifying 
the PA14 caiX upstream region. The radiolabeled PCR product was purified from a 5% 
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polyacrylamide Tris-borate-EDTA gel. The MBP-CdhR footprinting assay was 
conducted as in Brenowitz [25] and Hampel et al [21]. 
 
4.3.11. Fluorescent microscopy  
P. aeruginosa PAO1 strains WT, ΔcdhR, and ΔgbdR with the divergent 
fluorescent reporter PA5388-PA5389 intergenic region CFPYFP-DR2 (pJAM86) at the 
attTn7 site, were grown overnight in MOPS with 20 mM pyruvate and 5 mM glucose at 
37 °C. Cells were centrifuged, washed, and resuspended in MOPS to an OD600 of 1.0. A 
1/20 dilution was made and 1 µl was placed on the center of the agar pad (1.5% low 
melting agarose, MOPS, 20 mM pyruvate, and with or without 1 mM carnitine). The agar 
pad was placed upside down on a 50 mm glass bottom cell culture dish (Warner 
Instruments). Samples were imaged on a Nikon Ti-E, every 10 minutes for 6 hours, at 32 
°C and exposure time was 100 msec for phase and 500 msec for YFP. Image stacks were 
imported into Fiji 2.0.0-rc-29/1.49s [26] using the Bio-Formats Importer 5.1.1 [27].  A 
rolling variance filter on the contrast channel was used to define background areas, and 
after an additional threshold was applied, the find maxima macro was used to define cell 
areas.  Using masks from the contrast channel mean pixel intensity measurements were 
taken from the YFP channel.  A framewise background intensity correction was 







4.4.1. Promoter mapping reveals the CdhR binding site.  
The carnitine catabolism operon, caiX-cdhCAB-hocS (Fig. 1), encodes proteins 
that are responsible for the hydrolysis of short-chain acylcarnitines [16] and degradation 
of carnitine to glycine betaine [17, 29]. cdhR is divergently transcribed from the carnitine 
catabolism operon (Fig. 1), and was previously shown to be required for induction of 
caiX and growth on carnitine [17]. To expand upon this basic understanding of CdhR’s 
role in carnitine catabolism, we determined the binding site of CdhR by promoter 
mapping of PcaiX using four sequentially shorter lacZYA transcriptional reporters. The 
constructs end at base pair (bp) -22 from the caiX translational start site and begin at bp -
424 (pJAM22), bp -327 (pJAM23), bp -241 (pJAM24), and bp -137 (pJAM25)(Fig. 2). In 
the presence of carnitine all constructs except pJAM25 were induced, indicating that the 
binding site of CdhR is between bp -241 and -137 (Fig. 2). The binding site may also 
overlap with bp -137 with a partial site not sufficient to induce of caiX. 
 Primer extension was used to define the transcriptional start site of caiX and 
cdhR. Plasmids containing the target regions were used to increase RNA copy number, 
particularly for cdhR, as native transcripts are at low abundance [30]. The length of the 
caiX primer extension product place the transcriptional start site 25 bases upstream of the 
translational start site at a thymine residue. The length of the cdhR primer extension 
primer placed the transcriptional start site 63 bases upstream of the translational start site 




4.4.2. Glucose and glycine betaine repress the transcription of caiX. 
In P. aeruginosa the enzymatic activity of carnitine dehydrogenase (CDH) 
declines until no longer detectable if the cells are switched from carnitine to the preferred 
carbon source glucose, and the activity oscillates when carnitine is the sole carbon 
source. It is thought that oscillation occurs when the catabolic product glycine betaine is 
produced, resulting in initiation of a negative feedback oscillation loop [31]. To assess 
catabolite repression, we used the caiX-lacZYA transcriptional reporter (pJAM22) to 
determine if repression is transcriptionally regulated. Maximal catabolite repression is 
seen at 4 mM glucose, while GB represses transcription to a lesser extent and at a higher 
concentration (Fig. 3). 
 
4.4.3. MBP-CdhR binds the caiX upstream activating site in a concentration-
dependent manner. 
Based upon CdhR-dependent transcriptional induction of caiX, we assayed the 
capability of purified MBP-CdhR to bind to the activing site (UAS) of caiX. Using biotin 
labeled caiX UAS as the DNA probe and purified MBP-CdhR, electrophoretic mobility 
shift assays revealed that MBP-CdhR binds the caiX UAS in a concentration dependent 
manner (Fig. 4 lanes 1-4). The binding interaction between MBP-CdhR and caiX probe 
can be competed with unlabeled caiX probe (lane 5) and MBP-CdhR does not shift a 
nonspecific UAS, dhcA (lanes 6-8). These data demonstrate that MBP-CdhR binds 




4.4.4. Identification of the CdhR binding site sequence and bases required for 
induction of caiX. 
Promoter mapping and EMSAs determined the region of DNA essential binding 
of CdhR and transcriptional induction of caiX. To further characterize the CdhR DNA 
contact site and binding site sequence within the caiX UAS, we employed DNaseI 
footprinting. Purified MBP-CdhR and radiolabeled caiX UAS demonstrated the 
characteristic and site specific protection of DNA as protein concentration increased. 
Comparing the zone of protection to the A+G ladder we were able to identify the CdhR 
contact region, stretching 34 bases (Fig. 5). The CdhR binding site reveals the half sites 
each contain the sequence GGTCGC with 15 bases in between, which is very similar to 
the binding sites of two other P. aeruginosa AraC transcription factors, GbdR [21] and 
ArgR [32]. In order to further characterize the CdhR binding site, we made mutations in 
the distal repeat by systematically changing partially overlapping two bases to adenosines 
(pJAM122-127). Using LacZ as the reporter, induction of the mutated caiX binding sites 
was assessed to determine that the second guanine residue in the repeat is essential for 
caiX expression but complete abolishment of expression requires an additional 
transversion mutation of the adjacent locus thymine residue (Fig. 5).  
 
4.4.5. CdhR binds, but does not regulate the ABC transporter cbcXWV. 
After establishing the CdhR binding sequence, GGTCGC-[N15]-GGTCGC, we 
wanted to identify if the sequence was located elsewhere in the P. aeruginosa PAO1 
genome. Using the DNA motif search tool from the Pseudomonas Genome Database 
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website [33], only two sites were identified within intergenic regions, caiX-cdhR and 
cbcX-sdaB, both of which are involved in carnitine metabolism [15, 17]. CbcXWV is an 
ABC transporter and the core transporter proteins CbcWV are required for growth on 
carnitine [15]. A MBP-CdhR EMSA with the cbcX promoter DNA probe shows MBP-
CdhR binding in a concentration dependent manner (Fig. 6A), but the qRTPCR data 
reveals carnitine is not sufficient for induction of cbcX (Fig. 6B). We used the cdhCA 
deletion to eliminate production of GB from carnitine (Fig. 1) [17]. In order to induce 
cbcX, GB must be produced to allow induction of cbcX transcription via GbdR [21]. 
 
4.4.6. GbdR binds the intergenic region of caiX-cdhR.  
The ability of CdhR to bind a known member of the GbdR regulon (cbcX ) [21, 
34], the detection of the GbdR binding consensus in the caiX-cdhR intergenic region [21], 
and the overlapping position of the CdhR and GbdR binding sites led us to further 
investigate the role of GbdR in carnitine regulation. We predicted that GbdR would be 
able to bind the cdhR UAS and an EMSA with purified MBP-GbdR in association with 
the cdhR UAS showed that MBP-GbdR binds the cdhR UAS in a concentration 
dependent manner (Fig. 7A). When the GbdR conserved residues CG in the distal half 
site were mutated to AA, binding was lost (Fig. 6), as seen with the plcH and choE 
mutated distal half site [21]. Since GbdR binds the caiX-cdhR intergenic region, 
induction of caiX (pJAM22) was assessed in relation to GbdR. A gbdR mutant has 
significantly less induction of caiX but this defect is likely due to a defect in carnitine 
import (as discussed in chapter 3). In addition, these data suggest that GbdR is not the 
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transcriptional activator of cdhR since caiX is induced in a gbdR mutant, whereas in a 
cdhR mutant, caiX induction is completely abolished.  
 
4.4.7. CdhR is required for induction of cdhR expression.  
After establishing that CdhR and GbdR bind the intergenic region of caiX-cdhR, 
we wanted to determine expression of cdhR using a translational reporter in relation to 
CdhR and GbdR. Using two different translational fusions, one carried on a plasmid and 
one integrated into the chromosome at the attTn7 site, it became apparent that CdhR has 
a role in its own expression. In wild type carnitine increased expression of cdhR 
compared to the basal expression level (uninduced) (Fig. 8). In the absence of gbdR, 
carnitine still induces cdhR, but basal expression of cdhR is decreased compared to wild 
type and a cdhR deletion, suggesting that GbdR functions to relieve repression at this 
locus (Fig. 8). These data analyzing the expression of cdhR may represent a hierarchy of 
the transcription factors GbdR and CdhR which we will discuss below. 
 
4.5. Discussion 
 The metabolic diversity of P. aeruginosa is a product of the immense regulatory 
network encoded in the genome and it is this network of transcription factors (TF) that 
are a critical mechanism for sensing environmental cues [35]. One such family of 
transcription factors that controls carbon metabolism and virulence is the AraC 
transcription factor family. In this study we expand on our understanding of carnitine 
catabolism and how two AraC transcription factors, CdhR and GbdR, whose metabolic 
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pathways converge at glycine betaine (Fig. 1), are intertwined. We identified the CdhR 
enhancer site and through reporter and DNA binding assays reveal this site as an 
additional GbdR binding site. Through reporter fusions we were able to show that CdhR 
regulates its own expression is responsive to carnitine. We also show that GbdR binding 
to caiX-cdhR region assists in regulating carnitine catabolism by inhibiting repression of 
caiX and cdhR transcription and maintaining a basal cdhR expression level. 
The first question we addressed was how CdhR binds and regulates the carnitine 
operon. CaiF in E. coli is the only other carnitine regulator that has been characterized to 
date, and is a degenerate AraC TF that lacks the traditional N-terminal domain but 
maintains the helix-turn-helix DNA binding domains [36]. However, CaiF is transcribed 
in the opposite direction from the carnitine metabolism operon (caiTABCDE) and binds 
to inverted repeats in the enhancer site [36, 37]. P. aeruginosa and other Gram-negative 
bacteria that contain a carnitine catabolism operon capable of generating glycine betaine 
are organized in similar fashion to one another with an AraC-family transcription factor 
divergently transcribed from the catabolic operon [38]. CdhR binds to direct repeats and 
the binding site is upstream of the caiX promoter (Fig. 5), categorizing CdhR as a class I 
activator that requires both half sites for induction of caiX (Fig. 2).  
Kleber and Aurich analyzed the activity of carnitine dehydrogenase (CDH) with 
respect to glucose and glycine betaine and showed that glucose, as a preferred carbon 
source, is catabolite repressive [31], whereas glycine betaine leads to repression of CDH 
activity resulting in oscillations of activity as carnitine is catabolized to GB [31]. Our 
data shows that repression by glucose and glycine betaine is controlled at the level of 
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transcription (Fig. 3). Negative feedback by glycine betaine is likely GbdR dependent 
based on GbdR’s capability to bind the caiX-cdhR intergenic region and GbdR’s 
responsiveness to GB [39]. P. aeruginosa maintains intracellular glycine betaine pools 
and GbdR fine tuning carnitine catabolism may be directly related to sustaining the 
homeostatic levels of glycine betaine, as the pool has a physiological impact on nutrients, 
osmoprotection and virulence [40]. Chapter 5 address experiments to test whether this is 
the case. 
 We performed an alignment using the Pseudomonas.com DNA motif search tool 
of the newly identified CdhR binding sequence to the PAO1 genome and identified two 
intergenic regions: caiX-cdhR and cbcX-sdaB [33]. This led us to investigate if CdhR 
contributes to the regulation of carnitine import by the ABC transporter cbcXWV, which 
is required for growth on carnitine [15]. Even though CdhR binds to the cbcX upstream 
region in vitro, it does not contribute to cbcX expression (Fig. 6). We propose that an 
unknown BCCT transporter imports carnitine, it is degraded to GB, which drives 
expression of cbcXWV in a GbdR dependent manner allowing for a larger flux of 
carnitine which is needed for growth [15]. This is similar to the mechanism of choline 
import for cbcXWV induction, termed priming [34]. 
We previously characterized the GbdR regulon and identified the intergenic 
region of caiX-cdhR to have a GbdR binding site [21]. Here we report that GbdR binds 
the caiX-cdhR intergenic region in vitro and the conserved CG residues are necessary for 
GbdR binding, as mutating the residues to AA results in loss of binding (Fig. 7). Based 
upon the conserved residues being located in the distal half site [21], the orientation of 
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GbdR binding is likely oriented towards cdhR activation and not caiX. Interestingly, the 
GbdR and CdhR binding sites overlap in the caiX-cdhR intergenic region, which led us to 
hypothesize that GbdR has a role in regulating carnitine catabolism and in particular 
cdhR.  
 Based on what we know about GbdR and what we presented here, we propose a 
schematic for the interplay of the two AraC TFs and how they regulate carnitine 
catabolism. In the absence of carnitine, CdhR binds to its target site in a manner that 
inhibits cdhR expression.  GbdR can compete for the binding sites and prevent CdhR-
dependent inhibition by CdhR, based on comparisons of basal expression levels (Fig. 8). 
Analyzing the DNA sequence up and downstream of the CdhR binding site reveals 
multiple CdhR half sites. These half sites could be participating in CdhR inhibition of 
basal expression. CdhR inhibition of its own expression may be similar to the AraC 
‘light-switch’ mechanism (Figure in Chapter 1). In the absence of ligand, one AraC DNA 
binding domain binds an operator half site promoting DNA looping and prevents 
expression of the arabinose operon araBAD. Upon ligand binding AraC undergoes a 
conformational change promoting binding of both half sites of the enhancer and inducing 
transcription [41]. Another possibility is that CdhR oligomerizes along the DNA 
nucleated at these half sites and dampens cdhR basal expression. In this model, GbdR 
could compete for binding, supported by the lower basal expression in a gbdR mutant, 
where CdhR is binding and inhibiting cdhR expression. Furthermore, CdhR binding of 
carnitine causes a conformational change, allowing CdhR to increase expression of cdhR 
and caiX (Fig. 8). As the catabolic product GB builds up, the cell controls the flux of 
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carnitine catabolism by GB-dependent transcriptional repression, which is likely 
regulated by GbdR.  Fine tuning of this pathway is predominately controlled by GbdR, a 
principal regulator. 
In conclusion, we show regulation of carnitine catabolism is controlled by two 
transcription factors that contribute to fine tuning of the system depending on when and if 
ligands are present. We put forward a hierarchy of regulation, where one transcription 
factor trumps the next depending on ligand: GbdR+GB > CdhR+carnitine > GbdR > 
CdhR. This system has likely evolved to control nutrient acquisition, virulence, GB 
pools, and possibly other metabolic bi-products like formaldehyde and peroxide, which 





Table 1. Strains and plasmids used in this study 
 
Strain or plasmid Genotype or description                                          Reference 
P. aeruginosa PAO1 
MJ79 wild type [10] 
MJ80 ΔgbdR [20] 
JM236 ΔcdhR  This study 
JM253 wild type::88-89intYFPCFP-2 This study 
JM339 ΔcdhR::88-89intYFPCFP-2 This study 
JM340 ΔgbdR::88-89intYFPCFP-2 This study 
 
P. aeruginosa PA14 
MJ101 wild type [42] 
MJ11 ΔcdhR [17]  
MJ26 ΔgbdR [20] 
MJ262 ΔcdhCA [17] 
JM179 ΔcdhR ΔgbdR This study 
 
E. coli 
MJ340 wild type S17λpir  
DH5α NEB C2987 NEB 
T7Express NEB C3016 NEB 
 
Plasmids 
pMQ30 suicide vector, Gm
r
 [23] 
pMQ80 high-copy number Pseudomonas vector, Gm
r
 [23] 
pMal-C2X T7 Expressing vector, MBP N-terminal tag, Amp
r
 NEB 
pTNS2 plasmid carrying the attTn7 transposase [43] 
pUC18-mini-Tn7T-Gm Gm
r
 on mini-Tn7T [22] 
pUC18-mini-Tn7T-Gm-eyfpGm
r
 on mini-Tn7T with YFP [22] 
pUCP22 high copy # Pseudomonas stabilization vector, Gm
r
 [44] 
pMW5 lacZYA in pUCP22 [39] 
pMW79 PA14 genomic clone of PA5380-PA5389 in pMQ80 [17] 
pJAM22 promoter caiX-lacZYA transcriptional fusion-A This study 
pJAM23 promoter caiX-lacZYA transcriptional fusion-B This study 
pJAM24 promoter caiX-lacZYA transcriptional fusion-C This study 
pJAM25 promoter caiX-lacZYA transcriptional fusion-D This study 
pJAM50 PA5389 in pMal-C2X This study 
pJAM76 YFP-CFP in pMQ80 This study 
pJAM86 CFP PA5388-PA5389 intergenic region YFP in  This study 




pJAM90 PA5389 deletion contruct in pMQ30 This study 
pJAM122 promoter caiX-lacZYA transcriptional fusion This study 
pJAM123 promoter caiX-lacZYA mut 1 transcriptional fusion This study 
pJAM124 promoter caiX-lacZYA mut 2 transcriptional fusion This study 
pJAM125 promoter caiX-lacZYA mut 3 transcriptional fusion This study 
pJAM126 promoter caiX-lacZYA mut 4 transcriptional fusion This study 
pJAM127 promoter caiX-lacZYA mut 5 transcriptional fusion This study  
pJAM130 promoter caiX-lacZYA mut 6 transcriptional fusion This study 
pJAM131 C terminus of lacZ in pUCP22 This study 





Table 2. Primers used in this study 
 








Protein expression construct 
5389Mal-c2xF  GCATCAgaattcTCCCAGGACTTCTGGTTTCT 
5389Mal-c2xR  GCATCAaagcttTCAGCCTCGCTCAGCTCGA   
 
Primer extension 
5388primerextension  5'-fluorescein 6 fam-ACTGGCCAGGATCAGCAGG 






5389EMSA-F  ATGAaagcttGCAGCAGGAGAAACCAGAAG  










PA5388promF1  ATGAaagcttACAGCAGGTCGCCTTTCTT 
PA5388promF3 aagcttGTGCCAGCGGTAGAGGTC 
PA5388promF2  ATGAaagcttGCAGCAGGAGAAACCAGAAG 
PA5388promF4  aagcttCTGCAGTGCAAGAGCTGGT 
P5388pos ATGAaagcttCGCTTGGCAATGGCCAGGTCGCT 
P5388mut1  ATGAaagcttCGCTTGGCAATGGCCAAATCGCT 
P5388mut2  ATGAaagcttCGCTTGGCAATGGCCAGAACGCT 
P5388mut3 ATGAaagcttCGCTTGGCAATGGCCAGGAAGCT 
P5388mut4  ATGAaagcttCGCTTGGCAATGGCCAGGTAACT 









YFP R HindIII GCATCAaagcttATTACTTGTACAGCTCGTCCA 











Figure 1. Diagram of the P. aeruginosa PAO1 carnitine catabolism operon and the 
catabolic pathway. (A) Arrows represent the individual open reading frames of the 
carnitine catabolism operon and the regulator cdhR. Below the arrow is the designated 
gene name. (B) A diagram of the converging carnitine and choline catabolism pathways. 
Black arrows represent an enzymatic step in the catabolic pathway and the gene names 
are italicized below. The blue arrows represent positive regulation by either CdhR or 
GbdR and the T bar represents repression by BetI.  
 
Figure 2.  Promoter mapping of the upstream region of caiX exposes the CdhR 
binding site. Transcriptional fusions of lacZ to the upstream region of caiX starts at base 
pair -22 from the caiX translational start site and end at base pair -424 for pJAM22, -327 
for pJAM23, -241 for pJAM24, and -137 for pJAM25. P. aeruginosa PA14 carrying 
pJAM22, pJAM23, pJAM24, or pJAM25 were grown in MOPS with 20 mM pyruvate, 
20 µg ml
-1
 gentamicin, and induced with 1 mM carnitine. The cultures were subjected to 
Miller assays to assess relative induction of the different caiX transcriptional fusions. 
Error bars represent standard deviations from three replicates, and results are 
representative of three independent experiments. 
 
Figure 3.  caiX transcription is repressed by glucose and glycine betaine. P. 
aeruginosa PA14 with caiX-lacZ (pJAM22) was grown in MOPS, 20 mM pyruvate and 
20 µg ml
-1
 gentamicin. The positive control and samples have 1 mM carnitine. All 
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Catabolite repression samples have additional compound added; 10 mM, 20 mM, 30 mM 
or 40 mM glycine betaine (pH 7), or 2 mM, 4 mM or 10 mM glucose. Cultures were 
induced for 4 hours prior to running a Miller assay. Error bars represent standard 
deviations from three replicates, and results are representative of three independent 
experiments. **, P < 0.001; ***, P < 0.001; ****, P < 0.0001. 
 
Figure 4.  MBP-CdhR binds the caiX upstream region in a concentration dependent 
manner. EMSA with biotin labeled caiX DNA probe alone (lane 1) or with increasing 
concentrations of purified MBP-CdhR (lanes 2-4). A cold caiX probe was used to 
compete for binding of MBP-CdhR from the labeled probe (lane 5). A nonrelated dhc 
DNA probe was used to show specificity of MBP-CdhR binding to caiX (lane 6-8). 
 
Figure 5. The CdhR binding site sequence and key residues for induction are 
identified from DNaseI footprinting and Miller assays. (A) DNaseI footprinting assay 
was performed by taking the caiX promoter end labeled with P32 and adding increasing 
concentrations of MBP-CdhR. The samples were subjected to DNaseI treatment. The 
samples were run on a 5% polyacrylamide Tris-borate-EDTA gel and analyzed to 
determine the CdhR binding site. The first lane of the gel is the A+G sequencing ladder 
and the others are with or without MBP-CdhR. (B) The caiX enhancer site was mutated 
by changing two bases at a time in the caiX distal binding site to adenosines and fused to 
lacZ (pos, mut1-mut6). P. aeruginosa PA14 wild type carrying each of the plasmids were 
grown in MOPS with 20 mM pyruvate, 20 µg ml
-1
, and induced with 1 mM carnitine for 
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4 hours and then subjected to Miller assays. Error bars represent standard deviations from 
three replicates, and results are representative of three independent experiments. ****, P 
< 0.0001 
 
Figure 6. MBP-CdhR binds but does not regulate cbcX expression. (A) EMSA with a 
biotin labeled cbcX upstream region and purified MBP-CdhR in increasing concentration. 
(B) Relative expression of cbcX was calculated based on the expression in WT pyruvate 
normalized to the rplU transcript. Three biological samples were run in triplicate and the 
graph represents the mean values and SEM. n.s., not signiﬁcant; ***, P < 0.001. 
 
Figure 7. MBP-GbdR binds the caiX-cdhR intergenic region but does not induce 
transcription of caiX or cdhR. (A) EMSAs were performed with purified MBP-GbdR in 
increasing concentration with either the biotin labeled cdhR binding site probe or a cdhR 
mutant binding site probe. The mutated probe has the distal half site CG residues in 
relation to cdhR changed to AA. (B) β-galactosidase assay with a caiX-lacZ reporter 
plasmid (pJAM22) in wild type, ΔcdhR, or ΔgbdR strains were grown in MOPS, 20 mM 
pyruvate, 20 µg ml
-1
 gentamicin, and induced cultures have an additional 1 mM carnitine. 
Error bars represent standard deviations from three replicates, and results are 
representative of three independent experiments. 
 
Figure 8. CdhR promotes cdhR expression and GbdR dampens basal expression. (A) 
PA14WT, PA14ΔcdhR, PA14ΔgbdR, and PA14ΔcdhRΔgbdR carrying a cdhR-lacZ 
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translational plasmid reporter (pJAM135)  were grown in MOPS with 20 mM pyruvate, 
20 µg ml
-1
 gentamicin, and induced with 1 mM carnitine. The cultures were subjected to 
Miller assays. (B) PAO1WT, PAO1ΔcdhR, and PAO1ΔgbdR, all with the translational 
fusion cdhRyfp integrated at the attTn7 site, were grown on MOPS agar pads with 20 mM 
pyruvate and with or without 1 mM carnitine. Cells were imaged under phase contrast 
and YFP fluorescence every 10 minutes for 6 hours at 32 °C. Cells were analyzed for 
mean fluorescence at each time point by subtracting the background fluorescence 



































































Figure 5. The CdhR binding site sequence and key residues for induction are 
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Figure 7. MBP-GbdR binds the caiX-cdhR intergenic region but does not induce 
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 This dissertation focuses on Pseudomonas aeruginosa sensing and utilization of 
the environmental and host-derived compound carnitine, as well as its acyl derivatives, 
acylcarnitines. Carnitine and acylcarnitines are widely distributed in nature and are 
especially abundant in animal tissues [1]. P. aeruginosa can catabolize carnitine [2] and 
we showed for first time that it is capable hydrolyzing acylcarnitines to use the liberated 
carnitine, and its catabolic product glycine betaine, as osmoprotectants, inducers of a 
virulence factor, and as sole carbon, nitrogen, and energy sources. We identified a short-
chain acylcarnitine hydrolase, HocS, and determined how acylcarnitines are transported 
(Figure 1). Lastly, we expanded our understanding of how carnitine catabolism is 
regulated by the transcription factors CdhR and GbdR.  
Figure 1 is a model representing this dissertation in its entirety. Although 
represented in the periplasm, medium- and long-chain acylcarnitines are hydrolyzed 
extracytoplasmically by an unknown hydrolase to yield free carnitine and a medium- or 
long-chain fatty acid. The fatty acid can be imported and used as a sole carbon source.  
The liberated carnitine and free carnitine, along with short-chain acylcarnitines are 
imported through the ABC transporter CaiXCbcWV for growth. Alternatively, carnitine 
can function as an osmoprotectant, whether from medium- and long-chain acylcarnitines 
or free, by being imported through an unknown transporter, likely a BCCT. Once in the 
cytoplasm, short-chain acylcarnitines are hydrolyzed by HocS. Finally, carnitine 
catabolism is controlled by the AraC family transcription factor, CdhR. 
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Pseudomonas aeruginosa is found in soil, water, and can thrive on surfaces such 
as medical devices. It adapts to different environments by utilizing a wide range of 
compounds for nutrients and survival, such as carnitine and its acyl derivatives. For the 
most part, P. aeruginosa is thought to be a free- living noninfectious microbe, but in the 
right environment can cause disease, typically in people who are immunocompromised. 
What is often overlooked is P. aeruginosa’s ability to cause infection in plants, insects, 
reptiles, and other mammals besides humans. Many pathogens cause disease in a specific 
host, whereas P. aeruginosa is a widespread and resourceful pathogen, likely owing to its 
large genome that encodes diverse metabolic pathways and a large regulatory repertoire 
[3]. P. aeruginosa’s ability to metabolize carnitine and acylcarnitines is not essential for 
survival, suggesting that metabolism of carnitine and acylcarnitine is an additional tool in 
the metabolism toolbox. The ability to adapt and change genetic profiles quickly provides 
P. aeruginosa an advantage for establishing and persisting in various niches, a trait that 
can drive disease. 
We made large strides in understanding carnitine and acylcarnitine metabolism 
but there are still many questions remaining. The carnitine and acylcarnitine figure 
(Figure 1) has the majority of the transport and metabolism steps determined. Short-chain 
acylcarnitine transport and metabolism is complete, but the medium- and long-chain 
acylcarnitine hydrolase(s) still needs to be identified. The alternative carnitine transporter 
that confers osmoprotection, likely a BCCT, remains to be identified. And lastly, how 
carnitine is bound by the substrate binding protein, CaiX, and the carnitine regulator, 
CdhR, is still not understood. 
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5.2 Medium- and long-chain acylcarnitines (MCAC- LCAC) 
5.2.1. Identifying the MCAC-LCAC hydrolase(s) 
 We were the first to show that P. aeruginosa is capable of using acylcarnitines 
as sole carbon and nitrogen sources [4]. Alcaligenes sp., Pseudomonas putida, and 
Acinetobacter calcoaceticus, to name a few, all have been shown to catabolize 
acylcarnitines of varying length but no responsible gene has been identified [5-7]. The 
short-chain acylcarnitine hydrolase, hocS, was the first gene of any acylcarnitine 
hydrolase gene to be ascertained [4]. We still have yet to determine the medium- and 
long-chain acylcarnitine hydrolase(s). There are three methods that could be used to 
identify the hydrolase(s). The first approach is to take an already existing P. aeruginosa 
PAO1 [8] or P. aeruginosa PA14 [9] transposon mutant library and screen separately for 
growth on a MCAC and a LCAC as sole nitrogen sources. The second approach is to 
perform a genetic screen by transposon mutagenizing P. aeruginosa PA14 wild type 
strain carrying the PcaiX-lacZ transcriptional reporter on the pJAM22 plasmid (strain 
JM92) and screen for loss of β-galactosidase activity in the presence of the MCAC or 
LCAC as a nitrogen source. The third would be microarray analysis on wild type P. 
aeruginosa grown on MCAC or LCAC as sole nitrogen sources to compare the 
expression profiles to the wild type strain grown with carnitine as the sole nitrogen 
source. Both MCAC and LCAC should be used in any of these screens, as there could be 
independent hydrolases for the two classes of acylcarnitines. P. putida can  grow on 10C 
-16C fatty acid chain lengths [6] and P. aeruginosa may have long-chain acylcarnitine 
hydrolase similar to P. putida but acquired or maintained a MCAC hydrolase due to its 
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pathogenic nature. The three proposed screens have inherent and known positive 
controls: carnitine catabolism genes (cdhCAB), transport genes (caiXcbcWV), carnitine 
regulator (cdhR), and genes required for glycine betaine catabolism to pyruvate (Figure 1, 
Chapter 4). In the β-galactosidase assay, those transposon mutants that are in the listed 
genes will be white, in the growth assay there will be no growth, and in the microarray 
they will be induced.  
 
5.2.2. Why not octanoylcarnitine? 
 I think a fascinating aspect and question of acylcarnitine catabolism is why P. 
aeruginosa doesn’t use octanoylcarnitine as a sole carbon or nitrogen source [4]; after 
identifying the MCAC-LCAC hydrolase(s), this question can be addressed. The transport 
data in Chapter 3 shows that octanoylcarnitine is not hydrolyzed as efficiently as the 
other acylcarnitines. Although other bacteria can hydrolyze octanoylcarnitine [10], 
physiologic utility was generally not addressed except for B. subtilis employing the 
liberated carnitine as an osmoprotectant [11]. Interestingly, P. aeruginosa may have 
evolved a selective hydrolase as a survival strategy to combat the antimicrobial effects of 
caprylic acid [12-14], the direct product of octanoylcarnitine hydrolysis. Determining the 
protein structure or using gain-of-function mutagenesis to restore octanoylcarnitine 
would provide insight into the mechanism of octanoylcarnitine exclusion. Specific amino 
acid residues in the hydrolase may provide steric hindrance by interacting with the fatty 





5.3.1. Transporter for osmoprotection 
 The observation that carnitine induces caiX and functions as an osmoprotectant 
in the absence of the ABC transporter cbcWV, suggests that there is one or more 
additional carnitine transporters. We hypothesize that carnitine can be imported through a 
betaine/choline/carnitine transporter (BCCT) particularly at high salt concentrations. The 
only characterized BCCT that is known to transport carnitine is caiT in E. coli and P. 
mirabilis [15, 16]. Since CaiT does not confer osmoprotection [17] and no homologs are 
predicted in P. aeruginosa, it is unlikely that P. aeruginosa uses a BCCT similar to CaiT. 
P. aeruginosa does possess BetT1, BetT2, and BetT3; BCCTs that are driven by proton 
motive force, transport glycine betaine and choline, and provide osmoprotection [18, 19]. 
These BetT transporters are good candidates for the alternative carnitine transporter. The 
betT1, betT3, cbcVbetT1, cbcVbetT3, and betT1betT3 [18] mutants are available and 
would be a great starting point to fully understand carnitine transport. If the BetT proteins 
are not the alternative carnitine transporter, transposon mutagenesis of the cbcV mutant 
can be performed. Screening for lack of growth in a hyperosmotic environment will 
identify the carnitine specific BCCT. 
  
5.3.2. CaiX ligand specificity  
 The P. aeruginosa quaternary amine SBP CbcX binds choline and, to a lesser 
extent, glycine betaine [20]. Based on our growth data, CaiX is analogous to CbcX and 
binds multiple ligands: carnitine, acetylcarnitine, and butyrylcarnitine, and would be 
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interesting to see which of these ligands is preferred for CaiX. Using radiolabeled 
compounds and performing transport assays [20], would give insight into ligand 
preference. Carnitine is more prevalent than short-chain acylcarnitines in the environment 
[21] and animal tissues [22], which may be mirrored by the ligand preference of CaiX. 
 
5.4. Regulation of carnitine catabolism 
5.4.1. Ligand binding 
 It has been shown through reporter assays and via analysis of epistasis that 
CdhR is responsive to carnitine, but ligand binding has not been definitively shown. 
Ligand binding studies of AraC-family TF have been difficult due to the unruly nature of 
AraC TFs but binding has been shown in a few instances [21-23]. Using recombinant 
CdhR and radioactive carnitine, far western or equilibrium dialysis assays would show 
ligand binding by CdhR. It would be important to extend ligand binding studies to GbdR 
to tease apart the role GbdR has as a dominant regulator of carnitine and choline 
catabolism. 
 
5.4.2. Catabolite repression of carnitine catabolism 
 The role of GbdR in catabolite repression of carnitine catabolism is an intriguing 
question. Glucose and glycine betaine can both repress the transcription of caiX. For GB, 
this catabolite repression control is predicted to be important for negative feedback as 
carnitine is converted to GB. This repression may be regulated by GdbR, supported by 
our previous published data that GbdR responds to GB [26-28] and data presented here 
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showing that GbdR binds the caiX-cdhR intergenic region. Reporter experiments in a 
gbdR mutant will help elucidate the source of transcriptional repression, but will need to 
take into account GbdR-dependent activation of the carnitine and GB transporter ABC 
transporter cbcWV [20]. To circumvent the defect of GB and carnitine transport in a gbdR 
mutant, placing a constitutive promoter at the native locus of caiXcbcXWV, or having the 
GB-carnitine transport system in trans would alleviate a GB and carnitine transport 
defect.   
 
5.4.3. How is cdhR transcription regulated?  
 There are a few things we know about the regulation of cdhR transcription: 
GbdR is not an activator of cdhR transcription and CdhR plays a role in its own 
regulation. A cdhR mutant with stop codons truncating the ORF maintains the transcript 
but not the protein, which allows us to assess transcript levels by qRT-PCR in a cdhR 
mutant. In Chapter 4, I propose a mechanism for CdhR and GbdR influencing 
transcription by regulating CdhR binding to the caiX-cdhR DNA region, either by 
binding half sites and looping the DNA or by protein oligomerization (Figure 2) along the 
DNA. There are additional CdhR and GbdR half sites in the intergenic region and within 
caiX and cdhR (Figure 3). I hypothesize that they contribute to the observed 
transcriptional repression. By strategically adding a reporter in the CdhR half site rich 
area and/or mutating certain half sites we can elucidate if these half sites function as 
operator sites. This can be expanded to GbdR but may prove to be difficult or very time 
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consuming because in Figure 3 I have marked the most common distal half site GbdR 
binding sequence, not the other possible GbdR binding sites.  
 
5.5 Concluding remarks 
 Carnitine metabolism in P. aeruginosa has been known for over fifty years but it 
was not until recently that the genes responsible for carnitine catabolism were discovered; 
and it was not until this work that acylcarnitine metabolism was characterized in P. 
aeruginosa (Figure 1). We show how acylcarnitines are transported into the cell, and for 
the first time, identify the gene responsible for encoding a short-chain acylcarnitine 
hydrolase. Although the medium- and long-chain acylcarnitine hydrolase(s) is still 
unknown, there are clear benefits for P. aeruginosa maintaining an acylcarnitine 
degradation pathway, including the products being as an osmoprotectants, to induce 
virulence factors, and to function as carbon, nitrogen, and energy sources.  We further 
expanded upon the regulation of this system to include characterization of the CdhR 
binding site, investigation of cdhR expression, and exploration of the regulatory hierarchy 
between the transcription factors CdhR and GbdR.  
Utilization of carnitine and acylcarnitines by P. aeruginosa contributes to its 
metabolic versatility and likely fine- tunes adaptation to various environments. Carnitine 
and acylcarnitines in soil and plants provide nutrients and osmoadaptation capabilities to 
survive the ever- changing environment, but may also provide P. aeruginosa an 
advantage in the human host and establishment of infection. Long-chain fatty acids are a 
carbon and energy source in mouse chronic wound infections [29], and these fatty acids 
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could partially be coming from long-chain acylcarnitine catabolism. Additionally, the 
carnitine catabolism genes are increased in expression by 5 to 15 fold compared to the 
succinate control in chronic wound infections [29]. These findings from Turner et al. lead 
to the hypothesis that carnitine and acylcarnitine metabolism are important for 







Figure 1. Diagram of carnitine and acylcarnitine metabolism. Abbreviations: OM is 
outer membrane, IM is inner membrane, SCAC is short-chain acylcarnitine, MCAC is 
medium-chain acylcarnitine, LCAC is long-chain acylcarnitine, HocML is hydrolase of 
O-acylcarnitine medium long, HocS is hydrolase of O-acylcarnitine short chain, FA is 
fatty acid, and BCCT is betaine/choline/carnitine transporter. 
 
Figure 2. Proposed mechanism of cdhR expression. Red and purple bars are CdhR and 
GbdR half sites, respectively. Red monomers are CdhR and purple monomers are GbdR. 
Black diamonds are carnitine and yellow triangles are glycine betaine (GB). Blue and 
green lines are representations of cdhR and caiX expression levels, respectively. 
 
Figure 3. DNA sequence of caiX and cdhR with CdhR and GbdR half sites. The DNA 
sequence colored green is the caiX sequence, red is the intergenic region, and blue is the 
cdhR sequence. The underlined and yellow highlighted sequence is the identified CdhR 
binding site. The GCGACC is the CdhR half site binding sequence and is underlined in 
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The data presented below is pertinent to this thesis but is not incorporated into 
Chapters 2-4. Therefore, this section has some experiments briefly described and the 
results are stated. 
 
 
6.2. Induction of caiX with varying concentrations of carnitine 
 
 To determine the sensitivity of caiX induction by carnitine, the concentration of 
carnitine was titrated and a Miller assay was performed. We were able to assess the 
inducing limit of caiX by carnitine.  
Pseudomonas aeruginosa PA14 wild type carrying PcaiX-lacZYA (pJAM22) was 
grown overnight at 37 °C in MOPS minimal media supplemented with 20 mM pyruvate, 
5 mM glucose, and 20 µg ml
-1
 gentamicin. Cells were collected by centrifugation, 
washed, and inoculated into MOPS minimal media with 20 mM pyruvate, 20 µg ml
-1
 
gentamicin, and with or without carnitine ranging from 1 mM to 250 nM. Cells were 
induced for 4 hours at 37 °C while shaking. A β-galactosidase assay was performed 
according to the method of Miller in duplicate. 
The induction of caiX is similar from 1 mM to 250 µM carnitine. 125 µM of 
carnitine induces caiX to about 70 % of 250 µM and there is a sharp decrease in induction 
of caiX at 1 µM (Figure 1). Therefore any of the experiments performed in this thesis, 
whether it is 1 mM or 500 µM of the inducing agent, does not alter the relative induction 
observed. This is noted because there are some experiments have inducing compounds at 
1 mM of the L-isomer compound compared to 1 mM DL-racemic mixture. 
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6.3. CdhR senses and responds to acetyl- and butyrylcarnitine 
Short-chain acylcarnitines, acetyl- and butyrylcarnitine, are imported into the cell 
via the ABC transporter CaiXcbcWV as described in Chapter 4. Once in the cytoplasm 
the carnitine catabolism operon, caiXcdhCABhocS, is induced. The question addressed 
was does CdhR sense short-chain acylcarnitines and induce caiX, or do they need to be 
hydrolyzed first. 
Pseudomonas aeruginosa PA14 wild type and ΔhocS carrying PcaiX-lacZYA 
(pJAM22) were grown overnight at 37 °C in MOPS minimal media supplemented with 
20 mM pyruvate, 5 mM glucose, and 20 µg ml
-1
 gentamicin. Cells were collected by 
centrifugation, washed, and inoculated into MOPS minimal media with 20 mM pyruvate, 
20 µg ml
-1
 gentamicin, and induced with 1 mM carnitine, acetylcarnitine, or 
butyrylcarnitine. Cells were induced for 4 hours at 37 °C while shaking. A β-
galactosidase assay was performed according to the method of Miller in triplicate, three 
independent times. 
Both acetyl- and butyrylcarnitine induce caiX in a hocS mutant similar to wild 
type (Figure 2). These data indicate that short-chain acylcarnitines are likely sensed by 
CdhR and do not need to be hydrolyzed to induce caiX.  
 
 
6.4. Purification of CdhR and GbdR 
 
 CdhR and GbdR are members of the AraC family transcription factors (TF). As 
described in Chapter 1, AraC TFs have an N-terminal ligand binding and dimerization 
domain. In order to study ligand binding and protein interactions, it is beneficial to have 
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the protein in its native conformation and not have a protein fused to the N-termini. To 
purify the protein without any tags we perform affinity purification with heparin. Heparin 
is glycoaminoglycans that is negatively charged and structurally and charged similar to 
DNA. CdhR and GbdR are DNA binding proteins (the C-terminal domain is the DNA 
binding domain) and therefore heparin can be used to purify the TFs (Figure 3). 
 CdhR was constructed by PCR amplifying with primers 5'- 
TCAcataTGTCCCAGGACTTCTGGT and 5'- ACTggtacCGTCAGCCTCGCTCAGCTC 
using PA14 as template DNA. The product was digested with NdeI and KpnI and ligated 
into similarly cut pET30a. GbdR was constructed by amplifying with primers 5'-
ACGcatATGACCACGTACGCGCCC and 5'-ACTggatccTCAGATCCGCACGCTGGCG using 
PA14 as the template DNA. GbdR PCR product was digested with NdeI and BamI and 
ligated into the similarly cut pET30a. Both CdhR and GbdR carrying plasmids, pJAM91 
and pJAM100, respectively, were transformed into T7Express E. coli and selected on LB 
100 µg ml
-1
 kanamycin plates. E. coli strain JM256 (CdhR) and JM273 (GbdR) were 
grown overnight in LB 100 µg ml
-1
 kanamycin and inoculated into 1 L LB with 75 µg ml
-
1
 kanamycin. Cells were grown at 37 °C to an OD600 nm of 0.4, induced with 1 mM 
IPTG, and induced for 3 hours. Cells were collected by centrifugation and resuspended in 
3 ml 20 mM TrisHCl with 150 mM NaCl, Halt cocktail protease inhibitor (Thermo), and 
lysed by French press. Lysate was spun at 4 °C for 30 minutes and the supernatant was 
syringe filter sterilized with a 0.22 µm filter and applied to a heparin column. The column 
was washed in wash buffer (100 mM PBS, 150 mM NaCl, pH 7.4) with an additional 350 
mM NaCl and then eluted with wash buffer plus 500 mM NaCl. Elution fractions were 
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dialyzed in 20 mM TrisHCl, 150 mM NaCl, 1 mM EDTA, at pH 7.4 overnight in a 20K 
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